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Abstract
The prevalence of alcohol use disorders in Europe is 7.5%. Alcohol dependence
is traditionally considered a brain disorder where ethanol interacts with
several receptors for neurotransmitters. Pharmacological treatments of addiction
currently target these receptors but demonstrated only limited therapeutic effect,
and the relapse rate is still very high. This PhD work was dedicated to the study of
alterations of the gut in alcohol-dependence. We observed important alterations
of the gut microbiota in a large fraction of alcohol-dependent subjects, that was
associated with a leaky gut barrier, which enabled the translocation of bacterial
products from the gut lumen to the systemic circulation. These bacterial products
induced an inflammatory response that correlated with psychological symptoms
of alcohol dependence including depression, anxiety and craving. The results of
this thesis open a new field of research for the treatment of alcohol dependence,
targeting the gut microbiota.
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FOREWORD 
While it may seem that the rise in drug-related deaths has become a 
recent phenomenon, the loss of some of the most celebrated men and women 
in history due to alcohol has been a surprisingly constant and tragic reality 
over time. Plenty of actors, writers and singers have experienced the descent 
into alcoholism. Some recovered and some did not win the battle. Here are 
various examples. 
 
The most recent loss is the depression-related suicide of Robin Williams 
whose genius comic impressions touched a generation of moviegoers. He 
experienced two decades of sobriety before his three-year alcohol relapse 
occurred. Sir Anthony Hopkins, renowned for his portrayal of Hannibal 
Lecter in The Silence of the Lambs, has been sober for 30 years and claims 
“the compulsive side of my nature is still present but now it does not control 
my life. I feel like a survivor”. Other actors came to alcoholism such as 
Mickey Rourke, whose erratic career has perfectly matched his state of 
sobriety, and Mel Gibson, whose neighbors repeatedly filed complaints with 
police during very pronounced crises.  
 
Crafters of the written word have not been immune to this disease, 
among them such influential writers as Edgar Allan Poe, one of the pioneers 
of Science Fiction; F. Scott Fitzgerald, author of The Great Gatsby as well as 
lauded poets Verlaine, Rimbaud, Baudelaire. All have fallen victim not only 
to their success, but also to the excessive consumption of alcohol. 
 
Many singers have struggled with alcoholism like the legendary guitarist 
Eric Clapton, who has known many tragedies in his life and wrote in his 
autobiography: “in the lowest moments of my life, the only reason I didn't 
commit suicide was that I knew I wouldn't be able to drink any more if I was 
dead”. Recently, the British singer Amy Winehouse joined Club 27 because 
of her alcohol and drug addiction. Also, David Bowie, in addition to cocaine 
addiction, spiraled down into alcoholism. In 1977 Berlin, he said “I’ve been a 
real idiot some of my life and I put myself in ridiculously dangerous 
situations. Now I seem to have been getting through it”.  And that became 
part of that wonderful song “Heroes”, reflecting that you can overcome some 
incredible odds. 
 
“And I’ll drink all the time 
‘Cause we’re lovers 
 We can beat them, forever and ever 
 We can be heroes, just for one day” 
 
   
 
SUMMARY 
Alcohol dependence has traditionally been considered a brain disorder. 
Neurobiological studies have demonstrated the impact of chronic ethanol consumption on the 
concentration of several neurotransmitters involved in the brain reward circuit. Therefore, 
pharmacological approaches targeting these neurotransmitters have been developed to treat 
alcohol addiction. Most of the clinical studies clearly showed that these pharmacological 
agents are far from being totally convincing at improving clinical outcomes, and the relapse 
rate in this disease is still very high. Alcohol-dependent subjects frequently develop emotional 
and psychological disturbances such as depression, anxiety and craving that are known to play 
an important role in the drinking behavior and influence the probability of relapse after a 
period of sobriety. 
In addition to the deleterious effect of ethanol on the brain, many other peripheral 
organs are damaged. In this PhD work, we have focused on the effect of heavy and chronic 
alcohol consumption on the gut and more particularly on the gut barrier and on the gut 
microbiota which is now considered an “exteriorized” organ placed within the body. We 
tested whether alterations in the gut barrier and in the gut microbiota composition and 
functions occur in alcohol-dependent subjects and whether these changes could be related to 
psychological symptoms of addiction. We also analyzed the systemic inflammatory response 
which could be seen as a mediator in the gut-brain interactions. 
In the first study, we found that alcohol-dependent subjects presented with increased 
intestinal permeability (also called leaky gut), which permit the translocation of endotoxin 
LPS from the gut lumen to the systemic circulation. LPS comes from the cell wall of Gram 
negative bacteria inhabiting the gut and is a potent pro-inflammatory agent. Alcohol-
dependent subjects also presented with a low-grade systemic inflammation which persisted 
after 3 weeks of alcohol abstinence. Finally, we showed an important relationship between 
inflammatory markers and the severity of depression and alcohol craving. 
In the second study, we found that in addition to LPS, peptidoglycan which derived 
from Gram positive bacteria could also cross the leaky gut barrier and both could activate the 
peripheral blood mononuclear cells (PBMCs) to induce the release of pro-inflammatory 
cytokines IL-1β and IL-8. The improvement of alcohol craving score during the alcohol 
withdrawal was associated with the decrease of specific inflammatory markers in PBMCs, 
and IL-8 was found to be the best predictor of the psychological outcome. 
In the last study, we observed that only a subset of alcohol-dependent subjects 
presented gut leakiness, independently of the amount of alcohol consumed. Deep analysis of 
the gut microbiota composition and functionality revealed that subjects with leaky gut had 
also altered gut microbiota (called dysbiois) that persisted after 3 weeks of alcohol abstinence. 
Specific bacteria or metabolites produced by the bacteria could therefore be involved in the 
gut barrier regulation. More importantly, subjects with leaky gut and altered gut microbiota 
presented with a more severe form of dependence including higher levels of depression, 
anxiety and alcohol craving compared to subjects without dysbiosis, and this could influence 
the probability of relapse after detoxification. The results of this third study showed, for the 
first time in human alcohol-dependent subjects, an association between the gut and the 
psychological symptoms of addiction.  
All these data are in favor of the existence of gut-brain axis in alcohol-dependent 
subjects, where inflammation could play a role in the communication between a peripheral 
organ that was initially “simply” devoted to absorption and fermentation of nutrients, and the 
central nervous system. However, other mechanisms underlying gut-brain interactions remain 
to be investigated, in particular the role of the vagus nerve, of tryptophan metabolism or the 
possibility that bacterial metabolites would enter the bloodstream and exert neuroactive 
properties. 
 The prevalence of alcohol use disorders reaches 7.5% of the population in Europe. 
All social classes are concerned. The high fraction of patients who resume alcohol drinking 
few months, few weeks or even directly after a detoxification program is a reality difficult to 
accept for the medical community, for the patients and their family. The persistence of 
inflammation and dysbiosis observed at the end of detoxification supports the idea that new 
strategies, targeting the gut and not the brain, might be beneficial in the treatment of alcohol 
dependence. More particularly, the use of nutritional factors called prebiotics appears to be 
the most promising strategy to improve, naturally and in a safe way, gut and psychological 
health in alcohol-dependent subjects. 
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The introduction has been divided into three sections: 
In the first part, we describe the health, social and economic consequences of the harmful 
use of alcohol. Then, we expose the brain neurochemical mechanisms involved in the 
development of alcohol dependence and of alcohol withdrawal syndrome and the current 
treatments proposed to alcohol-dependent patients. As emotional and psychological 
symptoms are frequently developed in alcohol-dependent subjects, the psychological models 
of alcohol dependence are also briefly introduced.  
Alcohol consumption has many deleterious consequences on the brain, but other 
peripheral organs are also damaged. The second part of the introduction focuses on the effect 
of heavy and chronic alcohol consumption on the gut, and more particularly on the intestinal 
barrier function as well as on the gut microbiota composition and functionality. In order to 
understand the potential impact of gut dysfunction on the psychological symptoms of alcohol 
dependence, the mechanisms underlying the communication between the gut and the brain are 
described. 
In the last section, we develop the concept of sickness behavior which suggests that pro-
inflammatory cytokines, produced following peripheral infection, act on the brain to induce 
mood and behavioral changes.  When inflammation persists and becomes chronic, mood 
changes can lead to the development of depression thought the activation of a specific enzyme 
described in this third section. 
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1 ALCOHOL USES AND MISUSES 
 
Alcohol consumption has been described in society since early history. It is frequently 
associated to important social events and takes an important place in many cultures. However, 
excessive drinking is also an important public health problem as recently defined by the 
World Health Organization (WHO):  
 
 
 
“Besides the numerous chronic and acute health effects, alcohol consumption is also 
associated with widespread psychosocial consequences, including violence, child neglect and 
abuse, absenteeism in the workplace, and many other impacts. Considering the significance of 
alcohol consumption compared to other health risks, the harmful use of alcohol is not given 
proper attention in public policy, particularly since other lesser health risks have higher 
priority”. 
        Global status report on alcohol and health, WHO, 2011 [1].  
 
 
 
In the first section of this chapter, we will describe the health, social and economic 
consequences of harmful alcohol-drinking. In the second section, we will elaborate on 
different characteristics of excessive drinking when it becomes a psychiatric disorder.   
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1.1 Harmful use of alcohol: health, social and 
economic consequences 
 
Alcohol is a psychoactive substance with dependence-producing properties. 
Consumption of alcohol and problems related to alcohol vary widely around the world, but 
the burden of disease and death remains significant in most countries. The harmful use
1
 of 
alcohol is the third leading risk factors for disease and disability and is a causal factor in more 
than 200 disease and injury conditions. The harmful use of alcohol is responsible for 
approximately 3.3 million deaths each year. In addition to its deleterious effect on health, the 
harmful use of alcohol can also have serious social and economic consequences for 
individuals other than the drinker and for society at large [2]. 
 
1.1.1 Alcohol consumption 
Alcohol is consumed almost worldwide but there is wide variation in total alcohol 
consumption among regions (figure 1-1) due to socio-demographic factors, prevalence rates 
of abstention, culture such as Islam religion and level of economic development. Globally, 
individuals above 15 years of age drink on average 6.2 liters of pure ethanol per year (or 13.5 
grams of pure alcohol per day). The highest consumption levels are found in the developed 
countries, in particular the WHO European Region (which includes the Russian Federation). 
In Belgium, the average consumption is 11 liters of pure ethanol per person per year. 
 
                                                 
1
 The harmful use is defined as a pattern of alcohol use that is causing damage to health, and the damage may be 
physical (e.g. liver cirrhosis) or mental (e.g. depressive episodes secondary to heavy alcohol consumption). 
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Figure 1-1: Total alcohol per capita (aged 15 years and older) consumption, in liters of pure alcohol, WHO 2010 
[1]. 
 
1.1.2 Health consequences for drinkers 
The harmful use of alcohol is the third leading risk factor for disease and disability 
(figure 1-2). In 2012, 5.1% of the global burden of disease and injury, as measured in 
DALYs
2
, were attributable to alcohol. Because alcohol starts killing or disabling people at 
relatively young age, the harmful use of alcohol is the first leading risk factor for mortality 
and the overall burden of disease in the 15-59 age group. Alcohol consumption has been 
identified as a component cause for more than 200 disease and injury conditions and more 
than 30 conditions include alcohol in their name or definition (e.g. alcohol dependence, 
alcoholic liver disease, fetal alcohol syndrome). This indicates that these disease conditions 
would not exist at all in the absence of alcohol consumption.  
 
                                                 
2
 Disability-adjusted life years (DALYs) represent a time-based measure of overall burden of disease for a given 
population. DALYs are the sum of years of life lost due to premature mortality as well as years of life lost due to 
time lived in less than full health. 
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Figure 1-2: Global percentages of DALYs attributes to 19 leading risk factors by income group, WHO 2004 [1]. 
In 2012, 5.9% of all deaths worldwide (7.6% for men, 4.0% for women) were caused 
by alcohol consumption. It means that one death out of twenty is due to alcohol. Figure 1-3 
shows the distribution of these 5.9% alcohol-related global deaths by broad disease category. 
The highest numbers of deaths are from cardiovascular diseases, followed by unintentional 
injuries, gastrointestinal diseases (mainly liver cirrhosis) and cancers. Compared to other 
diseases, neuropsychiatric disorders cause more disability than mortality. Almost 25% of 
alcohol-attributable DALYs were due to neuropsychiatric disorders whereas only 4% for all 
alcohol-attributable deaths would have a neuropsychiatric origin. 
The degree of risk for harm due to alcohol use varies with the drinker’s age, sex, 
familial factors, socioeconomic status as well as drinker’s behavior and alcohol exposure. 
Indeed, alcohol-related harm is also determined by three related dimensions of drinking: the 
volume of alcohol consumed, the pattern of drinking and also the quality of alcohol 
consumed.  
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Figure 1-3: Distribution of alcohol-attributable deaths, as a percentage of all alcohol-attributable deaths by broad 
disease category, WHO, 2012 [2] 
 
1.1.3 Socioeconomic consequences for drinkers 
In addition to harm to physical and mental health, alcohol consumption is often 
associated with socioeconomic consequences such as loss of earnings, unemployment, family 
problems, stigma and barriers to accessing health care. 
Alcohol is a valued commodity. When earnings are low, heavy drinking may further 
impoverish the drinker and the drinker’s family [3, 4]. Alcohol intoxication, dependence or 
withdrawal states results in poor performance, loss of productivity or absenteeism at the work 
place, break-up and dysfunction in family life [3]. Also, there is a clear tendency to 
marginalize and exclude from society habitually intoxicated persons and their families and it 
has been shown that heavy alcohol users receive less priority in health care [5, 6]. 
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1.1.4 Harms to other individuals 
The harmful use of alcohol can have health and social consequences for the drinker 
but can also result in harm to other individuals. The harms done by people’s drinking to others 
involve both socioeconomic consequences and health problems such as intentional (e.g. 
violence, homicide) or unintentional (e.g. traffic crash, workplace accident) injuries, child 
neglect or abuse, fetal alcohol syndrome, as well as mental health impact for relatives who 
may be frightened by the actions of the drinkers [7]. 
A recent study assessed the harms caused by the misuse of twenty drugs, which were 
scored according the harms that the drug produces to the individuals (harms to users) and the 
harms that the drug produces to others (harms to others) [8]. As shown in figure 1-4, the study 
revealed that the most harmful drugs to users were heroin, crack cocaine and 
metamphetamine, whereas the most harmful drug to others was alcohol. When the two scores 
were combined, alcohol was the most harmful drug, with heroin and crack cocaine in 
second and third positions. 
 
 
Figure 1-4: Scatter plot displaying harm to users and harm to others of different drugs, Nutt et al., The Lancet, 
2010 [8]. 
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1.1.5 Harms to society at large 
The harmful use of alcohol results in a significant health, social and economic burden 
on society. There are three major categories of alcohol-attributable social and economic costs. 
The first category is the direct economic costs of alcohol consumption which include health 
care services (e.g. hospitalizations, ambulatory care, nursing home care, prescription 
medicines) and the police and criminal justice system [9]. The second category is indirect 
costs due to absenteeism, loss of productivity, unemployment, premature pension [10]. A 
third category is intangible costs which are costs assigned to pain and suffering, and more 
generally to a reduced quality of life for the drinkers and their families [10]. Alcohol-
attributable costs have been estimated at about 125 billion euros in the European Union in 
2003 [10]. 
Despite the large health, social and economic burden associated with harmful use of 
alcohol, it remained a relatively low priority in public health policy [2]. 
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1.2 Alcoholism as a psychiatric disease  
 
“All things are poison and nothing is without poison, only the dose permits something not to 
be poisonous.” 
Paracelsus (1496-1541) 
1.2.1 Definition, diagnosis and epidemiology 
Alcohol use in itself may not be considered a pathology. The British Medical Association 
published the following guidelines in order to minimize the risk of health harms associated 
with drinking [11]: 
 Men should drink no more than 21 units of alcohol per week, no more than 4 units in 
any given day, and have a least 2 alcohol-free days a week. 
 Women should drink no more than 14 units of alcohol per week, no more than 3 units 
in any given day, and have a least 2 alcohol-free days a week. 
 Pregnant women should not drink alcohol at all. 
World-wide recommendations on alcohol consumption show wide disparity among 
countries, also because one standard alcohol unit varies greatly. In most European countries, 
one unit contains 10 grams (g) of pure alcohol. The amount of liquid in the glass is therefore 
adapted according to the strength of alcoholic beverage (figure 1-5). In the United Kingdom, 
one unit is equal to 8g of ethanol, in the USA 14g and in Japan 19.75g. In Belgium, there is 
no official guideline on alcohol consumption.  
 
Figure 1-5 : One standard drink (one alcohol unit) contains 10g of pure alcohol, Bertin A., Addica, 2004 [12]. 
 Introduction   
 
13 
 
  In psychiatry, several definitions have been proposed to describe the misuse of 
alcohol. The distinction between different pathologies related to alcohol use in psychiatry 
depends on the presence or absence of different psychiatric symptoms. The diagnosis of 
alcohol dependence is based on criteria described in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM). In 1952, the American Psychiatric Association published the first 
edition (DSM-I). In all the studies described in this manuscript, patients were selected upon 
criteria of the fourth edition (DSM-IV) published in 1994.  
Alcohol dependence is defined as a cluster of behavioral, cognitive and physiological 
phenomena that develop after repeated alcohol use and that typically include a strong desire to 
consume alcohol, difficulties in controlling its use, persisting in its use despite harmful 
medical and social consequences, a higher priority given to alcohol use than to other activities 
and obligations, increased tolerance, and sometimes a physiological withdrawal state [2]. The 
exact criteria are depicted in table 1-1.  
Since May 2013, the fifth edition (DSM-5) is available, in which a general evolution 
can be observed compared to DSM-IV: substance abuses are described as a continuous 
progression rather than a categorical perspective. Although there is considerable overlap 
between DSM-5 and DSM-IV, there are several important differences. For instance, DSM-IV 
distinguishes alcohol-dependence from alcohol abuse, which is a less severe psychiatric 
disease and which essentially insists on the consequences of drinking rather than on a specific 
symptomatology, while DSM-5 integrates the two disorders into a single disorder called 
“alcohol use disorder” (AUD) where a progression in the severity is described by a sub-
classification in mild, moderate and severe forms of AUD. Moreover, DSM-5 adds alcohol 
craving as a criterion for AUD diagnosis, which was not included in the prior edition  [13]. 
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Table 1-1 : A comparison between DSM-IV and DSM-5, National Institute on Alcohol Abuse and Alcoholism, 
2013 [13]. Under DSM-IV, two distincts disorders were described: alcohol abuse and alcohol dependence. 
Anyone meeting one or more out of 4 of the “abuse”criteria (items 14) within a 12-month period would be 
diagnosed as “alcohol abuser”. Anyone meeting three or more out of 7 of the “dependence” criteria (items 
511) within the same 12-month period would be diagnosed as “alcohol-dependent”.  Under DSM-5, anyone 
meeting any two of the 11 criteria during the same 12-month period would receive a diagnosis of “alcohol use 
disorder” (AUD).  The severity of AUD is defined as mild if 2 to 3 symptoms are present, moderate if 4 to 5 
symptoms are present, severe if 6 or more symptoms are present. Overall, the DSM-5 alcohol use disorder 
criteria are nearly identical to the DSM-IV alcohol abuse and dependence criteria combined, with two 
exceptions: DM-5 eliminates legal problem as a criterion but adds craving as a new criterion for AUD diagnosis. 
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The most recent statistics related to AUDs date back to 2010 and include alcohol-
dependence as well as harmful use of alcohol [2]. Worldwide, AUDs are significantly more 
prevalent among males compared to females. Table 1-2 shows the prevalence of AUDs in 
some countries of the WHO European Region. In Belgium, 5.8% of the population suffers 
from AUDs whereas the disorder is present in 30% of males in some countries of Eastern 
Europe. 
 
 Alcohol use disorders 
Total            Male         Female 
WHO European Region 7.5 12.6 2.9 
Italy 1.0 1.3 0.8 
Netherlands 1.2 1.7 0.8 
Spain 1.3 2.3 0.4 
France 5.5 8.8 2.5 
Belgium 5.8  8.8 3.0 
Switzerland 8.0 13.5 2.6 
United Kingdom of Great Britain  
and Northern Ireland 
11.1 16.3 6.0 
Slovenia 11.6 19.7 3.8 
Belarus 16.6 29.8 5.5 
Russian Federation 17.4 31.0 6.2 
Hungary 17.7 31.0 6.0 
 
Table 1-2: This table shows the extent of alcohol use disorders (AUDs) prevalence (%) in selected countries of 
the WHO European Region in 2010. Based on 12-month prevalence estimate including people aged 15 years or 
more. WHO, 2012 [2]. 
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1.2.2 Biological and psychological models of alcohol dependence 
 
1.2.2.1 Biological models 
The person’s initial decision to use alcohol is influenced by genetic, psychosocial and 
environmental factors. Once it has entered the body, alcohol promotes continued alcohol-
seeking behaviors by acting directly on the brain. A major goal of basic research is to 
understand the neural underpinnings associated with the transition from alcohol use to alcohol 
abuse and dependence. Reinforcements (positive or negative) and neuroadaptation 
contribute to the development of addiction.  
Reinforcement is a process in which a response or behavior is strengthened based on 
previous experiences and it appears to be regulated by multiple neurotransmitter systems 
described below [14]. Positive reinforcement describes a situation in which a rewarding 
stimulus, such as euphoria or pleasure induced by alcohol ingestion, increases the probability 
to drink alcohol. This positive motivating factor is frequent in the early stages of alcohol use 
and abuse. Negative reinforcement occurs when the individual drinks alcohol to avoid or 
alleviate aversive stimulus such as withdrawal symptoms (anxiety, irritability, tremors …) or 
negative affects related to drinking. It is involved in a later stage of addiction, when 
dependence has developed, and is commonly accepted as a major factor involved in the 
persistence of the drinking habits in alcohol-dependent subjects. 
Neurobiological hypothesis currently ascribes these positive and negative 
reinforcement processes to changes in brain neurotransmitters. Indeed, alcohol interacts with 
several neurotransmitters systems in the brain’s reward circuit, a functional area that 
plays an important role in the emergence of the addiction and that is constituted by neurons 
located in the mesolimbic system (ventral tegmental area, nucleus accumbens, and prefrontal 
cortex), amygdala, striatum and hippocampus (figure 1-6). Neurotransmitters involved in this 
circuit are dopamine, opioids, serotonin, gamma-aminobutyric acid (GABA) and glutamate 
[15].  
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Figure 1-6: Location of human  brain regions that constitute the brain reward circuit and are affected by alcohol 
drinking, Clapp P. et al., Alcohol Research and Health, 2008 [15]. 
Dopamine and endogenous opioids are released in the brain after alcohol ingestion and 
are both involved in the positive reinforcement. Serotonin (or 5-hydroxytryptamine, 5-HT) is 
involved in the regulation of emotional states and evidence indicates that it is also important 
in the regulation of alcohol consumption [16]. For example, increasing the level of serotonin 
in synapses can decrease alcohol intake [17]. However, serotonin would not play a role in 
positive or negative reinforcement but rather in the ability to control impulsions or 
compulsions. GABA is the major inhibitory neurotransmitter in the brain and acts via two 
receptors called GABAA and GABAB. Conversely, glutamate is the major excitatory 
neurotransmitter in the brain and exerts its effects via several receptor subtypes, including the 
N-methyl-D-aspartate receptor (NMDA). 
A short term alcohol exposure increases inhibitory neurotransmission and inhibits 
excitatory neurotransmission 
A short term alcohol exposure increases GABA activity in the brain through two 
mechanisms: it acts on the pre-synaptic neuron to increase GABA release, and acts on the 
postsynaptic neuron to facilitate the GABAA receptor activity. In contrast to its effects on 
GABA, alcohol inhibits glutamate activity in the brain. A short-term alcohol exposure leads 
therefore to a state of sedation and decreased anxiety [18]. 
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Long-term alcohol exposure leads to compensatory neuroadaptation that induces decrease 
in inhibitory neurotransmission and increase in excitatory neurotransmission. 
Following chronic exposure, evidence suggests that the brain restores equilibrium by 
decreasing GABAA function and increasing excitatory activity of glutamate. This 
compensatory changes participate in the development of sensitization (i.e. an increase in the 
reinforcement value of alcohol following repeated exposures), tolerance (i.e. a decrease in the 
reinforcing efficacy of alcohol following repeated exposures, which means that a person must 
drink progressively more alcohol to obtain a given effect on brain function), alcohol 
withdrawal syndrome (see section 1.2.3) and dependence [14]. 
Alcohol addiction also involves negative reinforcement driven by activation of the stress 
system  
The transition to dependence involves the dysregulation not only of the brain reward 
circuit (mainly involved in the positive reinforcement) but also of circuit that mediates 
behavioral response to stressors. The brain stress system involves the corticotropin-releasing 
factor (CRF) which is produced by the hypothalamus (and by extrahypothalamic brain areas) 
and activates the hypothalamic-pituitary-adrenal (HPA) axis that results in the release of 
stress hormone cortisol. CRF release is activated under conditions of stress as well as during 
chronic administration of alcohol and during acute withdrawal. The dysregulation of the brain 
CRF system could contribute to the negative emotional state (e.g. anxiety) and the alcohol-
seeking behavior that fosters increased alcohol consumption and could also participate to 
relapse. The development of aversive emotional states that drive negative reinforcement has 
been defined as the “dark side” of addiction by Koob G. and Le Moal M. [19]. This negative 
reinforcement process also involves the dysregulation of other systems such as dynorphin, 
norepinephrine and neuropeptide Y. 
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1.2.2.2 Psychological models 
Neurobiological models of addiction developed in animals cannot be directly 
transposed to the humans. The behavioral expression of addiction measured in animals cannot 
exactly mimic the human behavior and we need to rely on psychological models to develop 
appropriate testing of hypothesis. 
Alcohol-dependent subjects are characterized by an intense desire to drink alcohol 
referred as craving [20]. Craving may occur in situations where the dependent subject 
cannot obtain a drink, or when he is exposed to situations that evoke drinking (cues). The 
latter dimension may be related to positive reinforcement. Craving is also frequently linked to 
negative emotional states including anxiety and depression and correlations have frequently 
been observed between these dimensions in alcohol-dependent subjects [21, 22]. This may be 
related to the negative reinforcement which is a major process involved in drinking tendency 
in chronic alcoholism. 
In psychology, the dual process model of addiction recently developed by Wiers and 
colleagues in a cognitive and neuroscience perspective proposes that addictive behaviors 
develop as a result of an imbalance between two systems in the brain: an impulsive system 
which includes automatic responses to emotional and motivational stimuli, and a regulatory 
executive system which includes controlled processes [23]. Briefly, the executive system 
regulates the ability to inhibit a motivational process (e.g. alcohol drinking). Evidence 
indicates that the long-term effects of heavy alcohol consumption sensitize the appetitive 
motivational processes and negatively affect the controlled regulatory processes, with 
impairment of cognitive and executive abilities. In other words, chronic alcohol consumption 
strengthens the motivational and emotional processes and weakens the controlled executive 
system. This results in an increased alcohol use. The loss of control of alcohol drinking 
behavior, that may result from this imbalance, is an important criterion for alcohol 
dependence diagnosis and is referred as “failure of efforts to cut down alcohol drinking due to 
the inability to control alcohol use” in the DSM-IV. 
In order to evaluate both automatic and controlled processes, psychological questionnaires 
that test mood, emotions and motivation and neuropsychological tests that evaluate control 
processes were used in our studies: 
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 Emotional states: depression, anxiety 
 Motivational state: alcohol craving 
 Cognitive functions: selective attention, working memory 
 Executive functions: inhibition, flexibility and decision making  
A previous study [22] has analyzed the effect of a 3-week alcohol withdrawal on these 
functions and has shown that emotional state and alcohol craving decreased significantly 
during withdrawal but remained higher than in a control group at the end of withdrawal. This 
study also showed that executive functions were impaired in alcoholic subjects at the onset of 
withdrawal and no improvement was observed at the end of withdrawal. These remaining 
deficits likely contribute to the weak ability of alcohol-dependent subject to resist drinking, 
and thus increase the probability of relapse. However, another study [24] showed that 
executive functions improve significantly after 6 months of abstinence. 
One aim of this thesis is to investigate whether the psychological variables described 
above are related to biological parameters (inflammation, intestinal permeability and gut 
microbiota) and whether they progress in parallel during alcohol withdrawal.  
 
 
1.2.3 Alcohol withdrawal syndrome 
1.2.3.1 Clinical symptoms of alcohol withdrawal 
Alcohol withdrawal syndrome consists of the physiological and psychological effects 
that occur if a chronic drinker suddenly abstains from alcohol use [20]. It results in 
hyperactivity of the glutamate system and varies significantly among alcoholics in both its 
clinical manifestations and its severity. Alcohol withdrawal symptoms generally appear 
within hours after the last drink and are the following: hand tremors, agitation, higher heart 
rate, elevated blood pressure, headache, sweating, nausea, vomiting, loss of appetite, craving 
for alcohol, anxiety, irritability, insomnia, and also most severe manifestations such as 
hallucinations (auditory or visual), seizures and delirium tremens. Even without treatment, 
most of these manifestations will usually resolve several hours to several days after their 
appearance [25]. Also, it has been shown that repeated cycles of chronic alcohol exposure and 
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withdrawal may have progressively important consequences on the brain, exacerbate the 
psychological and physiological symptoms of withdrawal and increase the incidence and 
severity of seizures, and finally render the dependent subjects more vulnerable to relapse. This 
process referred as “kindling” is due to increased neuronal hyperexcitability and 
excitotoxicity following repeated withdrawal experiences [26, 27].  
 
1.2.3.2 Neurochemical mechanisms underlying alcohol withdrawal 
The first neurochemical explanations for withdrawal from alcohol were proposed by 
Himmelsbach in 1941 and involved mainly the major inhibitory neurotransmitter GABA, the 
major excitatory neurotransmitter glutamate and their receptors GABAA and NMDA, 
respectively [28]. The Himmelsbach’s concept can be expressed as a seesaw (figure 1-7). 
Before alcohol exposure, the brain is in a balanced state. When a person consumes alcohol, its 
acute effect is to unbalance the neurochemical equilibrium of the brain leading to inhibition 
(e.g. sedation and incoordination). This inhibition is induced by the potentiation of GABA 
actions and by the inhibition of NMDA receptors. If the alcohol exposure continues over a 
long period of time, an opposing chemical adaptation (neuroadaptation) occurs within the 
brain, that tends to restore the equilibrium. This neuroadaptation consists in reducing the 
number of GABAA receptors on neurons’ surface (down regulation) and producing more 
NMDA receptors (up regulation). In other words, the brain develops tolerance and 
dependence for alcohol. When alcohol exposure ceases, the brain neurochemistry is now 
unbalanced thereby tilting the seesaw in the opposite direction, with an increased action of the 
excitatory neurotransmitter glutamate. The result is the development of a withdrawal 
syndrome that includes signs and symptoms of hyperactivation that were described above. 
Moreover, it has been shown that during alcohol withdrawal, dopamine and serotonin release 
is reduced in the nucleus accumbens [29]. This could result in the development of depression, 
anxiety and emotional discomfort which are important psychological aspects of the 
withdrawal syndrome. 
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Figure 1-7: The Himmelsbach model for dependence and withdrawal, adapted from Littleton J., Alcohol Health 
& Research World, 1998 [28]. 
 
1.2.3.3 Treatment of withdrawal symptoms 
The most common pharmacological treatment given during detoxification is a 
benzodiazepine that acts, like alcohol, to enhance activation of GABAA receptors [30, 31]. 
The main goal of this treatment is to restore the balance between excitation and inhibition in 
neurons in order to prevent the life-threatening onset of major withdrawal signs such as 
seizures and delirium tremens. However, benzodiazepines should be carefully used as there is 
a risk of dependence. Also, it is possible that other harmful sequelae of withdrawal (e.g. nerve 
cell damage [32]) exist that are not controlled by current treatments.  
Alcoholics are often deficient in thiamine (vitamin B1) due to insufficient nutritional 
intake and reduced intestinal absorption [33].  Thiamine is an essential cofactor required for 
the functioning of several enzymes involved in carbohydrate metabolism that leads to the 
production of various molecules such as nicotinamine adenine dinucleotide phosphate 
(NADH), neurotransmitters (glutamate, GABA), nucleic acids, antioxidant (glutathione), 
myelin, and adenosine triphosphate (ATP) that provides energy to the cells [34]. Cells of the 
nervous central system are particularly sensitive to thiamine deficiency. Decrease in thiamine-
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using enzymes activity leads to brain lesions due to oxidative stress, cell damage and cell 
death (i.e necrosis) induced by lack of ATP.  These brain lesions in alcoholics are associated 
with a neurological disorder known as Wernicke-Korsakoff syndrome that consists in mental 
confusion, impaired ability to coordinate movements and cognitive deficits. As described 
earlier, alcohol withdrawal is associated with a hyperexcitability of neurones which therefore 
require more energy. Accordingly, thiamine is administrated to patients who start a 
detoxification program in order to limit the development of neurological disorders.  
 
 
1.2.4 Treatment of alcohol dependence 
Alcohol dependence is a chronic relapsing disease. Without pharmacological adjunct 
to psychosocial therapy, up to 70% of patients resume drinking within one year [35]. 
Although abstinence remains the ultimate goal in treating alcohol dependent subjects, 
pharmacological agents have been developed in order to reduce the frequency of heavy 
drinking, the craving and improve abstinence rate and quality of life. Most of these agents 
target the neurotransmitters that mediate alcohol reinforcement effects and to date, two 
medications have been approved by the Food and Drug Administration (FDA): naltrexone and 
acamprosate. A third FDA approved agent, disulfiram (Antabuse®) targets alcohol 
metabolism. 
Naltrexone is a µ-opioids receptor antagonist. In two meta-analytic studies [36, 37], 
naltrexone has been demonstrated to be efficacious at reducing the risk of relapse among 
recently abstinent alcohol-dependent individuals. However, the naltrexone’s effect size is 
small, with a corresponding number needed to treat
3
 of 7. Due to the small effect size and the 
bad pill-taking compliance (due to adverse effects such as nausea), some studies have failed to 
demonstrated naltrexone’s efficacy in treating alcohol-dependence [38]. A recent study 
including 1383 patients have shown that naltrexone associated with medication management 
to enhance compliance reduced the risk of a heavy drinking day compared with placebo [39]. 
                                                 
3
 Here, the number needed to treat is the number of individuals who need to be treated to prevent relapse in a 
single individual. 
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However, to date, there is insufficient data to ascertain naltrexone’s efficacy over more 
prolonged periods [36]. Nalmefen (Selincro®), another drug targeting opioid receptors has 
recently been recognized in Europe as a treatment for alcohol-dependence allowing a 
reduction of alcohol consumption rather than increased abstinence rates [40]. It also appears 
as a new strategy for the treatment of alcohol-dependence.    
Acamprosate is an NMDA glutamate receptor antagonist. European studies have 
clearly demonstrated efficacy for acamprosate as a treatment for alcohol dependence although 
its therapeutic effect size is small, with a number needed to treat of 8 [41]. In contrast, to date, 
studies in the U.S. have been unable to find any therapeutic benefit of acamprosate compared 
to placebo among a heterogeneous group of alcohol-dependent individuals [39]. The reason 
for this discrepancy between the results of U.S. and European studies has not been 
established. However, in 2013, a new double-blind, placebo-controlled randomized trial 
conducted in Germany in 426 patients found that neither acamprosate nor naltrexone 
treatment for 3 months supplied any additional benefit compared with placebo [42]. 
Serotonin reuptake inhibitors (SSRIs) have been shown to decrease ethanol 
consumption in animals [43]. Although the preclinical results were promising, there is, at 
present, little support for the proposal that SSRIs are efficacious in the treatment of alcohol 
dependent individuals [44]. Moreover, there is no current evidence to recommend SSRIs over 
placebo for the treatment of depressed alcoholics [45]. Regarding dopamine system, neither 
dopamine receptor antagonists nor agonists have been demonstrated to be efficacious in the 
treatment of alcohol dependence [44]. 
Baclofen is a GABAB receptor agonist. Evidence for the efficacy of baclofen for 
alcohol dependence is largely based on three placebo-controlled, double-blind trials [46–48]. 
In two studies conducted in Italy [46, 47], compared to placebo, baclofen was shown to 
promote abstinence and reduce alcohol-associated craving and anxiety. However, the third 
American study [48] did not find evidence that baclofen is superior to placebo in the treatment 
of alcohol dependence. Moreover, questions still remain about optimal dosing and duration. 
To date, there is not enough evidence to support the use of baclofen as first line medication 
but it may be considered in patients with liver cirrhosis when other medications are 
contraindicated [49]. 
Disulfiram has been used for treating alcohol dependence since the 1940s. It is an 
aversive agent which inhibits the enzyme aldehyde dehydrogenase and prevents the 
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metabolism of acetaldehyde, the primary alcohol metabolite. The accumulation of 
acetaldehyde in blood causes unpleasant effects such as headache, sweating, nausea, 
palpitation, lowered blood pressure. These symptoms discourage further alcohol consumption. 
However, serious side effects have also been reported, including hepatotoxicity and psychotic 
reactions. Disulfiram has no effect on craving for alcohol. Therefore the efficacy is limited to 
patients who are highly compliant and receive their medication under supervision [44]. 
Given the complex neuroadaptive changes that occur during chronic alcohol exposure 
and withdrawal, it is no surprising that no single pharmacological agent has proven to be fully 
successful in the treatment of alcoholism. Most of the studies clearly showed that agents 
targeting neurotransmitters have no effect or small effect in the improvement of clinical 
outcomes. Moreover, among mental disorders, alcohol abuse and dependence had the largest 
treatment gap
4
, with a mean of  92% in Europe, indicating that less than 10% of the patients 
are actually treated [50] (figure 1-8). This treatment gap could be explained by the denial 
associated to the disease, the social stigma but also by the lack of efficiency of current 
pharmacological treatments. 
Altogether, these observations support the idea that up to now, all medications 
targeting the brain failed to treat in a convincing manner this important population of patients. 
The aim of the thesis is to displace the focus from the brain to peripheral organs, such as the 
gut, in order to find new potential targets in the treatment of alcohol dependence.  
 
                                                 
4
 The treatment gap represents the absolute difference between the true prevalence of a disorder and the treated 
proportion of individuals affected by the disorder. Alternatively, the treatment gap may be expressed as the 
percentage of individuals who require care but do not receive treatment. 
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Figure 1-8: Treatment gap in mental disorders, adapted from Kohn R. et al., Bulletin of the WHO, 2004 [50]. 
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2 ROLE OF THE GUT IN ALCOHOL 
DEPENDENCE 
 
“All diseases begin in the gut” 
Hippocrates (460-370 B.C.) 
2.1 Gut barrier 
 
2.1.1 Physiological, morphological and immunological 
characteristics of the gut barrier 
The intestinal mucosal surface is unique among tissues in that it is constantly in 
contact with a vast, diverse and dynamic microbial community. Therefore, the intestinal cells 
must sense and respond appropriately to this potential immunological challenge of the luminal 
content. In humans, the intestinal epithelium encompasses 200 m
2
 of surface area and the 
most abundant cell is the enterocyte [51]. Enterocytes are linked with their neighboring cells 
thanks to apical intercellular junctional proteins, known as tight junctions (TJs) as well as 
adherens junctions (AJs). TJs are composed by several proteins such as claudins, occludin 
and zonula occludens and regulate the paracellular pathway. Enterocytes, together with the 
junctional complexes, constitute a physical barrier that prevents bacterial penetration while 
allowing nutrient absorption.  
Also, enterocytes produce a variety of antimicrobial substances that kill or inactivate 
microorganisms and maintain homeostasis [52]. These natural “antibiotic” molecules are 
members of diverse families: α- and β-defensins, cathelicidins, lysozyme, phospholipase A2, 
RNAses and C-type lectins such as RegIIIγ in mice (called HIP/HAP in humans) [53]. 
Gut surfaces harbor other less-abundant epithelial cells that limit the penetration of 
bacteria into host tissues: the Goblet cells and the Paneth cells [51] (figure 2-1). Goblet cells 
express proteins (like MUC2) responsible for the secretion of large quantities of mucins 
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which form a protective layer of gel-like mucus over the luminal site of the epithelium [54]. 
In the colon, the mucus is composed by two distinct layers. The outer layer is colonized with 
bacteria whereas the inner layer is resistant to bacterial penetration – likely due to the fact that 
antimicrobial factors secreted by epithelial cells are retained in this inner layer. Paneth cells 
are situated at the base of small intestinal crypts and harbor secretory granules containing 
antimicrobial proteins that are discharged in the gut lumen following bacterial stimuli [52]. 
This type of cell is absent in the colon [55]. 
 
Figure 2-1: Epithelial barrier of the intestine, Gallo R. and Hooper L., Nature Review Immunology, 2012 [53]. 
Also, subepithelial immune cells play an essential role in defending the intestinal 
mucosa against invading bacteria [56] (figure 2-2) . With the help of dendritic cells, B 
Lymphocytes (plasma cells) present in the lamina propria secrete bacteria-specific 
immunoglobulin A (IgA), which are translocated across the epithelium and deposited on the 
apical surface of epithelial cells. IgA are essential in maintaining luminal 
compartmentalization of intestinal bacteria. Other T lymphocytes intercalated between 
intestinal epithelial cells contribute to the restoration of homeostasis following mucosal injury 
by secreting growth factors and pro-inflammatory cytokines. Also, macrophages located in 
the lamina propria can quickly phagocyte and kill invading bacteria that breach the mucosal 
surface. Finally, M cells, which are present in the lymphoid tissue of the small intestine, and 
enteroendocrine cells function as important sensors of intestinal luminal contents [57]. 
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The intestinal immune response towards gut bacteria is regulated by pattern 
recognition receptors (PRRs) which recognize specific molecular pattern of bacteria and other 
microorganisms (called PAMPs). These receptors include Toll-like receptors (TLRs) which 
are transmembrane proteins highly expressed by intestinal epithelial cells and immune cells,  
and nucleotide oligomerization domain-like receptors (NLRs such as NOD1 and NOD2) 
which are expressed in the intracellular cytoplasmic compartment. The stimulation of these 
receptors by bacteria activates a signaling cascade that leads to the synthesis of pro-
inflammatory cytokines, chemokines, and antimicrobial proteins [58, 59].  
 
Figure 2-2: Cells and molecules forming a physical barrier against bacterial invasion, Duerkop BA et al., Cell, 
2009 [51]. 
Several studies [60, 61] suggest that defects leading to reduced antimicrobial proteins 
and/or mucus production are associated with bacterial invasion of the intestinal barrier and 
subsequent inflammation that characterizes inflammatory bowel diseases. Also, the alteration 
of enterocytes and the disruption of TJs contribute to the increase in intestinal paracellular 
permeability, also referred as “leaky gut” which enables the translocation of bacterial toxins 
from the lumen to the systemic circulation.  
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2.1.2 Methods to assess intestinal permeability 
The evaluation of gut barrier alterations includes histological analysis of TJs structures 
from intestinal biopsy (invasive method) or the assessment of blood endotoxins. However, 
noninvasive intestinal permeability test in vivo has been widely used to assess the intestinal 
barrier function in health and diseases conditions.  
The principle of the intestinal permeability test is to measure urinary excretion of orally 
administrated tests substances. The “ideal” test substance must have specific physicochemical 
properties such as water solubility, non-toxic, not metabolized before, during and after 
permeating the intestine, nondegradable by intestinal bacteria, not naturally present in urines 
[62]. The most common test probes are the following: 
 Polyethylene glycol-400 (PEG-400) 
 Monosaccharides: mannitol, L-rhamnose 
 Disaccharides: lactulose, sucrose 
 Radioactive probes: 51Cr-EDTA and 99mTc-DTPA 
Each probe has its own advantages and disadvantages. Despite its radioactivity, 
51
Cr-
EDTA presents the closest characteristic of an ideal probe.  Indeed, very low 
51
Cr-EDTA 
permeability has been reported through intact intestinal mucosa [63]. However, the absorption 
of the probe is increased following damage of intercellular junctions, which regulate the 
paracellular pathway. Moreover, 
51
Cr-EDTA has been proved to be useful for the assessment 
of colonic permeability as this probe is not degraded by enteric bacteria [64]. The other tests 
probes have characteristics that prevented their use in our study. For instance, PEG-400 
demonstrates a considerable physiologic absorption, probably due to its lipophilic properties 
which allows transcellular permeation. Sugars could be produced endogenously, have osmotic 
action, and more importantly, can be degraded by colonic bacteria [62, 63].  
In our study, a Nutridrink
5
 solution containing 50 µCi of 
51
Cr-EDTA was drunk by the 
subjects after an overnight fast and bladder emptying. Urines were collected during 24 hours. 
Normal food and fluid intake was allowed during the test day. Radioactivity was detected in 
                                                 
5
 The permeation rate of the probe can be influenced by the osmolarity of the solution. The study by Peeters et 
al. [65] reported the lowest interindividual variations with the Nutridrink, compared with other solutions. 
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urines by using a gamma-counter and results were expressed as the percentage of ingested 
dose found in urines. 
Bjarnason et al. reported an increased in intestinal permeability in alcoholics using 
51
Cr-
EDTA, which returns to normal after at least 2 weeks of abstinence [66]. They also 
demonstrated increased gut permeability in inflammatory bowel diseases [67] and coeliac 
disease [68]. Interestingly, in 1987, Wood et al. [69] reported abnormal gut permeability in 
psychiatric patients, which could not be attributed to established bowel disease. 
 
2.1.3 Effect of ethanol and its metabolites on the gut barrier 
function 
Few studies have investigated the effect of ethanol intake on intestinal barrier function 
in humans. Some studies have shown that acute alcohol intake induces an increase in 
intestinal permeability in non-alcoholic healthy subjects [70–72], while the majority of data 
focuses on the effect of chronic alcohol abuse and report an increased in intestinal 
permeability in alcoholic subjects [66, 71–74]. The subjects taken into consideration have 
been often diagnosed with hepatic damage. However, these studies have mainly investigated 
the effect of ethanol on small intestinal permeability. Data on the effects of ethanol on colonic 
barrier function are lacking. Only one animal study has shown that oral administration of 
ethanol in rats resulted in increased colon permeability [75]. Yet, although ethanol is mainly 
absorbed in the small intestine, ethanol in excess and its metabolites can also reach the colon 
and their effect on the colonic permeability deserve to be tested. 
Mechanisms by which ethanol and its metabolites alter the intestinal barrier 
Several direct and indirect mechanisms underlying the ethanol-induced barrier 
dysfunction have been proposed.  
Ethanol and its metabolite acetaldehyde can induce direct epithelial cell damages, with 
ultrastructural and histological changes in intestinal mucosa including enterocyte alterations, 
decrease in mucosal surface area, inflammatory cell infiltration, decreased number of mucin-
secreting goblet cells [76–78]. In vitro studies using Caco-2 cell monolayer (human epithelial 
colorectal adenocarcinoma cells) have highlighted several mechanisms by which ethanol and 
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acetaldehyde disrupt TJs, destabilize cytoskeleton and subsequently form large gaps between 
adjacent cells. These include myosin-light chain kinase (MLCK) activation [79], NF-κB 
activation [80], up-regulation of intestinal circadian clock gene expression [81], decrease ZO-
1 protein expression through ethanol-induced miR-212 overexpression [82]. Oxidative stress 
has also been involved in gut barrier alteration. Indeed, ethanol induces increased paracellular 
permeability of Caco-2 cells via inducible nitric oxide synthase (iNOS)-mediated generation 
of reactive oxygen species (ROS), resulting in oxidation of microtubule cytoskeleton and TJs 
disassembly [83, 84]. The involvement of iNOS has been confirmed in vivo where the 
inhibition of this enzyme attenuated the ethanol-induced gut leakiness and the associated 
endotoxemia in rats [85]. Evidence revealed that acetaldehyde has higher potency than 
ethanol to induce intestinal barrier dysfunction [86]. Acetaldehyde reduces the activity of 
protein tyrosine phosphatase that results in increased phosphorylation of TJs and AJs proteins 
and loss of interaction between these junctional complexes [87, 88]. It also induces 
hyperacetylation of microtubular protein [89]. 
Also, a recent study in mice [90] has shown that chronic alcohol exposure suppresses 
gene and protein expression of RegIIIg, an antimicrobial peptide which might contribute to 
alteration of gut barrier integrity and microbial changes. Pro-inflammatory cytokines, 
especially TNFα and IFNγ, has been demonstrated to regulate TJs and cause disruption of the 
gut barrier [91]. Finally, the intestinal microbiota can also modulate the gut barrier integrity. 
Indeed, animal studies have shown that amelioration of ethanol-induced barrier dysfunction 
can be achieved using antibiotics [75], dietary fibers [92] or live bacteria (probiotics) [93]. 
Therefore, ethanol-induced gut microbiota alterations [94] could be considered an indirect 
mechanism by which ethanol can alter the gut barrier. This hypothesis has never been tested 
in human alcoholics and is one of the main topics of the Chapter 3 of this PhD work, in which 
we have measured in parallel the intestinal permeability and the gut microbiota of alcohol-
dependent subjects.  
Overall, this alcohol-induced increased intestinal permeability enables the 
translocation of luminal antigens, mainly bacterial endotoxins such as lipopolysaccharides 
(LPS) into the portal circulation. This can have drastic effect on the liver as bacterial toxins 
can activate hepatocytes and Kupffer’s cells (liver macrophages), which subsequently release 
pro-inflammatory cytokines, that results in hepatocellular damage, and consequently, 
alcoholic liver disease (ALD) [95].  
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2.2 Gut microbiota 
 
2.2.1 Gut microbiota composition 
The human gastrointestinal tract is the natural habitat for 10
14
 microorganisms [96], 
which represent 10 times the number of human cells in the body. This large and dynamic 
bacterial community is called the “gut microbiota” and has an approximate mass of 2 kg. The 
microbiome, that refers to the collective genomes of all members of the gut microbiota, 
contains 150 times more genes than the human genome [97]. The gut microbiota can be 
considered an organ within an organ and maintain a symbiotic relationship with the host. The 
human host provides a nutrient-rich environment and the microbiota provides indispensable 
functions that humans cannot exert themselves. Indeed, intestinal bacteria have long been 
appreciated for the benefits they provide to the host: they supply essential nutrients such as 
vitamins, metabolize indigestible compounds, defend against pathogen colonization. 
Moreover, they contribute to the development of intestinal architecture and to the functioning 
of immune system. Evidences now support that certain aspects of health and disease may 
depend on the status of the microbiota [98].  
The gut microbial communities of an individual can be represented as a phylogenetic 
tree with several hierarchical levels (figure 2-3). The higher taxonomic level is the “phylum”. 
Firmicutes is the major Gram positive phylum and Bacteroidetes is the major Gram negative 
phylum. Together they constitute over 90% of the total gut bacteria. The remaining bacteria, 
accounting for less than 10% of the total population, belong to the Proteobacteria, 
Fusobacteria, Actinobacteria, Verrucomicrobia, Spirochaetes, and Cyanobacteria [51]. Then, 
each phylum is divided successively into class, order, family, genus, species, and strains. It is 
generally accepted that, in adult, the microbiota consists up to 500-1000 different species 
[99].  Arumugam et al. [100] has identified 3 clusters called “enterotypes” (enriched in 
Bacteroides, Prevotella, or Ruminococcus) in the human gut microbiome that vary in species 
and functional composition. They suggest that enterotypes are driven by groups of species 
that together contribute to the preferred community compositions. However, this notion of 
“enterotypes” is currently under debate [101, 102], and diet appears to be an important factor 
that mediates variations in bacterial compositions [103]. 
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Figure 2-3: Phylogenetic tree based on the 16S rRNA bacterial sequences, representing colonic bacterial 
diversity of an individual, adapted from Ley RE et al., Cell 2006 [96]. 
The scarcity of bacteria in the upper tract seems to be due to the composition of the 
luminal content (acids, bile, and pancreatic secretions) which kills most ingested 
microorganisms, and because of the phasic propulsive motor activity toward the ileal 
extremity. By contrast, the large intestine contains the core of the microbial ecosystem with 
high densities of living bacteria (figure 2-4) [104]. 
 
Figure 2-4: Composition and luminal concentrations of dominant microbial species in various regions of the 
gastrointestinal tract, Sartor RB., Gastroenterology, 2008 [105]. 
A large number of factors can influence the gut microbiota composition, from birth to 
old age (figure 2-5). At birth, the method of delivery (vaginal vs. Cesarian section) already 
shapes the microbial communities of babies [106, 107]. Then, other environmental factors 
such as diet, life-style, antibiotic use, stress, injury can modulate the microbiota. Among 
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dietary factors, probiotics and prebiotics are interesting nutritional tools that can positively 
modified the microbial composition and/or activity.  
Probiotics are live microorganisms, which when administrated in adequate amounts 
confer a health benefit on the host (definition of the World Health Organization / Food and 
Agricultural Organization of the United Nation, 2001). Most of probiotics are bacteria 
(mainly Lactobacillus, Bifidobacterium) or yeasts (Saccharomyces). The probiotics can 
introduce missing bacteria or supplement present bacteria with known beneficial functions for 
the host.  
The concept of prebiotics was introduced for the first time by Gibson and Roberfroid 
in 1995 [108]. A prebiotic is a selectively fermented ingredient that results in specific 
changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring 
benefit(s) upon host health [109]. Unlike probiotics, prebiotics target the microbiota already 
present within the ecosystem. Human enzymes are not able to degrade most of the complex 
carbohydrates. These ingredients can be prebiotics that reach the colon and are fermented by 
commensal bacteria. However, not all undigested carbohydrates are prebiotics. Three criteria 
are required to have prebiotic effect: 1) resistance to gastric acidity, hydrolysis by mammalian 
enzymes and gastrointestinal absorption; 2) fermentation by intestinal microbes; 3) selective 
stimulation of the growth and/or activity of intestinal bacteria associated with health and 
wellbeing [110]. The most widely accepted prebiotics are inulin-type fructans such as fructo-
oligosaccharide (FOS) and galactooligosaccharide (GOS). Although promise does exist with 
several other dietary carbohydrates, well conducted human trials are required to confirm their 
prebiotic effects. 
Disruption of the gut microbiota, known as dysbiosis, can lead to a variety of diseases 
including inflammatory bowel diseases, colon cancer, irritable bowel disease, obesity and 
metabolic syndrome, nonalcoholic fatty liver diseases, auto-immune diseases and finally 
mood and behavior changes [98]. The relationship between gut microbiota alteration and 
psychological changes in alcohol-dependent subjects is one of the main topics of the Chapter 
3 of this PhD work.  
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Figure 2-5: The gut microbiota in development and disease,  Nicholson et al., Sciences, 2012 [98]. 
 
2.2.2 Gut microbiota activity and functionality 
The intestinal microbiota has a huge metabolic capacity which complements our 
physiology with functions that are indispensable for human life. For example, the intestinal 
microbiota is responsible for host metabolism regulation and energy harvest from non-
digested nutrients. It is involved in the synthesis of vitamin K and in the metabolism of bile 
acids and polyphenols. Moreover, the gut microbiota provides colonization resistance toward 
potential pathogens, provides trophic effects on epithelial cells and stimulates the immune 
function of the host [111]. The human microbiota is characterized by a significant degree of 
functional redundancy, meaning that different bacteria can perform similar functions and 
metabolize the same substrates [96]. This functional redundancy confers stability. Therefore, 
not only the composition but also the functional capacity of the intestinal microbiota is highly 
important regarding clinical endpoints. Metagenomic studies have applied next generation 
pyrosequencing techniques to assess the functional capacity of the gut microbiota by detecting 
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the bacterial genes [112]. However, it is important to note that the detection of genes does not 
mean that they are functionally relevant. Therefore, to gain better insight into the activity and 
functionality of the intestinal microbiota, other approaches must be considered such as 
metabolomics [113]. Metabolomics can be applied to different type of samples such as feces, 
breath, urines and plasma. Certain breath, blood and urine metabolites result from co-
metabolism by the host and the intestinal microbiota, whereas large amount of fecal 
metabolites are primarily derived from the action of the intestinal bacteria. In addition, fecal 
metabolic profiling appears to be a potential useful approach to understand microbiota-gut 
barrier interactions.  
In summary, the main functions of the gut microbiota are the following: metabolic, 
trophic, immune and protective. 
 
 
2.2.2.1 Metabolic function 
The colonic microbial fermentation produces various metabolites which type and amount 
depend on the composition of the gut microbiota, on the transit time and on substrates 
available for fermentation. The colonic bacteria can ferment endogenous host-derived 
substrates such as mucus and pancreatic enzymes, as well as dietary components that escape 
digestion in the upper part of the gastrointestinal tract. Basically, two types of bacterial 
fermentation occur in the colon (figure 2-6) [113]: 
- The carbohydrate fermentation which occurs mainly in the proximal part of the 
colon. The metabolic endpoint is the generation of short-chain fatty acids.  
- The protein fermentation of dietary and endogenous peptides (from mucus and 
pancreatic enzymes), which takes place in the distal colon, can generate compounds 
with toxic properties. 
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Figure 2-6: Different metabolites produced from colonic fermentation of carbohydrates and proteins, Hamer 
HM et al., AJP-Gastrointestinal and liver physiology, 2012 [113]. 
Although they received less attention in the literature, the gut microbiota is also able to 
transform lipid compounds from the diet, such as cholesterol and polyunsaturated fatty acids 
(PUFAs). The PUFA-derived metabolites like conjugated linoleic acids or conjugated 
linolenic acids could have beneficial effects on the host and should be taken into account in 
the next future [114, 115].  
 
2.2.2.1.1 Saccharolytic microbial fermentation 
The majority of intestinal bacteria use the glycolytic pathway to derive energy from 
carbohydrates that have not been digested in the upper part of the intestine [116] such as 
inulin, oligofructose, oat bran, resistant starches, cellulose, hemicellulose, pectins, gums and 
other unabsorbed sugars. These carbohydrates are initially converted to pyruvate and acetyl-
CoA (figure 2.7). Pyruvate is then transformed into lactate, succinate and propionate while 
acetyl-CoA is converted into acetate, butyrate and ethanol. Acetate, propionate and butyrate 
are the main short-chain fatty acids (SCFAs) found in fecal samples. SCFAs, particularly 
butyrate, have been shown to have beneficial impacts for health: they provide energy for 
colonocytes, decrease luminal pH to inhibit pathogen growth, improve ions absorption 
(calcium, magnesium, iron), reinforce various components of the colonic defense barrier, have 
anti-inflammatory properties, improve insulin sensitivity and promote satiety [117, 118]. 
After carbohydrate fermentation, some intestinal bacteria which possess the enzymes 
aldehyde dehydrogenase (ALDH) and alcohol dehydrogenase (ADH) can catalyze the 
reduction of acetate to acetaldehyde and then to ethanol [116] (figure 2-7). These bacteria are 
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called ethanol-producing bacteria. Ethanol found in the gut can therefore have two origins: 
exogenous (alcohol consumption) and endogenous (produced by bacterial enzymes). 
 
Figure 2-7 : Simplified diagram of carbohydrate fermentation in the large intestine, adapted from Macfarlane S. 
and Macfarlane GT, 2003 [116]. The SCFAs predominantly found in colon appear in blue. 
  
2.2.2.1.2 Proteolytic microbial fermentation 
Although the carbohydrate fermentation has shown to be beneficial for the host, the 
proteolytic fermentation results in the production of metabolites that could be detrimental for 
the host’s health and that have been implicated in the etiology of colorectal cancer and 
ulcerative colitis [119]. Proteins and peptides that enter the large intestinal can have 
exogenous (diet) or endogenous (pancreatic enzymes, host tissues) origin and are the target of 
various proteases and peptidases [120]. The resulting short peptides and amino acids then 
become available for fermentation by the intestinal bacteria. The fermentation of branched-
chain amino acids (BCAAs – valine, isoleucine and leucine) leads to the production of 
branched-chain fatty acids (BCFAs) such as 2-methyl propanoic acid, 2-methyl butanoic acid 
and 3-methyl butanoic acid. The bacterial degradation of aromatic amino acids tyrosine and 
tryptophan results in the production of phenolic and indole compounds, respectively (figure 2-
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8). The end-products of tyrosine metabolism include mainly phenol and 4-methyl phenol (also 
called p-cresol) while tryptophan degradation generates indole and 3-methyl indole (also 
called skatole). Fermentation of sulfur amino acids (methionine, cysteine, taurine) by sulfate-
reducing bacteria results in the production of hydrogen sulfide (H2S). SCFAs can also arise 
from protein fermentation but in small amount. 
 
Figure 2-8: Degradation pathway of the aromatic amino acids tyrosine and tryptophane, adapted from Windey 
K. et al., 2012 [119]. Metabolites detected in the study described in chapter 3 are circled.  
Phenolic and sulfur-containing compounds are potentially toxic. For instance, phenols 
are believed to act as co-carcinogens [121]. Moreover, two independent studies [122, 123] 
have shown that phenol exposure decreases the transepithelial electric resistance in a dose-
dependent manner,  in parallel with an increase in the paracellular flux of mannitol or dextran-
FITC in intestinal epithelial cells culture, reflecting a general increase in epithelial 
permeability. The change in paracellular permeability observed after phenol treatment 
correlate with the delocalization of TJs claudin-1 and ZO-1 from intercellular junction to 
cytosol [122]. By contrast, indole has been shown to reinforce the epithelial intestinal cell 
barrier in vitro [124].  H2S produced by sulfate-reducing bacteria is an extremely toxic agent 
that has been shown to induce genomic DNA damage in colonocytes [125]. 
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It is important to note that BCFAs, phenolic and indoles compounds are not produced 
by human enzymes and are therefore unique colonic bacterial metabolites. Any changes 
observed in these metabolites may therefore result from a change in the gut microbiota 
composition or a change in dietary protein intake. 
 
2.2.2.2 Trophic function 
It has been reported that modulation of gut microbiota by using prebiotics are 
associated with an increased endogenous production of glucagon-like-peptide 2 (GLP-2), 
whose production may improve mucosal barrier function by increasing the rate of crypt cell 
proliferation and villus elongation [126]. Also, SCFAs stimulate epithelial cells proliferation 
and differentiation in the small and large intestine in vivo through mechanisms involving the 
autonomic nervous system [127], the release of growth factors or gastrointestinal peptides like 
gastrin or cholecystokinin [128, 129], or by acting directly on genes that regulate proliferation 
and cell growth [130]. 
 
2.2.2.3 Immune function 
The gastrointestinal tract is the primary site of interaction between the host immune 
system and microorganisms. The intestinal immune system is able to distinguish commensal 
from pathogenic bacteria. On the other hand, intestinal bacteria can also shape and modulate 
the immune responses and these complex interactions play an important role in health and 
diseases [131].  Many examples can illustrate the gut microbiota – immune system 
interactions. For instance, germ-free animals show defects in the development of gut-
associated lymphoid tissues, decreased IgA and antimicrobials production, thinner and less 
cellular lamina propria and are therefore more susceptible to infection [111]. Deficiencies of 
specific immune genes such bacterial flagellin receptor TLR5, inflammasome component 
NLRP3 and NLRP6, or intracellular receptor NOD2 for peptidoglycan recognition are 
associated with gut dysbiosis [132–135]. The bacterium Faecalibacterium prausnitzii exhibits 
anti-inflammatory properties by increasing the production of IL-10 by peripheral 
mononuclear cells, reducing TNFα production in the colon and improving intestinal disease in 
mice [136]. Also, it has recently been shown that Crohn’s disease and ulcerative colitis 
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patients have a specific reduction in this gut bacterium [136, 137]. F. prausnitzii can also 
exhibit anti-inflammatory action via the production of butyrate which, apart from being an 
important energy source for the colonocytes, can exert direct immune-modulatory effects 
through inhibition of NF-κB, inhibition of the IFN-γ production and signaling and up-
regulation of the peroxisome proliferator-activated receptor-γ (PPARγ) [117]. Several clinical 
studies suggest that the luminal administration of butyrate improve inflammation and 
symptoms in active ulcerative colitis patients [138–140]. Finally, butyrate as well as other 
SCFAs, are the ligands of G-protein-coupled receptors, GPR41 and GPR43 expressed in 
immune cells and in colonic mucosa. Activation of these receptors is required to induce an 
appropriate immune response during immunological challenges [141].   
 
2.2.2.4 Involvement in the barrier function 
The bacteria inhabiting the gut participated to the intestinal “barrier effect” through 
several mechanisms [104]. Bacteria compete for attachment sites in the brush border of 
intestinal epithelial cells and non-pathogenic adherent bacteria therefore prevent the 
attachment of pathogenic and enteroinvasive bacteria. Bacteria also compete for nutrient 
availability and produce antimicrobial substances which inhibit the growth of their 
competitors. SCFAs also play a role in the regulation of gut barrier function. Indeed, in vitro 
studies have shown that SCFAs up-regulate the expression of antimicrobial peptides in 
different colon epithelial cell lines [142]. Moreover, propionate and butyrate have been shown 
to increase the expression of MUC2 gene which encodes the most important mucin of the 
intestinal mucus layer [143]. The protective effect of butyrate on intestinal permeability seems 
to occur at low concentration (up to 2mM) [144, 145] while at higher concentrations (8mM), 
butyrate increased the permeability of Caco-2 cell line [146]. 
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2.2.3 Techniques used to characterize the gut microbiota 
composition and functionality  
 
2.2.3.1 Taxonomic analysis 
Until the 1990s, knowledge of the gut microbiota was limited to culture-based 
technique, an approach that has been used since the early 20
th
 century. However, this 
approach left substantial gaps in the catalog of intestinal bacterial species because anaerobic 
(uncultivable) bacteria outnumber aerobic bacteria by a factor of 100-1000 [104].  The 
development of culture-independent techniques has revolutionized our understanding and 
identifying of microbial communities and revealed their complexity. Most of these new 
techniques are based on sequence analysis of the 16S ribosomal RNA gene (16S rRNA gene 
also called 16S rDNA). Basically, these techniques bring information about 1) the microbial 
diversity of the gut microbiota, 2) the qualitative and quantitative measure of bacterial 
species, 3) the changes in the gut microbiota in relation to disease [147].  
The ribosome is a complex molecular machine indispensable for messenger RNA 
(mRNA) reading and protein synthesis (translation). Ribosome consists of two major 
components, a small subunit and a large subunit. Each subunit is composed of one or more 
ribosomal RNA (rRNA) molecules as well as proteins. Prokaryotes have 70S ribosomes
6
 that 
consist of a small (30S) subunit and a large (50S) subunit. The 30S subunit contains one 16S 
RNA molecule and the 50S subunit contains two RNA molecules, 5S and 23S (figure 2-9). 
16S rRNA genes are highly conserved between bacterial species and are therefore used for 
phylogenetic (bacterial) identification. However, 16S rRNA gene sequences contain 
hypervariable regions that can provide species-specific signature. 
                                                 
6
 The unit of ribosome measurement is the Svedberg unit, a measure of the rate of sedimentation in 
centrifugation. 
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Figure 2-9: Representation of 70S bacterial ribosome, Fraher MH et al., Nature Review Gastroenterology and 
Hepatology, 2012 [147]. 
Culture-independent techniques used to characterize the intestinal microbiota are 
based on the extraction of DNA from a sample containing microbial communities (stool 
sample, colon biopsy) followed by PCR amplification of 16S rRNA gene (figure 2-10). These 
techniques include denaturating gradient gel electrophoresis (DGGE), terminal restriction 
fragment length polymorphism (T-RFLP), fluorescence in situ hybridization (FISH), DNA 
microarray, quantitative polymerase chain reaction (qPCR) and next-generation sequencing of 
the 16S rRNA gene. The two latter techniques have been used in this thesis for the 
characterization of gut microbiota of alcohol-dependent subjects and are therefore described 
below. 
 
Figure 2-10: Overview of the techniques used to characterize the gut microbiota, Fraher MH et al., Nature 
Review Gastroenterology and Hepatology, 2012 [147]. 
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Next-generation sequencing describes sequencing technologies that deliver sequence 
data at fast rate (and quite low cost). “454 Pyrosequencing” was used in this thesis and 
consists of a massive parallel sequencing of 16S rRNA gene amplicons. Briefly, following 
DNA extraction from stool samples, 16S rDNA was amplified by PCR using universal 
oligonucleotides primers
7
 that target highly conserved regions of 16S rDNA. This 
amplification results in the formation of new double-stranded 16S rRNA gene amplicons. 
Amplicons are then fragmented into single-strand and then immobilized on beads. 
Pyrosequencing differs from Sanger sequencing in that pyrophosphate is released when a 
nucleotide is incorporated by the polymerase rather than chain termination with 
dideoxynucleotide. This technique allows phylogenetic identification and identification of 
new unknown bacterial species. However, it requires complex bioinformatics and biostatistics 
analyses. The kind of bacteria present in the sample can be identified by comparison of their 
16S rRNA gene sequences to previously analyzed sequences found in the Ribosomal 
Database Project [148]. By convention, all the 16S rRNA gene sequences are assembled into 
operational taxonomic units (OTUs) based on the percentage of sequences identity. Therefore, 
the percentage of sequence identity defines the taxonomic level. For instance, OTUs 
containing sequences with ≥ 99% identity are considered to be from the same strain; OTUs 
with ≥ 97% identity are considered to be from the same species, while different species from 
the same genus have ≥ 95% identity [149].  
In our study, the pyrosequencing was used in combination with qPCR, also known as 
real-time PCR. qPCR is useful to quantify specific bacteria or a specific group of bacteria 
using appropriate primers. Indeed, primers can be designed to target all bacterial phyla (to 
known the total bacterial load) as well as single species. This technique therefore reliably 
quantifies the amount of DNA present in the sample by reference to a standard curve derived 
from parallel amplification of known target bacteria number. The disadvantage of qPCR is the 
inability to identify novel and unknown species. 
One limitation of all these new technologies is that they map the content of the 
microbes present in the gut without giving any indication on their activity. Therefore, in this 
thesis, metabolomics analyses of stool samples were performed in order to assess the 
                                                 
7
 In this study, 27F and 338R primers were used to amplified 16S rDNA 
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functionality of the gut microbiota. In reality, knowing “who is there” is not sufficient. 
Essential question is “what are these microbes really doing?” [112]. 
 
2.2.3.2 Functional analysis 
Metabolomics aims at the comprehensive and quantitative analysis of wide arrays of 
metabolites in biological samples. The “metabolome” is the complete set of metabolites that 
exists in a biological sample.  There is a strong possibility that changes in metabolite levels 
reflect the functional status of a biological system because alterations of their levels occur 
downstream of DNA, RNA and proteins [150]. Therefore, metabolomics is the endpoint of 
the “omics cascade” and is the closest to phenotype. Moreover, it involves the study of fewer 
molecules than genomics, transcriptomics and proteomics (figure 2-11).  
 
Figure 2-11: The “omics” cascade, from Yoshida M. et al., J Gastroenterol (2012) [150]. 
Large-scale metabolome analysis commonly used analytical platforms such as 
1
H-
nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) [113]. Each of 
these methods has its own merits and demerits and there is no single-instrument platform that 
currently can analyze all metabolites. MS technique requires a prior separation of the 
metabolites present in the sample by using gas chromatography (GC) or liquid 
chromatography (LC). This separation reduced the complexity of the mass spectra due to 
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metabolite separation in a time dimension and delivers additional information on the physico-
chemical properties of the metabolites. MS-based methods are considerably more sensitive 
than NMR spectroscopy. NMR has the potential for high-throughput fingerprint, minimal 
requirement for sample preparation but only metabolites present in high abundance will be 
detected.  
GC-MS method was used in this thesis to characterize the volatile organic compounds 
(VOCs), which are important component of the metabolome, in alcohol-dependent subjects. 
Briefly, the metabolites present in the sample pass through a capillary column in the GC along 
with a carrier gas (e.g. helium gas). As they travel the length of the column, the metabolites 
are separated according to their chemical properties and are eluted from the column at 
different times, called the retention time. Then the metabolites are directed to the MS. A 
conventional MS consists of an ionization source, mass analyzer, and detector. The first step 
is to ionize the molecules which results in the creation of fragments with specific mass and 
charge. Then mass analyzer separates the molecule based on their mass to charge value (m/z 
ratio). The information is then converted into an electric current by electron multiplier 
(detector) for quantification and data analysis [151]. 
Therefore, each metabolite is defined by: 
  Its retention time (RT), measured by GC 
  Its m/z value, which is its molecular mass divided by its charge, measured by MS 
Metabolite identification is achieved by use of existing libraries of chromatographic 
retention times and m/z values such as Automated Mass Spectral Deconvolution and 
Identification System (AMDIS) provided by the US National Institute of Standard and 
Technology (NIST). 
Due to the overwhelming amount of metabolites found in samples, multivariate analysis is 
commonly used in metabolomics studies. The multivariate methods should be selected 
according the aim of the study. However, it is generally appropriate to use several methods to 
maximize the extraction of information. If the aim of the study is sample classification and 
prior information about the sample identity is not known, unsupervised method such as 
principal component analysis (PCA) can be used. PCA attempts to reduce multi-dimensional 
data on a 2D or 3D plot, which can be comprehended by the human mind. The plot is a 
Introduction 
48 
 
Cartesian coordinate system in which the axes (principal components) represent the greatest 
variation of the data. PCA is a good data visualization tool. On the other hand, if the sample 
identity is known and the aim of the study is to discover characteristic biomarkers (e.g. 
comparing samples from healthy and diseased subjects), supervised method such as principal 
least square-discriminant analysis (PLS-DA) can be used. Loading plots derived from PCA or 
PLS-DA are used to determine the metabolites that contribute to the separation of subjects 
into different groups. If the concentration of a particular metabolite is found to be altered 
through multivariate analysis, univariate analysis can be used to test the statistical significance 
of the change. This typically involves the use of Student’s t-test or one-way analysis of 
variance (ANOVA) depending on the number of study groups. 
 
 
2.2.4 Effect of ethanol on gut microbiota composition and 
functionality 
The idea that the gut microbiota could be altered by ethanol consumption came from 
experimental and clinical data showing that the bacterial endotoxin lipopolysaccharide (LPS), 
which derives from the cell wall of Gram negative bacteria inhabiting the gut, is a key factor 
in the development of alcoholic liver disease. Indeed, elevated endotoxin levels and liver 
injury has been reported in rats fed with ethanol [152] and in human alcoholics [74, 153, 154]. 
Lowering serum endotoxins levels by giving antibiotics [155], oats [92] or probiotics 
Lactobacillus [93, 156] attenuates ethanol-induced liver damage in rats. Thus, endotoxin and 
possibly other gut-derived bacterial products are involved in the development of liver disease 
in alcoholics. Three possible mechanisms have been proposed to explain the elevation of 
blood endotoxins in alcoholics: 
 Increased production of endotoxins by abnormal gut microbiota composition or 
bacterial overgrowth [90, 157–159]. 
 Increased permeation of endotoxins through the gut due to gut leakiness. 
 Decreased function of liver Kupffer cells. 
It was therefore pertinent to characterize the composition of gut microbiota and identify 
the alterations that occur in response to chronic alcohol consumption.  The first experimental 
study that investigated whether chronic ethanol consumption affects gut bacterial composition 
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was conducted by Mutlu et al. in 2009 [160]. The authors showed that chronic ethanol 
treatment induced alterations of the mucosa-associated colonic bacterial microbiota in rats. 
The authors hypothesized that dysbiosis could contribute to endotoxemia and liver disease 
both by increasing endotoxins production and by chronic deleterious consequences on gut 
barrier function. Then, another study investigated in more details the change in enteric 
microbiome by using pyrosequencing technology and found reduced abundance of Firmicutes 
and Lactobacillus as well as increased Bacteroidetes in mice continuously fed with ethanol 
[90]. The third and most recent study [161] examining the gut microbiota of alcohol fed mice 
showed that chronic alcohol consumption induced a reduction in Firmicutes (unclassified 
Lachnospiraceae and Ruminococcaceae), Bacteroidetes, and an increase in Proteobacteria, 
Actinobacteria and in Lactobacillus. The authors suggested that alcohol-induced microbial 
shifts could be driven by change in luminal pH. The discrepancies seen across the different 
animal studies could be due to the different time periods of alcohol feeding and methods used. 
However, in animals, the improvement of the alcohol-induced gut microbiota alterations have 
been reported after supplementation with prebiotics [90, 160] and probiotics [160, 161].  
In human, only very few studies tried to relate changes in the gut microbiota with alcohol 
consumption. A study by Kirpich et al. [162] showed, by culturing stool samples, that 
alcoholic patients had decreased numbers of Bifidobacterium, Lactobacillus and Enterococcus 
compared to healthy controls. After 5 days of probiotic supplementation and alcohol 
abstinence, these bacteria returned to numbers seen in controls and improvement of liver 
enzymes was reported. In 2012, Mutlu et al. [94] characterized the gut microbiota 
composition in alcoholics using, non-cultured next generation sequencing technologies and 
showed that only a subgroup of alcoholics had altered colonic microbiota composition. 
Indeed, 31% of subjects were defined as “dysbiotic” and included alcoholics with and without 
liver disease, as well as actively drinking and sober alcoholics. The dysbiosis of colonic 
mucosa consisted mainly in lower abundances of Bacteroidetes and higher ones of 
Proteobacteria. These results suggest that chronic alcohol consumption rather than liver 
disease is the most important event that alters the gut microbiota. Moreover, the effects of 
alcohol abuse were not temporary but rather long-lasting since sober (> 1month) alcoholics 
were also dysbiotic. The authors also suggested that dysbiosis could contribute to gut 
leakiness but this remained speculative since the intestinal permeability has not been 
measured. Finally, although they characterized the microbial composition, the authors did not 
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assess the gut bacterial metabolites which may better differentiate alcoholics from healthy 
subjects and alcoholics with or without liver disease. 
Metabolomics analysis of fecal samples has already been used to study numerous 
digestive tract disorders including colorectal cancers, irritable bowel syndrome and 
inflammatory bowel diseases. However, metabolome analysis of alcohol-dependent subjects 
has never been reported. In 2013, a study by Xie et al [163] characterized the metabolic 
alterations of the whole gastrointestinal tract contents in rats following 8 weeks of chronic 
ethanol consumption. Elevated acetic acid levels were observed in the upper part of intestine 
in ethanol-fed rats, which is presumably due to the oxidation of ethanol to acetaldehyde and 
subsequent oxidation by mucosal or bacterial aldehyde dehydrogenase to acetic acid. 
However, in colon contents, ethanol consumption induced a significant decrease in SCFAs, 
BCAAs and BCFAs. No significant alteration of phenol and derivatives was observed.  The 
authors suggested that the reduced abundance of some metabolites in ethanol-treated rats 
could results from alterations of the gut microbiota. Unfortunately, the composition of gut 
microbiota was not analyzed in this study. 
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2.3 Gut-brain axis 
 
2.3.1 Mechanisms underlying gut to brain interactions 
Recent years have witnessed the rise of the gut microbiota as a major topic in health 
and disease physiology. Very quickly, it has become evident that gut microbiota can influence 
many aspects of physiology and studies revealed how changes in the composition of the gut 
microbiota could contribute to somatic diseases such as obesity, diabetes and inflammatory 
bowel diseases. Accumulating experimental data now indicate that the gut microbiota also 
communicates with the central nervous system (CNS) and thereby influence brain functions 
and behavior [164]. Indeed, four independent groups have shown that germ-free mice 
exhibited reduced anxiety-like behavior [165–167], as well as deficit in cognitive function 
like working memory [168]. Another study showed that antibiotic treatment administrated 
orally induces behavioral changes in mice while intraperitoneal (i.p.) injection did not 
influence behavior [169]. In these experimental studies, change in behavior was accompanied 
by alterations in brain chemistry.  
This chapter highlights the potential mechanisms underlying the communication 
between the gut and the brain (figure 2-12). The experimental approaches used to elucidate 
these mechanisms mainly include the use of germ-free animals (animals microbiologically 
sterile and maintained in sterile environment and thus lacking intestinal microbiota), animals 
with pathogenic bacterial infections and animals exposed to antibiotics or to probiotics agents. 
Importantly, there is growing evidence that this communication is bidirectional: microbiota 
influences CNS function, and the CNS influences gut microbiota composition. 
 
2.3.1.1 Involvement of the hypothalamus-pituitary-adrenal (HPA) axis 
It has been a long time since we know that stress and the associated activation of HPA 
axis can influence the gut microbiota composition [170]. Indeed, animal studies have shown 
that early-life stress [171] as well as chronic stress in adult mice [172] induce changes in gut 
microbiota composition which was associated with increased circulating inflammatory 
cytokines. On the other hand, the microbial content of the gastrointestinal tract can influence 
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the development of the HPA axis, as shown in a study of Sudo et al. where exposure to stress 
induce an exaggerated activation of the HPA axis in germ-free mice, which was fully reversed 
by reconstitution with the probiotic Bifidobacterium infantis [173]. 
It is also important to note that chronic stress disrupts the intestinal barrier [174] and 
increased the circulating levels of bacterial cell wall components [175]. Moreover, the high 
co-morbidity between stress-related psychiatric diseases, such as anxiety and depression, and 
gastrointestinal disorders is further evidence of the importance of this gut-brain interaction in 
pathophysiology [176]. 
 
2.3.1.2 Involvement of the immune system 
Gut microbiota and probiotics agents can have direct effects on the immune system 
[177] and are involved in the maintenance of gut homeostasis [51]. In addition, indirect 
effects of gut bacteria on the immune system can result in alterations of circulating levels of 
pro-inflammatory cytokines that affect the brain functions (see third part of the introduction). 
A study showed, in a rat model of maternal separation, mood disorders associated with 
enhanced peripheral IL-6. Behavioral and immune alterations were normalized by the 
administration of probiotic B. infantis [178].  
 
2.3.1.3 Involvement of the vagal tone 
The vagus nerve is the major nerve of the parasympathetic division of the autonomic 
nervous system and regulates several organ functions such as heart rate and gut motility. 
Approximately 80% of nerve fibers are sensory, conveying information about the state of the 
body’s organs to the CNS [179]. Some studies [180–183] have shown that the vagus nerve is 
involved in the gut-brain communications while others have demonstrated vagus-independent 
mechanisms [169, 184]. For instance, ingestion of Lactobacillus rhamnosus has been shown 
to decrease anxiety and depression-like behavior in healthy mice which was associated with 
alterations of brain GABA receptor expression. The behavioral and neurochemical effects of 
this bacterium were not found in vagotomized mice [182]. Similarly, the ability of B. longum 
to attenuate anxiety induced by chemical colitis was abolished by vagotomy [183]. However, 
how the gut microorganisms activate vagal afferents are currently unclear. 
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2.3.1.4 Involvement of tryptophan metabolism 
Tryptophan is an essential amino acid and the precursor of neurotransmitter serotonin. 
It can be converted into kynurenine by either indoleamine-2,3-dioxygenase (IDO) or hepatic 
tryptophan-2,3-dioxygenase (TDO). These enzymes are activated by inflammatory mediators 
and by corticosteroids. Kynurenine can then be converted into other metabolites which may 
have neuroactive properties (see chapter 3 of the introduction). A study has shown that the 
probiotic bacterium B. infantis can alter the tryptophan/kynurenine pathway which was 
associated with an antidepressant effect [185]. Interestingly, germ-free animal exhibit 
elevated plasma tryptophan levels and hippocampal serotonin concentrations compared with 
control animals [167]. 
 
2.3.1.5 Involvement of microbial metabolites 
Several molecules with neuroactive functions have been reported to be microbially-
derived and many of which have been isolated from bacteria within the human gut. For 
instance, Lactobacillus spp. and Bifidobacterium spp. produce the neurotransmitter GABA 
[186] through the same biosynthetic pathway as in neuronal tissue [187]. Serotonin and 
dopamine are produced by Lactobacillus spp., Escherichia spp., Streptococcus spp. [188] and 
metabolomics study showed that plasma serotonin level was strongly reduced in GF mice 
compared to conventional mice [189]. The levels of serotonin in the cortex and hippocampus 
were also significantly reduced in GF mice [165]. A recent study demonstrates that bacteria 
which constitute the normal microbiome in mice are able to produce large quantities of 
catecholamines [190]. These secreted neurotransmitters from bacteria may stimulate intestinal 
epithelial cells to release molecules that in turn modulate neural signaling to influence brain 
functions and behavior. 
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Figure 2-12: Pathways involved in the bidirectional communication between the gut microbiota and the brain, 
Cryan JF and Dinan TG, Nature Reviews, 2012 [164]. 
 
Bercik et al. recently published an interesting study which brought evidence that the 
gut microbiota could signal to the brain through multiple pathways [184]. The authors 
infected mice with a parasite to induce chronic gut inflammation and observed behavioral 
alterations consisting in increased anxiety-like behavior. These infected mice presented with 
decreased hippocampal level of brain-derived neurotrophic factor (BDNF) mRNA, increased 
plasma levels of kynurenine and pro-inflammatory cytokines TNFα and IFNγ. Several 
strategies were tested to prevent the behavioral alterations induced by the intestinal 
inflammation. First, they showed that vagotomy before infection did not prevent anxiety-like 
behavior, indicating that vagus nerve did not mediate the behavioral effects of the infection. 
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Secondly, treatment with anti-inflammatory agents normalized behavior of infected mice, 
reduced circulating cytokines and kynurenine levels, but did not influence BDNF expression. 
Thirdly, administration of probiotic Bifidobacterium longum also normalized behavior of 
infected mice, restored brain BDNF expression but did not affect cytokines and kynurenine 
levels. These results clearly showed that multiple routes are involved in the gut-brain 
communication. 
 
 
2.3.2 Modulation of the gut microbiota improves the psychological 
symptoms in clinical populations 
Individuals with chronic fatigue syndrome have altered gut microbiota composition 
and emotional disturbance like anxiety. There is now clinical evidence of a role of probiotic 
intervention in reducing anxiety and neurocognitive functions in these patients [191, 192]. A 
recent double-blind, placebo controlled, randomized study demonstrated that the oral intake of 
a probiotics formulation (Lactobacillus helveticus and Bifidobacterium longum) had 
beneficial psychological effects in healthy human volunteers [193]. Also, four-week intake of 
a fermented milk product containing mixture of probiotics by healthy women affected activity 
of brain regions that control central processing of emotion and sensation [194]. 
Gut microbial alterations are now well-established in somatic diseases such obesity, 
diabetes, and inflammatory bowel diseases. Recent clinical studies have shown variation of 
gut microbiota composition in psychiatric diseases such as autism [195, 196] and only one 
paper, published during the course of this PhD work, suggest that such changes occur upon 
alcohol-dependence [94]. 
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3 ROLE OF THE INFLAMMATORY 
RESPONSE IN ALCOHOL DEPENDENCE 
 
3.1 Sickness behavior theory 
Anyone who has experienced a bacterial or viral infection knows what it means to feel 
sick. When they are sick, the behavior of people changes dramatically and consists in 
lassitude, fatigue, inability to concentrate, loss of appetite, irritability, altered sleep pattern 
and withdrawal from normal social activities [197]. These uncomfortable symptoms are 
frequently ignored by physician or considered rather banal.  However, these symptoms 
contribute to a highly organized strategy of the organism to fight infection and facilitate the 
recovery following pathogen exposure. This strategy is called “sickness behavior” and 
consists in three components: fever, neuroendocrine changes (i.e., activation of the 
hypothalamic-pituitary-adrenal (HPA) axis) and behavioral effects of sickness described 
above [198]. The “sickness behavior” is triggered by pro-inflammatory cytokines produced by 
immune cells in contact with the invading pathogens. Indeed, infectious pathogens encounter 
dendritic cells, blood monocytes and tissue macrophages which express pattern-recognition 
receptors such as Toll-like receptors (TLRs). In humans, 10 TLRs have been identified that 
recognize mainly viral and bacterial structures [199, 200]. For instance, lipopolysaccharide 
(LPS), a component of the cell wall of Gram-negative bacteria, is recognized by TLR4 
whereas peptidoglycan (PGN) originating mainly from Gram-positive bacteria is recognized 
by TLR2 [201, 202]. Upon TLR activation, a signal transduction cascade leads to 
transcription factor activation and, in the end, production of cytokines such as tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β, IL-6 [203]. It has been shown that physiological 
concentrations of pro-inflammatory cytokines that occur after a peripheral infection act in the 
brain to induce the three components of sickness behavior (figure 3-1). 
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Figure 3-1: Cytokines-induced sickness behavior following peripheral infection. 
This communication between the peripheral cytokines and the brain raised an 
important question: what happens when the sickness response is prolonged? This condition 
actually occurs during a variety of chronic inflammatory diseases. In the 90’s, scientists 
suggested that there is an analogy between sickness behavior and depression and thereafter a 
role for cytokines in the development of depression was proposed [204–206] (figure 3-2). 
 
 
Figure 3-2: The relative onset, duration, and intensity of sickness behaviors and depressive-like behaviors 
following inflammation, Mood disorders and immunity, Walker A. et al., 2012. [207] 
This concept was supported by several clinical indirect evidences. For instance, it was 
reported that depressed individuals have increased circulating levels of pro-inflammatory 
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cytokines [208]. Furthermore, the prevalence of depressive disorders in patients afflicted with 
chronic inflammatory diseases is higher than normal. More direct clinical evidence comes 
from the potent neuropsychiatric side effects of immunotherapy. Indeed, 45% of cancer 
patients treated with IFN-α and IL-2 developed symptoms of depression [209–211]. However, 
this hypothesis of “cytokines-induced depression” illustrated by clinical observations failed to 
attract the interest of the psychiatrists’ community because the direct demonstration of a 
mechanistic link between inflammation and depression was missing. Therefore, behavioral 
tests that mimic human depression as well as pharmacological and genetic approaches were 
developed in animal models that allowed to prove a causative role for cytokines in depression 
[212]. More recently, clinical models in which healthy humans were injected intravenously 
with endotoxins to induce an inflammatory response, were used to establish the causality 
[213]. For instance, injection of Salmonella abortus endotoxin induced an increase in serum 
TNFα, IL-6 and cortisol together with the development of a depressed mood, increased 
anxiety and a decrease in memory performance [214]. Similar results were obtained after 
vaccination of healthy volunteers with Salmonella typhi who reported negative changes in 
mood [215]. Taken together, animal and human studies have demonstrated that inducing a 
pro-inflammatory state greatly increases the incidence of mood symptoms. 
Animal models have also enabled researchers to identify the mechanisms that mediate 
the behavioral effects of peripherally released cytokines on the brain. Several communication 
pathways were described: a fast neural route and slower humoral pathways (figure 3-3). 
 
 
3.1.1 Neural transmission of the cytokine message 
The vagus nerve innervates organs of the abdominal cavity. Its afferent nerves, which 
convey sensory information about the state of body’s organs to the central nervous system, are 
the target of pro-inflammatory cytokines.  
Peripheral administration of LPS induces the expression of cytokines in the brain 
[216]. The first demonstrations of the role of the vagus nerve in the transmission of 
information from the periphery to the brain have been published in the 90’s.  It was found that 
intraperitoneal (i.p.) injection of LPS caused a rapid increase in c-fos immunoreactivity within 
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the nucleus tractus solitarius. This marker of neuron activation localized to areas of 
projection of the vagus [217].  Other studies showed that subdiaphragmatic vagotomy 
abrogates the induction of synthesis of IL-1β in the brain in response to i.p. injection of LPS 
[218] and IL-1β [219] while leaving unaffected the pool of peripheral cytokines.  Finally, 
vagotomy drastically reduced the sickness response to i.p. LPS in rats [220]. Also, it has been 
proposed that activation of vagal afferents by peripheral cytokines is then transduced back 
into immune message in the brain. Locally produced cytokines would then alter brain 
functions by acting directly or indirectly in neurons [221]. 
In contrast to the previous findings, vagotomy does not block the pyrogenic action of 
i.p. LPS [222] or IL-1β [223] and does not block the induction of sickness behavior when 
cytokines are administrated intravenously or subcutaneously [224]. The latter findings suggest 
that additional humoral pathways are also required to mediate the brain effects of peripheral 
infection. 
 
 
3.1.2 Humoral transmission of the cytokine message 
Since cytokines are relatively large hydrophilic molecules that are unable to cross the 
blood-brain barrier, it was obvious that their action on the brain could not be direct. Several 
pathways of transmission from the immune system to the brain have been identified and are 
often represented by the production of intermediates at the level of blood-brain interface in 
response to circulating cytokines or microorganism components.  
For instance, the macrophage-like cells residing in the circumventricular organs and 
the choroid plexus express TLRs and can respond to pathogens by producing pro-
inflammatory cytokines. As these brain structures are devoid of a functional blood-brain 
barrier, the cytokines can enter the brain by volume diffusion [225].  Another way of 
communication involves IL-1 receptors that are located on perivascular macrophages and on 
endothelial cells of brain venules [226, 227]. Activation of these IL-1 receptors by circulating 
cytokines results in the local production of prostaglandin E2 (PGE2), which are the main 
mediators of cytokines-induced fever [226] and HPA axis activation [228]. Finally, studies 
have also shown the existence of cytokine transporters at the blood-brain barrier. The pro-
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inflammatory cytokines overflowing in the systemic circulation can gain access the brain 
though these saturable transport systems [229]. 
Engagement of these immune-to-brain communication pathways ultimately leads to 
the production of pro-inflammatory cytokines by microglial cells. In this way, the brain forms 
a “mirror” of the peripheral immune response. 
 
 
Figure 3-3: Afferent communication pathways from the periphery to the brain. Schedlowski M. et al., Brain, 
Behavior, and Immunity, 2014 [213]. 
 
Introduction 
62 
 
3.2  Role of indoleamine-2,3-dioxygenase in 
depression 
One key player of the action of cytokines in the brain is an enzyme known as 
indoleamine-2,3-dioxygenase (IDO) [230].  This enzyme is expressed in all tissues mostly in 
macrophages and microglia and is activated by pro-inflammatory cytokines, particularly IFN-
γ and TNFα [231]. IDO degrades the essential amino acid tryptophan, which is usually 
actively transported into the brain for the synthesis of serotonin. Degradation of tryptophan by 
IDO generates kynurenine which is biologically inactive but can be further metabolized into 
biologically active metabolites (figure 3-4). For instance, astrocytes, neurons and brain 
endothelial cells metabolize kynurenine into kynurenic acid which antagonizes NMDA 
receptors and shows neuroprotective effects [232]. On the other hand, macrophages and 
microglial cells metabolize kynurenine into downstream neurotoxic metabolites such as 
quinolinic acid which easily crosses the blood-brain barrier, generates oxidative radicals and 
acts as an agonist of NMDA receptors [232, 233]. This results in alteration of glutamatergic 
neurotransmission that could trigger the necessary conditions for the development of 
depression.  
 
Figure 3-4: IDO degrades tryptophan through the kynurenine pathway, Dantzer R.et al., Nature Reviews 
Neuroscience, 2008 [198].  
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In order to demonstrate the link between tryptophan metabolism and symptoms of 
depression, mice were treated with a selective competitive inhibitor of IDO prior to an 
intraperitoneal injection of bacille Calmette-Guérin (BCG) [234]. This treatment did not 
affect the expression of cytokines in the brain but reversed the rise in the 
kynurenine/tryptophan ratio in both blood and brain and finally prevented the BCG-induced 
depressive-like behavior. In this animal model, results indicate that BCG-induced pro-
inflammatory cytokines caused the activation of IDO which subsequently caused depressive-
like behavior by changing tryptophan metabolism. Similar results were obtained using genetic 
approach, with IDO knockout mice, which responded to bacterial infection by producing pro-
inflammatory cytokines but did not develop depressive-like behavior [234]. In cancer patients 
treated with cytokines, a reduction in serum tryptophan, without a change in other neutral 
amino acids, was observed after 1 month of therapy. The lower the circulating levels of 
tryptophan, the higher the severity of depressive symptoms [235, 236]. 
Animal studies have shown that brain pro-inflammatory cytokines are the cause of 
sickness behavior. These cytokines induce the downstream expression of IDO that causes 
depressive-like behavior. Therefore, IDO is suggested to be a master regulator responsible for 
the switch from sickness to depressive-like behavior [237, 238]. 
Also, a recent study [239] has shown that the enzyme tryptophan 2,3-dioxygenase 
(TDO) previously known to be expressed in the liver is also present in the brain (mainly in 
neurons and astrocytes). TDO can be activated by cortisol and its substrate tryptophan. Wu et 
al. found high expression of TDO and quinolinic acid in the hippocampus of Alzheimer’s 
disease patients. The authors suggested that elevated brain TDO expression and excessive 
formation of kynurenine-derived metabolites could be involved in the neurodegenerative 
processes and influence brain functions. 
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3.3 Chronic inflammation in alcohol dependence 
During the past few years, a new player has emerged in the field of alcohol abuse. As 
discussed above, this player is the immune system represented by peripheral and central 
inflammation. A substantial body of data now indicates that chronic alcohol abuse causes an 
increase in systemic and brain cytokines [240–242]. As previously described, brain cytokines 
could be responsible for behavioral changes and for psychological and cognitive symptoms 
associated with alcohol abuse. 
TLR4 seems to be required to induce neuroinflammation following alcohol 
consumption. Indeed, a specific mouse strain C3H/HeJ was identified to have a spontaneous 
mutation in the TLR4 gene making them endotoxins resistant as well as resistant to LPS-
induced sickness behavior [243, 244]. Moreover, alcohol-induced increase in cortical 
cytokines did not occur in TLR4-deficient mice [245]. 
However, alcohol-dependent subjects are not permanently infected by environmental 
bacterial or viral components that could trigger the production of inflammation. Therefore, the 
inflammatory response is likely induced by microorganisms that inhabit naturally the human 
body. One of the aims of this thesis is to analyze the activation of inflammatory pathways in 
response to bacterial components originating from the gut. 
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Alcohol dependence has traditionally been considered a brain disease. Pharmacological 
treatments that target neurotransmitters involved in the brain reward circuit has been widely 
tested but has proven only very partial efficacy, if any. Heavy and chronic alcohol 
consumption is known to have toxic impact on the gastrointestinal tract and organs that 
participate to the digestive process (liver, pancreas) and alcoholics are at risk of malnutrition. 
 The aim of this PhD work is to analyze gut alterations in alcohol dependence and to 
investigate whether what happens on the gut is related to alterations in emotional, 
motivational and cognitive functions that have been related to the development of alcohol 
dependence.  We also investigated which factors may underlie the potential gut-brain 
interactions. Finally, we tested the effect of a short-term alcohol withdrawal on gut functions 
and psychological dimensions. 
To follow that general aim, several hypotheses were developed, step by step, during the 
course of the 3 main studies of the thesis. Each study raised new questions that we tried to 
answer in the following study (figure 1).  
1. In vitro and animal studies, in the field of hepatology, have shown that alcohol exposure 
induced an increase in intestinal permeability as well as bacterial toxins translocation that 
may play a key role in the development of hepatic inflammation and damage leading to 
alcoholic liver disease. In the first chapter of this thesis, we developed a method to assess 
the small bowel and the colonic permeability of alcohol-dependent subjects versus 
matched healthy controls. We tested whether LPS translocation occurred and if it was 
related to the systemic inflammatory response. We also investigated whether 
inflammatory markers were correlated with the psychological and cognitive symptoms of 
alcohol dependence.  
The results of the first chapter revealed that circulating cytokines were related to 
depression and anxiety symptoms as well as craving for alcohol. However, the source of 
inflammation in alcohol dependence remained unclear.  
2. The second chapter of this thesis focused on peripheral blood mononuclear cells (PBMCs) 
and their potential contribution to the systemic inflammatory response. We tested whether 
bacterial toxins LPS and peptidoglycans, which originated from the gut and entered the 
bloodstream due to leaky gut, activated PBMCs and which intracellular pathways were 
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involved. Furthermore, we investigated whether the activation of inflammatory pathways 
were correlated with alcohol consumption and craving. 
3. Since leaky gut and gut-derived bacterial products seem to play an important role in the 
release of circulating pro-inflammatory cytokines that may influence emotions and 
alcohol craving, we analyzed, in the third chapter, the effect of alcohol dependence on the 
gut microbiota which has previously been described as a key factor in the regulation of gut 
barrier function and immune response. On the one hand, we performed a deep analysis of 
the gut microbiota composition by using two complementary approaches: the 
pyrosequencing of the 16S rRNA gene and the quantitative PCR. On the other hand, we 
performed metabolomics analysis in order to assess the functionality of the gut 
microbiota. Finally, we looked for the possible associations between gut microbiota, gut 
permeability and psychological symptoms of alcohol dependence.  
 
 
Figure 1: PhD work hypothesis. The number indicated on the line refers to the chapter in which the hypothesis 
was tested.  
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Although raising different questions, the three studies reported in the thesis were 
conducted according to a similar design which is directly dependent on the alcohol-
withdrawal procedure of the patients during their stay in the medico-psychological unit 
dedicated to the treatment of alcohol dependence in our academic hospital. The patients 
included in our study were diagnosed as alcohol-dependent according the DSM-IV criteria 
and were hospitalized for a detoxification program at the Unité Intégrée d’Hépatologie, 
Cliniques Universitaires Saint-Luc, Brussels.  This unit was created in a collaborative project 
of the department of Gastroenterology and Psychiatry to allow treatment of alcohol 
dependence and of the medical consequences of chronic alcohol consumption, and to provide 
psychiatric and psychological support to alcohol-dependent subjects in order to facilitate the 
possibility of developing a prolonged abstinence. An important aspect of the rehabilitation 
process is the alcohol withdrawal. The alcohol withdrawal program consists in 2 weeks at the 
hospital separated by one week where the patients go back home (figure 2). 
 
                 
Figure 2: Time line of the 3-week detoxification program. 
When the alcohol detoxification unit was created, in 2003, it was organized in a very 
well standardized manner, in a way to facilitate patients’ treatment but also the development 
of research activities. All patients arrived on Monday morning at the hospital (Day 0). They 
received vitamins B and most of them received benzodiazepines for which the dose is adapted 
according withdrawal symptoms. We selected, for the studies, patients that had consumed 
alcohol until their admission in the unit or the day before (on Sunday, or the night between 
Sunday and Monday). They were informed about the study and signed an informed consent 
form if they agreed to participate on Monday noon. Neuropsychological tests were performed 
Monday afternoon before they received the first dose of valium, if possible. All biological 
tests started Tuesday morning (Day 1), after an overnight fast. The patients were tested twice, 
at the beginning of the detoxification program (T1) as explained above, and at the end of the 
W1: Hospital W3: Hospital W2: Home 
Day 1: T1 Day 18: T2 
Day 0:  Admission 
Relapse? 
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third week of the detoxification program, after 18 days of abstinence (T2). The patients who 
resumed alcohol consumption during the second week (the week at home) were excluded 
from the study at T2. 
Patients were compared to 16 healthy subjects who consumed socially low amount of 
alcohol (<20g/day). The healthy controls were matched for age, sex and BMI.  
The patients presenting the following characteristics were excluded from the study: 
- diabetes, BMI > 30 kg/m2 and metabolic disorders 
- inflammatory bowel diseases : Crohn’s disease, ulcerative colitis 
- bypass gastric 
- cirrhosis and  liver fibroscan > F1 
- viral hepatitis 
- auto-immune diseases such as rheumatoid arthritis or lupus erythematosus 
- other dependence excepted tobacco dependence 
 
The patients who had used the following drugs within 2 months preceding the study were 
also excluded: 
- anti-inflammatory drugs  
- antibiotics 
- probiotics  
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1 CHAPTER 1  
ROLE OF INTESTINAL PERMEABILITY AND INFLAMMATION IN THE 
BIOLOGICAL AND BEHAVIORAL CONTROL OF ALCOHOL-DEPENDENT 
SUBJECTS 
 
Increased intestinal permeability and elevated blood lipopolysaccharides (LPS) have been 
described in animal models of chronic alcohol consumption and in patients that have already 
developed an alcoholic liver disease (ALD). Bacterial LPS are potent pro-inflammatory 
agents and have been shown to be involved in the development of hepatic inflammation and 
liver damage. The first aim of this study was to measure intestinal permeability, blood LPS 
levels and systemic inflammation in alcohol-dependent patients without ALD, to test the 
effect of alcohol-dependence itself and avoid bias linked to hepatic injury. In parallel to the 
biological measurements, we assessed the negative affects (depression, anxiety), alcohol 
craving and cognitive function (selective attention). The second aim of this study was to 
evaluate the effect of a short-term alcohol withdrawal on these biological and psychological 
parameters. Finally, in order to collect the first elements of a possible interaction between the 
gut and the brain in AD subjects, we tested correlations between the biological parameters and 
the behavioral ones. 
 
The results of this first chapter have been published in Brain, Behavior and Immunity 26 
(2012), 911-918. 
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Figure 1-1: Hypothesis scheme of Chapter 1. The aims of the study were to assess intestinal 
permeability, LPS translocation and systemic inflammation in alcohol-dependent subjects. We 
also tested whether inflammation was related to psychological symptoms such as depression, 
anxiety and alcohol craving. 
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1.1 Abstract 
Background and aims: Mood and cognition alterations play a role in the motivation for 
alcohol-drinking. Lipopolysaccharides (LPS) are known to stimulate inflammation that was 
shown to induce mood and cognitive changes in rodents and humans. Enhanced intestinal 
permeability and elevated blood LPS characterize alcohol-dependent mice. However, no data 
have been published in non-cirrhotic humans. Our first goal was to test whether intestinal 
permeability, blood LPS and cytokines are increased in non-cirrhotic alcohol-dependent 
subjects before withdrawal and if they recover after withdrawal. Our second goal was to test 
correlations between these biochemical and the behavioral variables to explore the possibility 
of a role for a gut-brain interaction in the development of alcohol dependence.  
Methods: 40 alcohol-dependent (AD) subjects hospitalized for a 3-week detoxification 
program were tested at onset (T1) and end (T2) of withdrawal and compared for biological 
and behavioral markers with 16 healthy subjects. Participants were assessed for gut 
permeability, systemic inflammation (LPS, TNFα, IL-6, IL-10, hsCRP) and for depression, 
anxiety, alcohol craving and selective attention. 
Results: Intestinal permeability and LPS were largely increased in alcohol-dependent subjects 
at T1 but recovered completely at T2. A low-grade inflammation was observed at T1 that 
partially decreased during withdrawal. At T1, pro-inflammatory cytokines were positively 
correlated with craving. At T2 however, the anti-inflammatory cytokine IL-10 was negatively 
correlated with depression, anxiety and craving. 
Conclusion: Leaky gut and inflammation were observed in non-cirrhotic alcohol-dependent 
subjects and inflammation was correlated to depression and alcohol craving. This suggests 
that the gut-brain axis may play a role in the pathogenesis of alcohol dependence.   
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1.2 Introduction 
Alcohol-dependence is a disorder that is present in 5 to 7% of the population of 
developed countries (Anderson and Baumberg, 2006; Grant et al., 2004). In addition to its 
familial, social, and professional consequences, it is also a major risk factor for several 
pathologies including liver or pancreatic diseases, cardiac diseases, cancers, and neurological 
or psychiatric disorders. This addiction is also the first cause of malnutrition in developed 
countries. Indeed, both human and animal studies have shown that heavy chronic alcohol 
consumption leads to mucosal damages that will interfere with the absorption of micro and 
macronutrients and with mucosal enzyme activities contributing to malnutrition (Bode and 
Bode, 2003). Alcohol-fed animals are characterized by an intestinal hyperpermeability and 
possibly a Gram-negative bacterial overgrowth in the upper small intestine that contribute to 
increased leakage of lipopolysaccharides (LPS) into the circulation (Adachi et al., 1995; Yan 
et al., 2010). LPS are potent pro-inflammatory agents that through a CD14-TLR4 receptor 
mechanism (Akira and Hemmi, 2003) activate the transcriptional factor NFκB to induce the 
production of inflammatory mediators such as pro-inflammatory cytokines, chemokines, nitric 
oxide and reactive oxygen species (Wheeler, 2003). This LPS-activated inflammatory process 
has been thought to play an important role in the development of alcoholic liver disease 
(Wheeler, 2003). These mechanisms have been mainly studied in rodent models of alcohol-
dependence (Adachi et al., 1995; Mathurin et al., 2000; Rao et al., 2004; Wheeler, 2003; Yan 
et al., 2010) but data on whether this also occurs in alcohol-dependent humans are scarce. 
 Among the human studies,  increased circulating LPS levels have been reported in 
subjects that have already developed liver damage and cirrhosis (Fukui et al., 1991; Parlesak 
et al., 2000) where the increased LPS levels have been also be attributed to dysfunctional 
Kupffer cells with reduced ability to detoxify endotoxins (Rao et al., 2004). Therefore, the 
rise in plasma LPS and subsequent inflammation in these patients can also be the consequence 
of the liver disease. The analysis of the effects of alcohol consumption in non-cirrhotic 
alcoholics would allow us to test the hypothesis that changes in intestinal permeability, LPS 
and low-grade inflammation may not only be a consequence but also play a role in continuing 
alcohol-dependence.   
  The influence of circulating cytokines on the human brain functions and the 
development of depression is supported by several studies (Dantzer and Kelley, 2007; Dantzer 
et al., 2008; Maes, 1999). Furthermore, an infection (Dantzer et al., 2008; Konsman et al., 
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2002) or the injection of LPS (Reichenberg et al., 2001) will induce several symptoms (fever, 
fatigue, anorexia, sleep abnormalities, loss of interest in social activities) and cognitive 
disturbances (e.g. memory or attention dysfunctions) that are close to symptoms of 
depression. These symptoms are induced by the effect of inflammation on the brain through 
both humoral and autonomic pathways (Konsman et al., 2002). These observations support 
the idea that inflammation induces a Sickness Behavior, which may play a role in the 
pathophysiology of some psychiatric diseases. Consistent with this idea, depressed subjects 
have higher plasma pro-inflammatory cytokines concentrations than controls (Dowlati et al., 
2010; Maes, 1999). On the other hand, the anti-inflammatory cytokine IL-10 seems to prevent 
LPS-mediated mood and cognition disturbances (Bluthe et al., 1999; Richwine et al., 2009; 
Van den Boogaard et al., 2010). In addition, depression plays an important role in the 
behavioural mechanism of addiction (Schuckit, 1994) and has been shown to be strongly and 
consistently correlated to alcohol craving (Andersohn and Kiefer, 2004; de Timary et al., 
2013) which could be defined as the appetitive urge to drink alcohol (Anton, 1999). Also, 
recent psychological studies indicated that negative affects (depression, anxiety) and craving 
largely improve during the alcohol-withdrawal (Cordovil De Sousa Uva et al., 2010; de 
Timary et al., 2008). Selective attention also improved during the detoxification programme 
whereas other cognitive functions such as executive functions (inhibition, flexibility, decision 
making) remained unchanged (Cordovil De Sousa Uva et al., 2010).  
Our first goal was to show that heavy chronic alcohol consumption induced an 
increase in intestinal permeability. Then, we tested whether this hyperpermeability was 
associated with a rise in plasma LPS levels (Cani et al., 2007; Cani et al., 2008) and systemic 
inflammatory response. Finally, we hypothesized that these biological changes would in turn 
influence the severity of depressive symptoms, the intensity of craving and consequently 
alcohol consumption. To test these hypotheses, alcohol-dependent subjects were carefully 
selected upon diagnosis as non-cirrhotic. They were assessed for intestinal permeability, 
plasma LPS levels, plasma pro- and anti-inflammatory cytokines levels, high-sensitivity C-
reactive protein (hsCRP) levels and for behavioural measures both at the onset and end of 
alcohol-withdrawal. This alcohol-dependent group was compared to a control group 
consisting of individuals matched for age and body mass index (BMI) and who socially 
consume low amounts of alcohol.   
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1.3 Material and methods 
Participants and procedure 
The study protocol was approved by the ethical committee of the hospital and all 
subjects signed an informed consent form prior to the investigation (B40320096274, 
Commission d’éthique biomédicale hospitalo-facultaire de l’UCL). A total of 52 subjects with 
diagnosis of alcohol dependence according to the DSM-IV criteria (APA., 1994) were 
clinically evaluated by a psychiatrist (PdT) and admitted to the gastroenterology ward for a 3-
week detoxification and rehabilitation programme. This programme consists of 2 weeks of 
hospitalization separated by 1 week where the patients return back home. All patients had 
kept on drinking until the day of admission to the detoxification ward or the day before. 
Patients were tested twice, on the day of or the day following their admission (T1) and on day 
18-19 (T2) corresponding to the last days of the detoxification program. Among the 52 
patients who were included, only 40 participated at both times of the testing.  The subjects 
who abandoned their treatment or who relapsed during the week at home were excluded.  
Also excluded prior to the study entry were patients who suffered from diabetes and Crohn’s 
disease or other chronic inflammatory diseases (such as rheumatoid arthritis), those who 
presented gastric bypass or other bariatric surgery, those who took antibiotics, probiotics or 
glucocorticoids and nonsteroidal anti-inflammatory drugs during the two months preceding 
enrollment, and subjects who presented with a diagnosis of cirrhosis. Transient liver 
elastrography (Fibroscan®) was applied to all patients in order to quantify liver stiffness 
which correlates with fibrosis grades, according to the METAVIR classification system of 
fibrosis (Bedossa and Poynard, 1996). Based on this evaluation, only patients without 
significant fibrosis (F0 and F1 scores) were included in the study (see supplementary material 
section 1). Alcohol-dependent patients were compared to 16 age- and BMI-matched controls 
who consume low amounts of alcohol (< 20g/day) (Table 1). 
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Table 1: Characteristics of the alcohol-dependent and the control groups 
 
a data are means ± SD. AD - T1 and AD - T2 refer to alcohol-dependent subjects tested at onset and end of the 
detoxification program respectively 
Measurement of intestinal permeability with 
51
Cr-EDTA 
We measured intestinal paracellular permeability with 
51
Cr-EDTA. This non-toxic 
probe was neither degraded by gut flora nor metabolized by the body and not naturally present 
in the urine (Bjarnason et al., 1995; Peeters et al., 1994). After an overnight fast and emptying 
of the bladder, patients drank a Nutridrink® (200ml, 150kcal/100ml) (Nutricia, Brussels, 
Belgium) containing 50µCi (1.85 MBq) 
51
Cr-EDTA. Urine was collected for 24 hours during 
two periods that were expected to reflect small (0-4h) and large (4-24h) bowel permeability, 
respectively. Urine creatinine was measured to ensure completeness of the collections and 
subjects with very low creatinine clearance rates (< 8mg/kg/24h) were excluded (De Ms et al., 
1993). Complete collections at T1 and T2 were obtained in 26 alcohol-dependent subjects and 
16 controls. The radioactivity was measured with a gamma counter (Cobra5003 Canberra 
Packard, Downers Grove, IL, USA). Results were expressed as percentages of the ingested 
dose normalized for creatinine. 
Biochemical analyses 
The LPS concentration was measured with the Limulus amebocyte lysate kinetic 
chromogenic methodology that measures the colour intensity directly related to the 
endotoxins concentration in a sample, using Endosafe-MCS (Charles River laboratories, 
Lyon, France). Plasma were diluted 1/10 with endotoxin-free buffer to minimize interferences 
in the reaction (inhibition or enhancement) and heated for 15 minutes at 70°C. Each sample 
was diluted 1/70 with endotoxin-free Limulus amebocyte lysate reagent water (Charles River 
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Laboratories, Wilmington, MA) and treated in duplicate, and 2 spikes per sample were 
included in the determination. All samples have been validated for recovery and coefficient of 
variation determination. The lower limit of detection was 0.01 EU/mL (Everard et al., 2011; 
Luoto et al., 2011). 
Plasma cytokines (interleukin (IL)-6, IL-10 and tumor necrosis factor (TNF) α) were 
determined in duplicate by multiplex immunoassay (Millipore, Belgium) and measured using 
Luminex®xMap® technology (Biorad, Nazareth, Belgium) following the manufacturer’s 
instructions. Plasma hsCRP was measured by an automated turbidimetry method (DxC 800, 
Beckman Coulter).  
Psychological tests 
All patients were tested for depression, anxiety, craving for alcohol and selective 
attention at T1 and T2 (see supplementary material section 2). 
The Beck Depression Inventory (BDI) is a 21-item self-report inventory designed to 
measure the severity of depressive symptoms, with a maximum score of 63 (Beck et al.,1996). 
The validated French translation of the second version of the BDI (BDI-II) was used in this 
study (Bourque and Beaudette, 1982).  
The state report of the State-Trait Anxiety Inventory (STAI Form YA) is a valid and 
reliable 20-item self-report inventory for measuring the state of anxiety (Spielberger et al., 
1983). The scores range from 20 to 80 where higher scores indicate greater anxiety. A valid 
French version was administered (Bruchon-Schweitzer and Paulhan, 1993).  
The Obsessive-Compulsive Drinking Scale (OCDS) is a questionnaire that assesses 
the cognitive aspects of alcohol craving during the preceding 7 days.(Anton et al., 1995) This 
14-question questionnaire provides a global craving score, as well as two sub-scores: an 
obsessive score (6 items) and a compulsive score (8 items). A valid French version was used 
in this study (Ansseau et al., 2000).  
Selective attention was evaluated with the validated double binary computerized task 
from the “Batterie d’Attention de William Lennox” (BAWL) in its version 4.0 (Leclercq, 
2007). Briefly, the subject was asked to react when a specific target appeared on the screen by 
pressing as quickly as possible the response button on the computer. The reaction time needed 
to press the button is calculated for each of the 40 targets.  
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Statistical analyses  
For each variable, normal distribution was tested with the Kolmogoroff-Smirnov test. As 
all biological measures exhibited non-normal distributions, a log-transformation was applied 
to obtain normality and statistical analyses were performed on log-transformed data. The data 
presented in the graphs are, however, non-transformed means ± standard error of the mean 
(SEM). Biological and psychological measures were analyzed using t-tests. Paired t-tests were 
performed to compare alcohol-dependent (AD) subjects at T1 and T2. Unpaired t-tests were 
performed to compare AD to controls (CT). Concerning selective attention, to detect a 
practice effect as a result of test-retesting, the control group was tested twice and data were 
analyzed with repeated-measures analysis of variance (ANOVA), with time as a within factor 
(T1 vs. T2) and group as a between factor (AD vs. CT). Correlations were calculated using 
Pearson’s moment correlations. Statistical analyses were performed using SPSS version 18.0 
and graphs with GraphPad Prism version 4.0. Statistical significance was defined for a p-
value lower than 0.05. 
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1.4 Results 
Increased intestinal permeability and LPS in alcohol-dependent subjects and recovery 
after withdrawal 
Intestinal permeability was measured by calculating the quantity of 
51
Cr-EDTA found 
in urines. At T1, the small bowel permeability was significantly higher in alcohol-dependent 
subjects than in controls, t (40) = 2.44, p < .05. It decreased significantly from T1 to T2, t (25) 
= 5.63, p < .001, and this decrease was observed in 92.5% of patients. At T2, it did not differ 
anymore from controls, t (39) = 1.01, p = .32. At T1, alcohol-dependent subjects had higher 
colon and total intestinal permeability than those of controls but the difference between 
groups did not reach significance. However, both colon and total intestinal permeability 
decreased significantly during withdrawal, t (25) = 2.22, p < .05 and t (25) = 3.66, p < .01 (fig 
1A). These observations suggest that the effects of alcohol on gut permeability are more 
prominent at the level of the small bowel than the colon. Patients at T1 also exhibited higher 
plasma LPS concentrations than controls, t (37) = 2.21, p < .05. It significantly decreased 
during withdrawal, t (23) = 2.27, p < .05, and at T2, LPS levels did not differ from controls 
(fig 1B). 
 
Figure 1: A 3-week detoxification program induced a total recovery of intestinal permeability and blood 
LPS. (A) Intestinal permeability was assessed by measurement of 
51
Cr-EDTA excreted in urine (n =26). The 
first 4-h urinary collection reflects the small bowel permeability and the second 20-h collection large bowel 
permeability. Total intestinal permeability was also calculated. (B) Plasma LPS concentrations measured in AD 
subjects (n = 27) and in CT. Results are means ± SEM. Creat: creatinine; EU: endotoxin units; LPS: 
lipopolysaccharide; CT: control group; AD-T1 and AD-T2 refer respectively to the alcohol-dependent group at 
the onset and at the end of withdrawal.* p < 0.05 as determined by a two-tailed Student’s unpaired t-test (AD vs 
CT).# p < 0.05 as determined by a two-tailed Student’s paired t-test (AD-T1 vs AD-T2). 
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Induction of plasma cytokines in alcohol-dependent subjects and partial decrease after 
short-term withdrawal 
The levels of pro-inflammatory cytokines TNFα and IL-6 were significantly higher in 
alcohol-dependent subjects than in controls at T1, t (44) = 3.77, p < .001 and t (31) = 2.185, p 
< .05, and at T2, t (44) = 3.50, p < .01 and t (28) = 2.20, p < .05 (fig 2A, B). The mean plasma 
cytokine concentrations decreased during withdrawal, although not significantly. The levels 
of plasma IL-6 decreased in only half of the patients. The TNFα concentrations decreased in 
66% of patients but increased in 33% of them. HsCRP, which is one of the acute phase 
proteins that increases during systemic inflammation, was significantly higher in alcohol-
dependent subjects than in controls at both T1, t (47) = 2.45, p < .05, and T2, t (48) = 3.12, p 
< .01 (fig 2D). There was no significant decrease of hsCRP levels from T1 to T2. The anti-
inflammatory cytokine IL-10 was two-fold higher in alcoholics at T1 than in controls but this 
difference did not reach significance (fig 2C). Surprisingly, plasma IL-10 decreased 
significantly during withdrawal, t (26) = 4.20, p < .001, and this decrease was observed in 
85% of the patients. At the end of withdrawal, IL-10 returned to the same level as controls. 
These results permit us to conclude that alcohol-dependent subjects indeed present with a 
low-grade inflammation, which is defined by a 2- to 3-fold increase in inflammatory 
cytokines and acute phase proteins (Petersen and Pedersen, 2005; Ross, 1999).  
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Figure 2: Change in inflammatory state during alcohol-withdrawal. Plasma (A,B) pro-inflammatory and (C) 
anti-inflammatory cytokines levels and (D) plasma hsCRP in AD and in CT group. Results are means ± SEM but 
corresponding p-values are derived from log-transformed data. TNFα: tumor necrosis factor α (n = 30); IL-6: 
interleukin-6 (n = 16); IL-10: interleukin-10 (n = 26); hsCRP: high-sensitive C-reactive protein (n = 31); CT: 
control group; AD-T1 and AD-T2 refer respectively to the alcohol-dependent group at the onset and at the end of 
withdrawal. * p < 0.05 as determined by a two-tailed Student’s unpaired t-test (AD vs CT).  # p < 0.05 as 
determined by a two-tailed Student’s paired t-test (AD-T1 vs AD-T2). 
 
Recovery of psychological markers during alcohol-withdrawal 
Depression and anxiety scores were significantly higher in alcohol-dependent subjects 
at T1 than in controls, t (51) = 9.95, p < .001 and t (45) = 6.74, p < .001, and decreased 
significantly from T1 to T2, t (39) = 10.11, p < .001 and t (39) = 6.83, p < .001.  However, at 
the end of withdrawal, both scores remained significantly higher than those of controls, t (50) 
= 4.51, p < .001 and t (42) = 3.18, p < .01 (fig 3A, B). For craving, the total OCDS score as 
well as the obsession and compulsion subscores were significantly higher at T1 in alcohol-
dependent subjects than in controls, t (53) = 22.61, p < .001 and t (45) = 20.94, p < .001 and t 
(51) = 19.86, p < .001 , and all three decreased significantly during withdrawal, t (39) = 15.63, 
p < .001 and t (39) = 14.33, p < .001 and t (39) = 12.93, p < .001, while remaining 
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significantly higher than those of controls at the end of withdrawal, t (50) = 5.51, p < .001 and 
t (45) = 6.04, p < .001 and t (53) = 3.88, p < .001 (fig 3D-F). Selective attention was evaluated 
using reaction times from the double binary task of BAWL. The results of the repeated-
measures ANOVA show a main effect of group, F (1, 54) = 19.98, p < 0.001, η2 = 0.27, 
meaning that the performances of alcohol-dependent subjects were lower than in controls. As 
expected, there was also a main effect of time, F (1, 54) = 17.13, p < 0.001, η2 = 0.24, 
indicating that subjects had a quicker reaction time at T2 than at T1 (practice effect) (fig 3C). 
Most importantly, there was a significant Time × Group interaction, F (1, 54) = 6.93, p = 
0.011, η2 = 0.11, showing that reaction times in alcohol-dependent subjects improved more 
than those of controls from T1 to T2. 
 
Figure 3: Decrease in emotional, motivational and cognitive disturbances during alcohol-withdrawal (n = 
40). (A, B) Comparison of levels of depression and anxiety in AD subjects and in controls. (C) Selective 
attention, measured by reaction times, was evaluated twice on each participant to detect a possible practice 
effect. Analyses were performed using repeated-measures analysis of variance (ANOVA), with time as a within 
factor (T1 vs. T2) and group as a between factor (AD vs. CT). (D,E,F) Comparison of total craving, obsessive 
and compulsive components of craving in AD subjects and in CT groups. Results are means ± SEM. BDI: Beck 
depression inventory; STAI: state-trait anxiety inventory; OCDS: obsessive-compulsive drinking scale; ms: 
milliseconds; AD: alcohol-dependent group; CT: control group; AD-T1 and AD-T2 refer respectively to the 
alcohol-dependent group at the onset and at the end of withdrawal.* p < 0.01 as determined by a two-tailed 
Student’s unpaired t-test (AD vs CT).# p < 0.001 as determined by a two-tailed Student’s paired t-test (AD-T1 vs 
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AD-T2). Data with different superscript letters were significantly different according to t-tests following 2  2 
MANOVA statistical analysis. 
 
Correlations between biological and psychological factors  
Cytokines have in the past been suggested to play a role in the development of 
psychiatric diseases and mostly in major depression (Dantzer et al., 2007; Dantzer et al., 
2008; Konsman et al., 2002; Maes, 1999). Here, we decided to test the possibility that 
intestinal permeability and inflammation that were observed to be abnormal in alcohol-
dependent subjects could be related to some behavioural symptoms that are specific to 
alcohol-dependence, particularly depression, anxiety, selective attention and alcohol craving.  
We first examined correlations in patients at T1. We found that IL-6 was positively 
correlated with depression (r = 0.44, p < .05). Moreover, all cytokines measured in this study 
were positively and significantly correlated with alcohol craving (TNFα: r = 0.44, p < .05; IL-
6: r = 0.52, p < .05; IL-10: r = 0.52, p < .01, hsCRP: r = 0.46, p < .01).We also observed that 
selective attention was significantly correlated with small bowel permeability (r = 0.38, p < 
.05) (fig 4). 
After three weeks of abstinence, it was the anti-inflammatory cytokine IL-10 that was 
this time negatively correlated with all psychological factors: depression (r = -0.45, p < .05), 
anxiety (r = -0.44, p < .05), craving (r = -0.48, p < .05) and selective attention (r = -0.39, p = 
.05). This suggests a potent psychological role for anti-inflammatory cytokines. However, the 
pro-inflammatory cytokine TNFα was still positively correlated with craving (r = 0.41, p < 
.05). Finally, we also observed that selective attention was positively correlated with large 
bowel permeability (r = 0.39, p < .05) and with hsCRP (r = 0.37, p < .05) (fig 4). 
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Figure 4: Correlations between biological and psychological factors at the onset (T1) and at the end (T2) 
of withdrawal. BDI: Beck depression inventory; STAI: state-trait anxiety inventory; OCDS: obsessive 
compulsive drinking scale; BAWL: batterie d’attention de William Lennox; IP: intestinal permeability.* p < 
0.05, ** p < 0.01. 
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1.5 Discussion 
Several animal and human studies support the view that alcohol-induced increase in 
intestinal permeability and portal LPS play a role in the development of alcoholic liver 
disease (Adachi et al., 1995; Bode et al., 2003; Keshavarzian et al., 2009; Mathurin et al., 
2000; Mutlu et al., 2009; Parlesak et al., 2000; Ramachandran et al., 2002; Rao et al., 2004; 
Wheeler, 2003; Yan et al., 2010). However, these previous human studies have always been 
done in alcohol-dependent subjects that had already developed liver damage (Parlesak et al., 
2000). The first aim of our study was to test whether intestinal permeability, circulating LPS 
and inflammatory response would be elevated in non-cirrhotic alcohol-dependent subjects. 
Our results clearly showed that these patients presented with a greater intestinal permeability 
than control subjects, predominantly in the small intestine. Interestingly, the permeability of 
all intestinal segments decreased significantly during withdrawal and reached at T2 the level 
observed in controls. This confirms the deleterious effect of alcohol on the small intestine, 
where alcohol is mainly absorbed (Inserm, 2001). The rapid recovery suggests that three 
weeks of abstinence are sufficient to restore a functional gut barrier, probably because of the 
rapid turn-over of intestinal mucosa (Creamer et al., 1961).  
Concerning circulating LPS that can be elevated in the case of gut impairment 
(Muccioli et al., 2010), we found that plasma LPS levels were significantly higher in alcohol-
dependent group at T1 than in controls but returned to normal at T2. This observation 
supports the view that severe alcohol intake may increase LPS levels independently of the 
development of cirrhosis. Our study is the first to observe intestinal hyperpermeability and 
increased LPS levels in non-cirrhotic alcohol-dependent humans, thereby confirming the 
results of a recent study in rats (Keshavarzian et al., 2009). The increase in LPS levels can 
probably be attributed to the increase in small intestine permeability. However, we cannot 
exclude that small intestinal bacterial overgrowth, that characterizes alcohol-dependent 
subjects (Bode et al., 2003; Bode et al., 1993), might also contribute to the increase in LPS. 
As mentioned above and in contrast with a previous study performed in obese animals (Cani 
et al., 2009) we failed to find a significant correlation between intestinal permeability and 
plasma LPS concentrations. This discrepancy may be explained by two reasons: firstly, in our 
study, blood samples were taken from the antecubital and not from the portal vein; secondly, 
the probe we used to assess permeability was 
51
Cr-EDTA, that has a molecular mass of 350 
Da, whereas LPS have a molecular weight of 2,000-20,000 Da (Caroff et al., 2002). Indeed, in 
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a previous study, LPS were found to correlate with permeability only when probes of large 
molecular weight were used (Mathurin et al., 2000; Parlesak et al., 2000). 
These bacterial lipopolysaccharides are the major components of the outer surface of 
Gram-negative bacteria and are considered to be powerful pro-inflammatory agents (Caroff 
and Karibian, 2003). We assessed the inflammatory markers of the alcohol-dependent 
subjects and observed that the levels of TNFα, IL-6, IL-10, and hsCRP were significantly 
higher than in controls at T1. Surprisingly, the anti-inflammatory cytokine IL-10 was the only 
one to totally recover at T2 whereas the pro-inflammatory cytokines TNFα, IL-6 and hsCRP 
only partially decreased. This indicated that IL-10 was the first cytokine that responded to the 
decrease in intestinal permeability and circulating LPS. Although the exact source of plasma 
cytokines remains unknown in alcohol-dependent subjects, we may hypothesize that IL-10, 
which is mainly produced by leucocytes (Sabat et al., 2010) and epithelial intestinal cells 
(Autschbach et al., 1998) could be more related to the intestine and that TNFα and IL-6 are 
mainly produced by the liver, after activation of Kupffer cells by LPS (Elsharkawy and Mann, 
2007). Indeed, IL-10 is commonly considered as a Th3 cytokine which is involved in immune 
tolerance by T cells at sites for first line of defense such as intestinal mucosa, where they have 
a protective role against the development of uncontrolled inflammation in the gut (Allez and 
Mayer, 2004). Moreover, IL-10 inhibits the production of pro-inflammatory cytokines by 
monocytes and macrophages (de Waal et al., 1991) and might hence play a significant role in 
maintaining a non-inflammatory immune status in the normal intestine (Autschbach et al., 
1998). In case of inflammatory bowel disease (IBD), the immunosuppressive effect of IL-10 
is probably not sufficient to control local inflammation (Autschbach et al., 1998; Kucharzik et 
al., 1995) since patients with IBD also have high levels of pro- and anti-inflammatory 
cytokines (Kucharzik et al., 1995). Our data also suggested that in alcohol-dependent subjects 
in whom there is systemic immune activation, the anti-inflammatory cytokines are increased 
to counteract the actions of pro-inflammatory cytokines. This may explain the strong 
correlations between IL-10 and TNFα (T1: r = 0.50, p < .01; T2: r = 0.51, p < .01) or IL-6 
(T1: r = 0.74, p < .001; T2: r = 0.45, p = .06) that we found in our study. Another evidence for 
the role of IL-10 in the intestine immune tolerance is the observation that IL-10 knock-out 
mice spontaneously develop chronic enterocolitis (Kuhn et al., 1993). All of these data 
support the fact that the recovery of plasma IL-10 observed in alcohol-dependent subjects 
during withdrawal could be related to the recovery of local inflammatory state that induced 
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intestinal permeability. On the other hand, the explanation for the lack of recovery of the pro-
inflammatory cytokines is unclear. It could be due to the persistence of liver inflammation. 
There is evidence of ongoing liver damage at the end of a 3-week withdrawal, as assessed by 
the persistence of liver stiffness on transient elastography measures after 30 days of 
abstinence (Gelsi et al., 2010) and the absence of total recovery of cytolytic enzymes 
observed in our patients (data not shown). However, we can also propose the hypothesis that 
the incomplete resolution of the general immune response could also contribute to the 
continuing low-grade inflammation observed at the end of the detoxification program. 
Our study also has a second important aim: to test the possible role of these markers of 
permeability and inflammation on psychological factors that play a central role in the 
development of alcohol dependence. We therefore decided to assess psychological factors that 
play a role in the development of alcohol dependence but that are also known to change 
during withdrawal. We observed, as expected, that scores of depression, anxiety, alcohol 
craving and selective attention were largely altered in alcohol-dependent subjects. All the 
scores recovered during withdrawal, following a pattern parallel to that of biological markers. 
However, despite a total recovery of intestinal permeability and circulating LPS after alcohol-
withdrawal, markers of inflammation and of psychological distress had only partially 
recovered. This suggests that they are not related only to the intestinal permeability.  
To test this last hypothesis, we looked for correlations between biological and 
psychological factors. Previous animal or human studies have shown some emotional and 
cognitive disturbances when inflammation was artificially induced by the injection of LPS.  
For instance, Sparkman et al. (2006) reported that IL-6 could be a key mediator of the deficit 
in working memory in mice injected with LPS. Reichenberg et al. (2001) reported that LPS 
injection in humans induced memory dysfunctions and an increase in depression and anxiety. 
Moreover, LPS-induced depression and anxiety were correlated with cytokines and cortisol 
levels. Interestingly, we observed that alcohol-drinking is a condition that naturally induces 
changes in LPS, intestinal permeability and cytokines, and hence resembles the artificial 
situations described above. In accordance with these previous reports, we observed at T1, 
when LPS levels are elevated, a correlation between the pro-inflammatory cytokine IL-6 and 
depression. However, we also found at T1 that cytokines IL-6, TNFα and IL-10 are correlated 
with alcohol craving. It is, to our knowledge, the first observation of a relationship between 
inflammation and craving in alcohol-dependent subjects, where craving is expected to play a 
central role in drinking behavior. Selective attention correlated with intestinal permeability at 
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both times of withdrawal. More importantly, we found at T2 that IL-10 was negatively 
correlated with depression and alcohol craving. These two markers are known to be important 
predictors of relapse after withdrawal (Andersohn et al., 2004) suggesting therefore an 
important role for the anti-inflammatory cytokine in abstinent alcohol-dependent subjects. 
Animal studies have suggested a role for IL-10 to prevent the effects of LPS on mood and 
cognition. Bluthé et al. (1999) showed that IL-10 injection in mice abrogated the depressive 
symptoms induced by central or peripheral LPS administration. More recently, LPS-induced 
fatigue and deficits in psychomotor coordination were found to be exacerbated in mice 
deficient in IL-10 (Krzyszton et al., 2008). Richwine et al. (2009) reported that LPS injection 
induced cognitive disturbances in IL-10-/- mice but not in wild-type mice. However, only one 
recent study mentioned a positive impact of IL-10 on human cognitive performances (Van 
den Boogaard et al., 2010). Whether IL-10 influences behavior through an inhibition of the 
secretion of pro-inflammatory cytokines (Bluthe et al., 1999; Di Se et al., 1995) or through a 
direct effect on the brain (Mesquita et al., 2008) is still under debate.  
In conclusion, our study is the first to demonstrate a relationship between heavy 
chronic alcohol consumption, increased intestinal permeability, increased circulating LPS and 
low-grade inflammation in non-cirrhotic alcohol-dependent subjects. Furthermore, the parallel 
changes of these biological markers and of psychological markers related to drinking behavior 
observed during withdrawal, suggest a role for a gut-brain interaction in alcohol-dependence. 
While pro-inflammatory cytokines are positively correlated with depression and craving at the 
onset of withdrawal, the anti-inflammatory cytokine IL-10 becomes negatively correlated 
with depression and craving at the end of the detoxification program, suggesting a potential 
protective role for this cytokine against relapse. Moreover, we can suggest that the incomplete 
recovery of pro-inflammatory cytokines after a short-term withdrawal could also contribute to 
the high number of relapses observed among these patients within several weeks or months 
following the detoxification program.  
Because correlation does not imply causal connections, further experimental studies 
using agents that directly affect the levels of inflammation are definitely needed to reinforce 
the evidence of the important role of cytokines in the behavior of AD subjects. However, this 
potential gut-brain interaction opens a new field of research for pharmacological interventions 
in alcohol-dependent subjects, targeting the gut or inflammation. Indeed current 
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pharmacological approaches of alcohol-dependence that only target brain neurotransmitters 
have proved so far to be modestly efficient (Johnson, 2010), eventually because they fail to 
take into account of intestinal permeability and inflammation as a driving force for the 
psychological components of alcoholic pathology. An interesting perspective would be to test 
whether nutritional factors such as probiotics or prebiotics that are known to have positive 
impacts on the gut barrier (Delzenne et al., 2011) will be able to reduce inflammation and 
improve mood and craving, as a new treatment of alcohol-dependence. 
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1.7 Supplemental information 
Section1: Diagnosis of cirrhosis 
Liver biopsy is still regarded as the gold standard for grading and staging the liver 
disease. However, this invasive procedure carries the risk of potential life-threatening 
complications (e.g. bleeding) and therefore, for obvious ethical reasons, liver biopsy cannot 
be justified in all patients for study purposes. Therefore, all of the subjects have 
systematically been evaluated by blood tests (biochemistry, haematology, coagulation), by a 
gastro-intestinal endoscopy (to check the signs of portal hypertension such as oesophageal 
and gastric varices), by liver Doppler-ultrasound (to evaluate the shape of the liver, 
splenomegaly with collateral intra-abdominal venous circulation or slowed down or inverted 
portal venous blood flow) and by a measurement of transient liver elastrography 
(Fibroscan®). This new non-invasive technique has been designed to quantify liver stiffness 
which has been correlated to liver fibrosis grades based on the METAVIR classification 
system of fibrosis. Validated cut-off has been published and studies clearly show that this 
technique is reliable in ruling out significant fibrosis and in confirming cirrhosis. 
Accordingly, we only selected F0 and F1 patients (i.e. absence of significant fibrosis) for the 
study. Liver biopsy has only been performed in patients in whom the non-invasive work-up 
suspected advanced fibrosis/cirrhosis which were by definition excluded from the study. 
Section 2: Assessment of psychological variables 
All patients were tested for depression, anxiety, craving for alcohol and selective 
attention at T1 and T2. 
The Beck Depression Inventory (BDI) is a 21 question multiple-choice self-report 
inventory designed to measure the severity of depressive symptoms. This questionnaire is 
valid, reliable and thought to be a good measure of depression severity in alcohol-dependent 
subjects. The validated French translation of the second version of the BDI (BDI-II) was used 
in this study. The BDI-II consists of 21 items measuring characteristic attitudes and symptoms 
of depression. Each item is rated on a 4-point scale ranging from 0 to 3. The BDI-II is scored 
by summing the ratings for the 21 items, with a maximum score of 63. 
The State-Trait Anxiety Inventory (STAI Form YA) is a valid and reliable self-report 
inventory for measuring anxiety. It evaluates how subjects are feeling at the present time 
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(state). The questionnaire consists in 20 items with a range of four possible responses to each 
(Likert scale; 1 = not at all, 2 = somewhat, 3 = moderately so, 4 = very much so). The range 
of scores is 20-80 and the higher score indicates the greater anxiety. A valid French version 
was administered. 
The Obsessive-Compulsive Drinking Scale (OCDS) is a self-report questionnaire that 
measures the cognitive aspects of alcohol craving during the preceding 7 days. This 
questionnaire comprises a total of 14 items, which can be divided into two subscales, a 6-item 
“obsessive” subscale (e.g. How much of your time where you are not drinking is occupied by 
ideas, thoughts, impulses, or images related to drinking?) and an 8-item “compulsive” 
subscale (e.g. How much of an effort do you make to resist consumption of alcoholic 
beverages?). Participants responded to each OCDS item on a Likert scale ranging from 0 to 4. 
Four compulsive items are related to alcohol consumption (e.g. How many drinks do you 
drink each day?). Because alcohol was prohibited during withdrawal, these items were 
eliminated and a modified 4-item “compulsive” subscore and a modified 10-item “total” score 
were computed. A valid French version was administered to all participants. 
Selective attention is evaluated by a computerized test that comes from the BAWL 
(Batterie d’Attention de William Lennox) in its version 4.0. The double binary task involves 4 
kinds of visual signals that appear one after the other on a screen and that are distinct by two 
features: the form (cross and circle) and the color (red and blue). The subjects have to react as 
quickly as possible only when the targets (red cross or blue circle) appear on the screen by 
pressing the response button on the computer. Therefore, they have to refrain from responding 
when the distractors (blue cross and red circle) are presented. There are 64 items and for each 
target, reaction time needed to press the button is calculated. The median of reaction times is 
considered for statistical analyses. To help subjects during this task, a picture with the 
different targets is put in front of them. 
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1.8 Complementary discussion and conclusion  
Besides the different aspects that were evoked in the discussion of the first paper 
published in 2012, the results obtained for the publication lead us to propose new 
interpretations that will be developed in this complementary discussion. 
Increased intestinal permeability and blood LPS levels have been involved in the 
pathophysiology of alcoholic liver disease. Here, we have shown for the first time that leaky 
gut and systemic endotoxemia occur in alcoholic subjects without liver disease, meaning that 
alcohol-dependence itself, and not hepatic injury, induces these changes. We have also shown 
that the enhanced gut permeability and blood LPS are transient and that they recover 
completely after 3 weeks of alcohol abstinence (T2). However, the low-grade systemic 
inflammation is still present at the end of the detoxification program. The psychological 
symptoms that are largely expressed in the patients at the beginning of the treatment are 
reduced at the end, but are also still present (figure 1-1).   
 
 
Figure 1-1: Summary of the results obtained in Chapter 1. 
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These observations led us to discuss several important points: 
First, LPS arise from the cell wall of intestinal Gram-negative bacteria and can induce 
a potent inflammatory response through an interaction with their receptors TLR4/CD14. 
Because LPS recovered totally at the end of withdrawal while pro-inflammatory cytokines 
were still present, we suggest that LPS is not the only bacterial toxin inducing a systemic 
inflammation. Indeed, the paracellular gut permeability is not selective to LPS and the altered 
gut barrier could also permit the translocation of other gut-derived bacterial toxins such as 
peptidoglycans that originate mainly from Gram-positive bacteria. The role of peptidoglycans 
in the generation of inflammatory response will therefore be investigated in Chapter 2. Also, 
it is important to note that the LPS measurement performed in this first study reflects actually 
the “endotoxin activity” and we did not take into account the different types of LPS 
originating from different bacteria and that could induce different immune responses. 
Moreover, the different ways of translocation (paracellular vs. transcellular – via 
chylomicrons), the degradation processes as well as the binding to proteins (like LPS-binding 
protein (LBP) or sCD14) make the plasma LPS level difficult to correlate with other 
parameters, such as the gut permeability. The measurement of LPS in feces supernatants 
could better reflect its real production-release by bacteria. 
Secondly, the comorbidity of alcoholism and depressive/anxiety disorders has been 
extensively documented [246, 247].  However, it remains unclear whether one of the 
disorders causes or predisposes to the other. Studies referred to the “tension reduction 
hypothesis” which proposes that alcohol is consumed for its anxiolytic effect which then 
promotes future alcohol intake [248]. Alcohol consumption is therefore a self-medication 
against anxiety or depression symptoms. Alternatively, clinical observations revealed that 
alcohol intake may also induce the development of anxiety symptoms and is seen as 
anxiogenic [249]. Although it has been shown that depressive/anxiety disorders promote 
alcohol consumption and vice versa, alcoholism promotes the development of 
depressive/anxiety disorders, the results of our study support the hypothesis that alcohol 
intake induces psychological symptoms. Indeed, at the beginning of withdrawal, alcohol-
dependent subjects had high scores of depression and anxiety. However, after 3 weeks of 
alcohol abstinence, the anxiety and depressive symptoms were significantly reduced. 
Furthermore, in clinical practice, alcohol detoxification is always required before treating 
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depressive disorders. However, even though alcohol abstinence largely improved the 
psychological symptoms, the patients included in our study remained with higher scores of 
depression, anxiety and craving at the end of withdrawal, compared to a control group. As the 
inflammatory markers correlated with the severity of psychological symptoms, these 
observations highlight the possibility that, in addition to the psychological interventions by 
psychologists or psychiatrists, reducing inflammation could help the patients to feel better and 
improve their psychological well-being, that is likely related to the probability of a relapse 
after detoxification [21].   
Finally, we assessed in vivo the intestinal permeability of patients and controls by 
measuring in urine the percentage of an ingested dose of 
51
Cr-EDTA. The originality of this 
study resides in the fact that we make a distinction between small bowel and colon 
permeability that was poorly reported in the literature. It has been shown that chronic alcohol 
consumption induced changes in the composition of gut microbiota which consists mainly in 
bacteria inhabiting the colon. Furthermore, gut bacteria may be involved in the regulation of 
intestinal permeability. Therefore, it does make sense to separate small and large bowel 
permeability which was made possible by using the probe 
51
Cr-EDTA that is not degraded by 
the colonic bacteria, unlike sugars (e.g. lactulose, mannitol). The results of the intestinal 
permeability test showed that the small bowel was mainly altered whereas the increase in 
colon permeability was not significant. However, one year after the publication of this study, 
we repeated the same test on a larger sample size and found that, on average, all intestinal 
segments were this time significantly altered by chronic alcohol abuse. Then, we observed 
carefully the value of intestinal permeability for each patient, one by one, and realized that, in 
a cohort of 60 alcohol-dependent patients, 43% of them had altered gut permeability whereas 
57% had gut permeability similar to that of healthy controls. This difference cannot be 
explained by the amount of alcohol consumed and is therefore related to another factor. This 
concern is discussed in details in Chapter 3.   
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The conclusions and perspectives of Chapter 1 are the following: 
 Increase in intestinal permeability and LPS translocation occurs in alcohol-
dependent subjects independently of the presence of liver disease. 
 The low-grade systemic inflammation is correlated with the psychological 
symptoms of alcohol-dependence, in particular with alcohol craving. 
 After a short-term alcohol withdrawal, leaky gut and endotoxemia fully 
recovered whereas inflammation and psychological symptoms persist. 
 The persistence of inflammation suggests that other gut-derived bacterial 
toxins could induce the release of inflammatory cytokines 
 Strategies aiming at reducing the inflammatory state could help alcohol-
dependent patients to improve their psychological distress. 
Results and discussion - Chapter 2 
106 
 
 Results and discussion - Chapter 2 
 
107 
 
2 CHAPTER 2 
ROLE OF INFLAMMATORY PATHWAYS, BLOOD MONONUCLEAR 
CELLS AND GUT-DERIVED BACTERIAL PRODUCTS IN ALCOHOL-
DEPENDENT SUBJECTS 
 
Recent studies suggest that inflammation could play a role in the development of 
psychiatric disorders. However, there are currently only little hypotheses on the mechanisms 
by which inflammation could develop in these disorders. In chapter 1 of the results section, 
we have shown that alcohol-dependent subjects developed a chronic low-grade systemic 
inflammation but the origin of blood pro-inflammatory cytokines is unknown. As alcohol 
abuse is associated with increased intestinal permeability and LPS translocation from the gut 
lumen to the blood, it is plausible that LPS induce an inflammatory response through 
interaction with their receptors expressed by immune cells. However, alteration of the gut 
barrier may also permit the translocation of other gut-derived bacterial products, such as 
peptidoglycan (PGN), that originate mainly from Gram positive bacteria. The immune cells 
that expressed Toll-like receptors which recognized specifically LPS and PGN are located in 
the gut mucosa, in the liver (Kupffer cells) as well as in the systemic circulation. Peripheral 
blood mononuclear cells (PBMCs) represent an essential defense barrier against gut-derived 
bacterial products entering the bloodstream and may potentially contribute to the systemic 
inflammation. 
The role of PGN has generally been neglected in the literature, while most studies on 
inflammation focused on the importance of LPS. In this Chapter 2, we tested whether gut-
derived bacterial products LPS and PGN activate the PBMCs, which intracellular pathways 
are involved, and whether PBMCs could contribute to the systemic inflammation. We also 
investigated whether activation of inflammatory pathways are related to alcohol consumption 
and alcohol craving. Finally, we tested the recovery of pathways activation after a short-term 
alcohol withdrawal.  
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The main strengths of this study reside in the fact that, first, we obtained data on a 
large cohort of alcohol-dependent subjects (n = 63). Secondly, as described in Chapter 1, we 
selected only alcohol-dependent subjects without alcoholic liver disease in order to assess the 
effect of alcohol-dependence itself and not to be biased by hepatic inflammation. 
Furthermore, the inflammatory pathways in PMBCs were analyzed under naturalistic 
conditions, without culturing cells or applying pathogen stimulation. Therefore, our results 
likely better reflect the real and pathophysiological impact of gut-derived bacterial products 
on immune response.  
 
The results related to this chapter have been published in Biological Psychiatry (2014) 
1;76(9):725-33. 
 
To make the reading and the understanding of this study easier to the reader, several 
figures originally inserted in the supplementary information of the article published in 
Biological Psychiatry will be inserted in the core of the manuscript. 
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Figure 2-1: Hypothesis scheme of chapter 2.  Alcohol-dependent subjects are characterized by a chronic 
systemic low-grade inflammation. However, the origin of inflammation is unknown. Leaky gut permits the 
translocation of LPS from the gut lumen to the systemic circulation. LPS induces an inflammatory response 
through interaction with receptors CD14/TLR4. These receptors are located in immune cells which can be found 
in the gut mucosa, in the liver or in the systemic circulation. The aims of this Chapter 2 were to determine 
whether LPS can activate peripheral blood mononuclear cells (PBMCs), which intracellular pathways are 
involved and whether PBMCs contribute to the systemic inflammation. Moreover, we investigated whether 
peptidoglycan can also cross the leaky gut barrier and whether it activates PBMCs though interaction with 
receptor TLR2.  
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2.1 Abstract 
Background: Inflammation might play a role in the development of several psychiatric 
diseases. However, the origins of processes that mediate inflammation remain unknown. We 
previously reported, in alcohol-dependent (AD) subjects, increased intestinal permeability, 
elevated blood lipopolysaccharides (LPS) levels, and low-grade systemic inflammation 
associated with psychological symptoms of alcohol dependence. In this study, we tested 
during detoxification peripheral blood mononuclear cells (PBMCs) inflammatory responses to 
gut-derived bacterial products and its relation to alcohol-craving. 
Methods: Sixty-three actively-drinking non-cirrhotic AD subjects were tested at the 
beginning (day 2) and end (day 18) of alcohol detoxification and compared with 14 healthy 
subjects.  Activation of various intracellular signaling pathways by gut-derived bacterial 
products was analyzed by qPCR, Western blotting and DNA binding assays (for transcription 
factors). Toll-like receptors activation was assessed by cell cultures.  
Results: In addition to LPS, we showed that peptidoglycans (PGN) may also cross the gut 
barrier to reach the systemic circulation. Both activate their respective Toll-like receptors in 
PBMCs. Chronic alcohol consumption inhibited the nuclear factor kappa B pro-inflammatory 
cytokine pathway, but activated the mitogen-activated protein kinase/activator protein 1 
pathway, together with the inflammasome complex. This resulted in increased mRNA and 
plasma levels of interleukin (IL)-8, IL-1β, and IL-18. Activated pro-inflammatory pathways, 
in particular IL-8 and IL-1β, were positively correlated with alcohol consumption and 
alcohol-craving scores. Short-term alcohol withdrawal was associated with the recovery of 
LPS- but not PGN-dependent receptors.  
Conclusions: LPS and PGN from the gut microbiota stimulate specific inflammatory 
pathways in PBMCs that are correlated with alcohol craving. 
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2.2 Introduction 
Recent studies suggest a role for inflammation in the development of several 
psychiatric diseases (1), including alcohol dependence (2), a disorder that affects 5–7% of the 
population in developed countries (3). Inflammation in alcohol dependence has been ascribed 
to a local pro-inflammatory effect of ethanol, either in the brain or in the liver (2).  However, 
heavy chronic alcohol consumption induces gut mucosal damage, increases intestinal 
permeability (4-6), induces changes in the composition of the gut microbiota (7,8) and 
bacterial overgrowth in the small intestine (9,10). Gut bacteria are classified into one of two 
major groups, according the multi-layered structure of their cell envelopes. Gram-negative 
bacteria are surrounded by a thin peptidoglycan (PGN) cell wall, which itself is surrounded by 
an outer membrane containing lipopolysaccharide (LPS). Gram-positive bacteria lack the 
LPS-associated outer membrane but are surrounded by layers of PGN many times thicker than 
is found in the Gram-negatives (11). The view that systemic inflammation could play a role in 
alcohol dependence and be induced by increased intestinal permeability and permeation of 
LPS is supported by recent data in humans (6). Nevertheless, the possibility of an 
inflammatory effect of other bacterial components such as PGN has not been tested to date.   
Gut-derived bacterial LPS and PGN interact with receptors on lymphocytes and 
monocytes, the membrane-bound Toll-like receptors (TLR4 and TLR2, respectively), and the 
cytosolic Nod-like receptors (NLRs) to elicit inflammatory responses (12,13). Upon receptor 
activation, a signal transduction cascade converges toward a common set of signaling 
molecules, leading to the activation of various transcription factors that drive the production 
of pro-inflammatory cytokines and type I interferons (14,15).  
TLR4 interacts with co-receptors CD14 and MD2 to activate signal transduction 
pathways through adaptor molecules, including myeloid differentiation primary-response 
protein 88 (MyD88) and TIR domain-containing adapter inducing IFN-beta (TRIF) (16-18). 
The MyD88-dependent pathway, which is common to most TLRs, leads to the activation of 
two distinct intracellular pathways: the  inhibitor of nuclear factor kappa-B (NFκB)  kinase 
(IKK) pathway, culminating in the activation of the transcription factor NFκB (14), and the 
mitogen-activated protein kinase (MAPK) pathway inducing  another transcription factor, 
activator protein 1 (AP-1) (19,20). TLR4 is also able to activate a second MyD88-independent 
Results and discussion - Chapter 2 
112 
 
pathway, which results more specifically in the induction of interferon regulatory factor 3 
(IRF3), leading to increased production of type I interferons, in particular interferon-beta 
(IFNβ) (21). PGN directly stimulate TLR2 receptors, whereas muramyl dipeptide (MDP), 
which is the minimal bioactive cytosolic structure of PGN, interacts with nucleotide-binding 
oligomerization domain (NOD)-like receptor (NLR) proteins NOD2 and NLRP3 (22,23). 
TLR2 and NOD2 also activate the MyD88-dependent pathway. The receptor NLRP3 forms 
the inflammasome, which is a multiprotein complex that also comprises the enzyme caspase-
1. This converting enzyme cleaves the precursor forms of interleukin (IL)-1β and IL-18 into 
mature and active cytokines (24).  
The aim of the present study is threefold: 1) Mechanistic: to test whether gut-derived 
bacterial products activate PBMCs, which intracellular pathways are involved, and whether 
they contribute to the systemic pro-inflammatory cytokines response under natural conditions 
in non-cirrhotic AD subjects; 2) Clinical: to assess whether activation of specific pathways, 
and especially the pro-inflammatory cytokines, are related to the amount of alcohol consumed 
and to alcohol craving; and 3) to investigate the recovery of pathway activation after 18 days 
of detoxification. 
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2.3 Material and methods 
Patients and Study Design 
Sixty-three actively drinking AD inpatients were recruited from the alcohol-
detoxification unit of the departments of gastroenterology and psychiatry, Saint-Luc 
Academic Hospital, Brussels, Belgium. The following minimal eligibility criteria were 
required: alcohol dependence according to the DSM-IV (25), and alcohol drinking until the 
day of admission. Exclusion criteria were as follows: the use of antibiotics, probiotics, 
glucocorticoids, and nonsteroidal anti-inflammatory drugs currently or during the two months 
preceding enrollment; patients with metabolic disorders such as diabetes and obesity (BMI > 
30 kg/m
2
), chronic inflammatory diseases (such as inflammatory bowel disease or rheumatoid 
arthritis), cancer, or other severe medical conditions, including cirrhosis or significant liver 
fibrosis (F≥2 on transient liver elastography) (see Supplemental Material). Fasting blood was 
drawn from the antecubital vein on the day following admission (T1) and at the end of the 
detoxification program, on day 18 (T2). Among the 63 patients, 41 participated to both time 
points (subjects who abandoned their treatment or resumed alcohol consumption were 
excluded at T2). AD patients were compared with 14 age-, gender-, and body mass index-
matched controls who consumed socially low amounts of alcohol (< 20 g/day). The study 
protocol was approved by the ethical committee of the hospital (reference B40320096274) 
and written informed consent was obtained from all subjects.  
 Alcohol Consumption 
At T1, patients were asked to self-report the number of drinks that they were having 
each day, prior to hospitalization. In a subset of 21 patients, alcohol consumption was 
evaluated more carefully, with the time-line follow-back (TLFB) approach (26), as detailed in 
de Timary et al. (27).  
Isolation of Human PBMCs and RNA 
PBMCs were isolated from blood by centrifugation on a Ficoll-Paque Plus gradient 
(GE Healthcare, Uppsala, Sweden) (Supplemental Material). RNA was extracted using 
TRIzol Reagent (Invitrogen, California, USA). 
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Reverse Transcription and Real-Time Quantitative Polymerase Chain Reaction 
cDNA was synthetized and quantitative PCR was performed with the Step One Plus 
device and software (Applied Biosystems, California, USA) by using the fluorogenic SYBR 
Green PCR Master Mix (Applied Biosystems), as previously described (28). The ΔΔ CT 
method was used for quantification normalized to ribosomal protein L19 RNA (internal 
standard). Primers (Supplemental Table S1) were designed with Primer Express design 
software (Applied Biosystems). 
Quantification of Transcription Factor Activation 
Activation of transcription factors (p65, c-Fos, phospho-c-Jun) in PBMCs was 
assessed, in whole cell extracts (Nuclear Extract kit, Active Motif, la Hulpe, Belgium) by 
using a sensitive TransAM detection kit (Active Motif) according to the manufacturer’s 
guidelines. 
Western Blotting 
Western blot analysis was performed on whole cell extracts according to standard 
electrophoresis and transfer techniques. Membranes were revealed with the PerkinElmer 
Western Lightning chemiluminescent detection system (PerkinElmer, Boston, USA) prior to 
quantification of the blots with the Molecular Imager ChemiDoc XRS System (Biorad, 
Nazareth, Belgium). Membranes were stripped (Fisher Scientific, Erembodegem, Belgium) 
and re-probed with several antibodies (Supplemental Table S2). β-Actin was used as a loading 
control. 
Plasma PGN and Cytokine Measurements 
Plasma was diluted 1:2 and detection of PGN was performed by using the 
Peptidoglycan ELISA kit (Cusabio Antibodies-online, Aachen, Germany) following the 
manufacturer’s guidelines. Plasma cytokines (tumor necrosis factor (TNF)α and IL-6, IL-1β, 
and IL-8 were assayed in duplicate with a multiplex immunoassay (Millipore, Molsheim, 
France) and Luminex xMap technology (Bio-Rad) following the manufacturer’s instructions.  
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Short-term Cell Culture and In Vitro Stimulation 
PBMCs from four AD patients and four healthy controls were cultured to test in vitro 
TLR activation upon LPS and PGN stimulation (Supplemental Material).   
Assessment of Alcohol Craving 
The Obsessive-Compulsive Drinking Scale (OCDS) questionnaire assesses the 
cognitive aspects of alcohol craving during the preceding 7 days (29) and provides a total 
craving score, as well as two subscores: an obsessive and a compulsive subscore 
(Supplemental Material). A validated French version was used in this study (30).  
Statistical Analysis 
Statistical analyses were performed with SPSS version 20.0 after log-transformation for 
non-normally distributed data. Independent t-tests were performed to compare AD subjects 
with controls (CT), and paired t-tests were performed to compare AD subjects at T1 and T2. 
Correlations were calculated by using the Pearson product-moment correlation coefficient and 
multiple regression by the stepwise method (Supplemental Material). Statistical significance 
was defined as a p-value of less than .05. Data presented in the graphs are non-transformed 
means ± standard error of the mean (SEM). 
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2.4 Results 
Demographic Data and Alcohol Consumption 
The principal demographic data are described in Table 1. The average values of 
alcohol consumption obtained by using the self-reporting approach (160 ± 100 g/day) and the 
TLFB approach (145 ± 69 g/day) were not statistically different (p = .53). 
 
Table 1: Characteristics of the alcohol-dependent and control groups 
 
a Data are means ± SD. AD - T1 and AD - T2 refer to alcohol-dependent subjects tested at the beginning and 
end of the detoxification program respectively; CT: control group; BMI: body mass index; ND: not defined. 
 
2.4.1 Mechanistic Analyses 
 
Increased Expression and Activation of the TLR4 Receptor Complex in PBMCs of AD 
Patients  
Since the TLR4 complex is principally involved in the recognition of bacterial LPS in 
immune cells, we first studied its expression in PBMCs.  The mRNA levels of TLR4 and 
CD14, the co-receptor required for LPS recognition by TLR4, were significantly increased in 
AD subjects (Figure 1A). In order to test activation of the TLR4 complex, we designed a cell 
culture based-experiment in which PBMCs were treated with physiological doses of LPS. 
After 6 h of stimulation, TNFα mRNA levels in PBMCs and TNFα protein concentrations in 
culture medium were higher in AD subjects than in controls, suggesting a higher reactivity of 
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AD subjects to LPS, in line with up-regulated activation of the TLR4 receptor complex 
(Supplemental Figure S1A, B). 
 
 
Figure 1: Increased expression of LPS and PGN-associated receptors in peripheral blood mononuclear 
cells (PBMCs) of alcohol-dependent (AD) patients.  (A) Increased mRNA expression of TLR4 and CD14 in 
PBMCs of AD subjects under naturalistic conditions. (B)  Increased plasma PGN concentration in AD subjects. 
(C) Increased mRNA levels of PGN-associated receptors (TLR2 and NOD2) and NLRP3 in PBMCs of AD 
subjects under naturalistic conditions. Data are means ± SEM.  AD: alcohol-dependent group; CT: control group; 
*p < .05, **p < 0.01, ***p < .001. 
 
 
Supplemental figure 1: Increased activation of LPS-associated receptor in peripheral blood mononuclear 
cells (PBMCs) of alcohol-dependent (AD) patients. To test TLR4 activation, PBMCs from AD and control 
subjects were cultured for 3 h and stimulated with low doses of LPS (0, 1, 5, 10 ng/mL) for 6 h. Tumor necrosis 
factor alpha (TNF) mRNA levels were measured in PBMCs (A) and TNF protein levels were assayed in 
culture medium (B). Data are means ± SEM.  AD: alcohol-dependent group; CT: control group; LPS: 
lipopolysaccharides. 
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Elevated Plasma PGN Levels and Increased Expression and Activation of PGN-
Associated Receptors in PBMCs of AD Patients  
We hypothesized that PGN might also cross the gut barrier. Plasma PGN levels were 
indeed elevated in AD subjects compared with controls (Figure 1B). We determined the 
expression of TLR2 and NOD2, which recognize PGN-associated components, and MDP, the 
minimal bioactive structure of PGN. Both mRNA levels were significantly increased in AD 
subjects compared with controls (Figure 1C). In addition, mRNA levels of NLRP3, a 
component of a multiprotein complex called inflammasome known to be activated by MDP, 
were also strongly increased in AD patients (Figure 1C). Interaction of ATP with the P2X7 
receptor may activate the inflammasome complex. Therefore, we measured plasma ATP 
levels, P2X7 and pannexin1 (PANX1) mRNA expression which is known to increase upon 
P2X7 activation (31,32).  Plasma ATP levels were lower in AD subjects and the expression of 
P2X7 and PANX1 remained unchanged or decreased, respectively, suggesting no 
involvement of the ATP/P2X7 complex in activating the inflammasome and IL-1β secretion 
(Supplemental Figure S2).  Finally, PBMCs were cultured in the presence of physiologically 
relevant doses of PGN. After 6 h of stimulation, mRNA levels of IL-1β were higher in 
PBMCs from AD than control subjects. In particular, a very small dose of PGN (1 ng/mL) 
induced strong up-regulation of IL-1β mRNA levels (Supplemental Figure S3A) and 
increased the IL-1β concentration in the cell culture supernatant from AD subjects 
(Supplemental Figure S3B). These results suggest that PGN also cross the gut barrier of AD 
subjects and likely contribute to the activation of PGN-specific receptors in PBMCs. 
 
Supplemental figure 2: No significant change in P2X7 receptor mRNA (A) and down-regulation of 
PANX1mRNA (B), a surrogate marker of receptor activation, in AD subjects at both time points (T1, T2) 
compared with CT. Furthermore, the plasma ATP level was lower in AD subjects at T1 compared with the CT. 
Taken together, these data argue against a role for ATP/P2X7 complex in activating the inflammasome and IL-
1β secretion. Data are means ± SEM. AD: alcohol-dependent group; CT: control group; T1 and T2 refers to the 
beginning and end of a 3-week alcohol withdrawal, respectively. *p < .05 compared with CT. 
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Supplemental figure 3: Increased activation of PGN-associated receptors in peripheral blood mononuclear 
cells (PBMCs) of alcohol-dependent (AD) patients. To test TLR2 activation, PBMCs from the AD and CT 
subjects were cultured for 3 h and stimulated with low doses of PGN (0, 1, 5, 10 ng/mL) for 6 h. IL-1β mRNA 
levels were measured in PBMCs (A) and the active form of IL-1β was assayed in culture medium (B).  Data are 
means ± SEM.  AD: alcohol-dependent group; CT: control group; PGN: peptidoglycans. 
 
Activation of TLR-Dependent Downstream Signaling in PBMCs of AD Patients 
TLR activates down-stream signaling pathways through interaction with various 
molecules. We therefore investigated the expression and activation of key components of the 
different pathways. First, we showed that the expression of MyD88 and the phosphorylated 
form of IL-1 receptor-associated kinase (IRAK-1) were higher in AD subjects, suggesting 
activation of the MyD88-dependent pathway (Figure 2A-C).  
 
Figure 2: Activation of the MyD88-dependent pathway in peripheral blood mononuclear cells (PBMCs) of 
alcohol-dependent (AD) subjects. (A) Increased mRNA expression of MyD88 in PBMCs of AD subjects under 
naturalistic conditions. (B) Representative Western blots of total and phosphorylated forms of interleukin-1 
receptor-associated kinase (IRAK1) protein expression. (C) Quantification of IRAK1 and p-IRAK1 expressions 
in Western blots by densitometry normalized to the loading control β-actin, showing that the expression of the 
phosphorylated and activated form of IRAK1 is higher in AD subjects compared with healthy CT. Data are 
means ± SEM. AD: alcohol-dependent group; CT: control group.  *p < .05, **p < .01. 
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Inhibition of the NFκB proinflammatory cytokine pathway in PBMCs of AD patients 
The NFκB proinflammatory cytokine pathway is one of the principal pathways 
activated upon TLR stimulation. In AD patients, mRNA levels of the NFκB subunits p65 and 
p105 (NFκB p50 precursor) did not differ from those of controls (Figure 3A). Moreover, the 
mRNA levels and protein expression of IκBα, the principal inhibitor of NFκB, were more 
than 3-fold increased in AD patients (Figure 3A-C). Subsequent analysis of the DNA binding 
activity of p65 showed that NFκB DNA binding was inhibited in AD patients (Figure 3D). To 
confirm inhibition of NFκB, we also assessed mRNA expression of the cytokines TNFα and 
IL-6 that are directly regulated by this transcription factor. TNFα levels were significantly 
lower in AD patients and levels of IL-6 did not differ significantly from controls (Figure 3E). 
All of these observations demonstrate inhibition of the NFκB proinflammatory cytokine 
pathway in PBMCs of AD patients. 
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Figure 3: Inhibition of the nuclear factor kappa B (NFκB) pro-inflammatory signaling pathway and 
activation of the mitogen-activated protein kinase (MAPK)/ activator protein 1 (AP-1) pathway in 
peripheral blood mononuclear cells (PBMCs) of alcohol-dependent (AD) subjects. (A) No induction of 
mRNA p65 and p105 NFκB subunit expression but a large increase in the mRNA level of the NFκB inhibitor 
IκB in PBMCs of AD subjects. (B)  Representative Western blots of IκB protein expression in PBMCs and 
quantification normalized to the loading control β-actin (C), showing increased IκB expression in AD subjects 
compared with CT. (D) NFκB p65 DNA-binding assay showing decreased p65 activation in AD subjects. (E) 
Decreased expression of tumor necrosis factor alpha (TNF) and no significant change of interleukin (IL)-6 
mRNA levels, respectively, in PBMCs of AD subjects. (F) Representative Western blots of MAPK protein 
expression in PBMCs  and quantification normalized to the loading control β-actin (G) showing an increased 
p38 phosphorylation (p-p38) and increased expression and phosphorylation (p-JNK) of the c-Jun amino-terminal 
kinase (JNK) in AD subjects compared with CT. (H) Increased mRNA levels of both AP-1 subunits, c-Fos and 
c-Jun, in PBMCs of AD subjects. (I) AP-1 DNA binding assay showing increased c-Fos and phospho c-Jun 
activation in AD subjects. (J) Increased mRNA levels of interleukin (IL)-1β, IL-8, and IL-18, which are, at least 
in part, regulated by transcription factor AP-1. Data are means ± SEM. AD: alcohol-dependent group; CT: 
control group; *p < 0.05, **p < .01, ***p < .001. 
 
Activation of MAPK and AP-1 pathway in PBMCs of AD patients 
MyD88-dependent TLR signaling also activates the MAPK signaling pathway, leading 
to activation of the transcription factor AP-1. We first assessed protein expression of MAPK 
p38, and JNK, known activators of AP-1. Western blot analysis showed increased 
phosphorylation of both proteins in AD patients compared with those of controls, suggesting 
activation of the MAPK pathway (Figure 3F, G). In addition, mRNA levels of c-Fos and c-
Jun, the two principal subunits of AP-1, were significantly up-regulated in AD patients 
(Figure 3H). Furthermore, c-Fos and phospho c-Jun DNA binding activities were also 
increased in AD subjects, confirming activation of AP-1 (Figure 3I). Finally, a 3.5-fold and a 
6-fold up-regulated expression of the cytokines IL-1β and IL-8, respectively, which are at 
least in part regulated by AP-1, as well as significantly higher levels of IL-18 (Figure 3J), add 
further arguments in favor of AP-1 activation in PBMCs of AD patients.  
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Weak activation of MyD88-independent pathway in PBMCs of AD patients 
The MyD88-independent pathway classically leads to activation of the interferon 
pathway and production of type I interferons. Although assessment of IRF3 and IRF7 mRNA 
levels did not show any significant difference between AD patients and controls (Figure 4A), 
the phosphorylated form of IRF3 was more expressed in AD subjects (Figure 4B, C). 
Therefore, we looked at the expression of the end product IFNβ and found no difference 
between groups (Figure 4A). In addition, genes directly regulated by IFNβ, such as OAS-1 
and ISG6-16, were not increased or only mildly increased in AD subjects, respectively 
(Figure 4A). Overall, these results suggest only a weak, if any, activation of the MyD88-
independent pathway in PBMCs of AD patients. 
 
Figure 4: MyD88-independent pathway in peripheral blood mononuclear cells (PBMCs) of alcohol-
dependent (AD) subjects.  (A) No induction of IRF3, IRF7 and interferon beta (IFNβ) mRNA levels as well as 
no or weak increase of the IFN-induced genes OAS-1 and ISG6-16, respectively, in PBMCs of AD subjects, 
suggesting that the MyD88-independent interferon pathway is not activated in AD subjects. (B) Representative 
Western blots of the total and phosphorylated forms of interferon regulatory factor 3 (IRF3) protein expression 
in PBMCs. (C) Quantification of IRF3 and phosphorylated IRF3 (p-IRF3) expression in Western blots by 
densitometry normalized to the loading control β-actin, showing increased expression of p-IRF3 in AD subjects. 
Data are means ± SEM. AD: alcohol-dependent group; CT: control group. *p < .05, **p < .01. 
 
Induction of Plasma Pro-inflammatory Cytokines in AD Patients 
We measured plasma TNFα, IL-6, IL-1β, and IL-8 concentrations and showed that 
they were all significantly higher in AD than in control subjects (Supplemental Figure S4). 
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Supplemental figure 4: Increased levels of plasma pro-inflammatory cytokines in AD subjects compared 
with healthy CT. Cytokines were measured in duplicate with a multiplex immunoassay. Data are means ± SEM. 
AD: alcohol-dependent group; CT: control group; IL, interleukin; TNF, tumor necrosis factor alpha. *p < .05, 
**p < .01. 
 
2.4.2 Clinical Analyses 
 
Correlations Between Alcohol Consumption and Expression of pro-inflammatory 
cytokines 
In the subset of 21 patients in whom alcohol consumption was evaluated with the 
TLFB approach, correlations between the amount of alcohol consumed and the mRNA levels 
of pro-inflammatory cytokines IL-1β and IL-8 and signaling pathways contributing to their 
activation was observed at T1 (Table 2). 
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Table 2: Activation status of signaling molecules and correlations with alcohol consumption and scores of 
craving 
 
Recap chart of signaling molecule status and correlations with alcohol consumption (expressed in g/day) at T1, 
with the obsessive subscore (Obs) of alcohol craving at T1 and correlations between the difference scores (Δ = 
T1 – T2) of inflammatory signaling molecules and the obsessive subscore of craving. OCDS: Obsessive 
Compulsive Drinking Scale; T1: beginning of withdrawal; T2: end of withdrawal. *p < .05, **p < .01, ***p < 
.001; NS: not significant; ND: not determined. 
 
Correlations Between Activated Inflammatory Pathways and Alcohol-Craving Scores 
The OCDS was administrated to 38 patients in order to assess alcohol craving. At T1, 
significant correlations were observed between the total score as well as the obsessive 
subscore of  OCDS and the mRNA expression of pro-inflammatory cytokines IL-1β and IL-8, 
and the intracellular signaling pathways involved in their activation. As the OCDS total scores 
decrease during withdrawal (T1: 18 ± 6 vs. T2: 5 ± 4, p<0.001) in parallel with reduction in 
inflammation, we also tested correlations between the difference scores (Δ) calculated by 
subtracting “inflammation T1 – inflammation T2” and “OCDS T1 – OCDS T2.” Significant 
correlations were found between Δ for IL-1β, IL-8 and Δ for total and obsessive OCDS scores 
(Table 2). 
As several inflammatory parameters were associated with alcohol craving, we used a 
multiple linear regression in order to detect which parameters were the best predictors of 
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craving. Using the stepwise method, we found that the IL-8 mRNA level was the best 
predictor of the outcome over and above all other predictors and accounted for 49% of the 
variance in craving (Table 3). 
Table 3 : Multiple regression report (stepwise method) 
 
Multiple R = .697, R
2
 = .49 (IL-8 mRNA accounted for 49% of the variance in craving with a significant 
association of the t-test with the β-value). B and SE B represent the unstandardized beta values and the 
associated- standard errors. β is the standardized coefficient with the associated t-test and significance. 
 
2.4.3 Effect of a Short-term Alcohol Withdrawal on Inflammatory 
Pathways 
 
To test the effect of alcohol withdrawal on the recovery of inflammatory pathways in 
PBMCs of AD patients, data at T1 and T2 for the patients that completed the entire study 
were compared (Table 4). Concerning the LPS activated pathway, TLR4 and CD14 mRNA 
levels decreased significantly with abstinence to values observed in controls.  For the PGN 
pathway, TLR2 and NLRP3 levels decreased from T1 to T2, but remained high in AD 
patients at T2. High NOD2 expression also persisted and was not affected by withdrawal.  
The AP-1 subunits c-Fos and c-Jun decreased significantly from T1 to T2, but both remained 
higher than in controls at T2. Despite evidence that stimulation of the TLR2 and MAPK/AP-1 
pathways was not completely abrogated after 18 days of abstinence, the mRNA levels of IL-
1β, IL-8, and IL-18 decreased to control levels at T2. Alcohol withdrawal reduced MyD88, 
but it remained above control levels at T2. High IκB levels persisted, and no change in the 
mRNA expression of NFκB subunits, TNF, and IL-6 levels were found during withdrawal.  
Plasma cytokines (TNFα, IL-6, IL-1β, and IL-8) remained higher at T2 in AD than in 
control subjects (not shown). 
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Table 4: Changes in the expression of inflammatory signaling molecule mRNA levels during alcohol 
withdrawal 
 
Data are means ± SD normalized for controls. AD-T1 and AD-T2 refer to the alcohol-dependent group at the 
beginning and at the end of withdrawal, respectively; CT: control group. a p < .01 compared with AD-T1; b p < 
.05 compared with AD-T1; c p < .05 compared with CT subjects; d p < .001 compared with CT subjects; e p < 
.001 compared with AD-T1. 
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2.5 Discussion 
Inflammation might play a role in the development of several psychiatric disorders, 
including major depression, schizophrenia, and autism (1, 33-36). In alcohol dependence, 
several preclinical and clinical studies have also suggested that inflammation plays a role in 
addictive behaviors (2, 37-39).  
To elucidate the contribution of PBMCs to inflammation, we analyzed pro-
inflammatory cytokines and their intracellular signaling pathways in PBMCs of 63 non-
cirrhotic, actively drinking AD subjects. AD subjects had elevated plasma PGN, IL-1β, and 
IL-8 levels and increased mRNA expression of IL-1β, IL-8 and IL-18 in PBMCs. Induction of 
these cytokines were likely related to increased expression and activation of the TLR2 
receptors, as well as activation of the transcription factor AP-1 and the NLRP3 
inflammasome, but to a lesser extent to LPS stimulation of the TLR4-MyD88-dependent 
pathway (Figure 5). Up-regulation of IL-1β and IL-8 mRNA levels positively correlated with 
alcohol consumption and craving. Alcohol withdrawal was associated with recovery of LPS- 
but not PGN-dependent receptors. 
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Figure 5: Proposed working model of the Toll-like receptor (TLR) and Nod-like receptor (NLR) signaling 
pathways in peripheral blood mononuclear cells (PBMCs) of non-cirrhotic alcohol-dependent (AD) 
subjects. AD subjects present with increased intestinal permeability (leaky gut) that favors the translocation of 
bacterial components (LPS and PGN) from the gut lumen to the systemic circulation.  The gut-derived bacterial 
products interact with their respective receptors (TLR4 and TLR2, NOD2) located in PBMCs and activate 
downstream signaling. These events principally result in activation of the MAPkinase-AP1 transcription factor 
pathway as well as in activation of the inflammasome leading to secretion of the pro-inflammatory cytokines 
interleukin (IL)-1β, IL-8 and IL-18. IL-1β and IL-18 are first transcripted as precursors (pro-IL1β and pro-IL-18) 
and then converted into mature and bioactive cytokines by the inflammasome complex. The NFkB pathway and 
the MyD88-independent interferon pathway are not or only weakly activated. Green arrows represent activated 
pathways and red arrows represent inhibited pathways. AP-1, activator protein 1; IFN, interferon; IRAK1, IL-1 
receptor-associated kinase; IRF, interferon regulatory factor; JNK, c-Jun amino-terminal kinase; LPS, 
lipopolysaccharides; MAPK, mitogen-activated protein kinase; MDP, muramyl dipeptide; MyD88, myeloid 
differentiation primary-response protein 88; NFκB, nuclear factor kappa B; PGN, peptidoglycan; TNF, tumor 
necrosis factor. 
 
In AD subjects, the origin and impact of inflammation was mainly attributed to a local 
effect of alcohol in the brain or the liver. We recently reported increased intestinal 
permeability, elevated blood LPS, and low-grade systemic inflammation in AD patients, 
findings that were also related to psychological factors (6), suggesting indirectly that gut-
derived bacterial products could play a role in the development of inflammation.    
Circulating PBMCs represent an essential defense barrier against gut-derived bacterial 
products entering the bloodstream that may potentially contribute to systemic inflammation. 
Since alcohol dependence naturally increases blood LPS (6) and PGN levels, inflammatory 
pathways were tested in PBMCs without culturing cells or applying pathogen-associated 
molecular pattern stimulation.  The inflammatory response in PBMCs of AD subjects has 
previously been analyzed only in studies that included low numbers of patients with 
significant liver disease (40,41).  Monocytes that were extracted from these patients were 
cultured and artificially stimulated with high LPS dose and showed an increase in NFκB 
activity and TNFα production, in contradiction to our findings. We included only patients that 
had not developed liver damage to test the effects of alcohol dependence itself and avoid 
potential bias linked to liver disease. Furthermore, the inflammation was tested under natural 
conditions.  Therefore, our results likely better reflect the physiological impact of gut-derived 
bacterial products on immune responses of PBMCs in AD subjects. 
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The transmembrane TLR and the cytoplasmic NLR, responsible for sensing the 
presence of LPS and PGN, were up-regulated in AD subjects, except for TLR5, which 
recognizes flagellin from flagellated bacteria (data not shown). PGN-associated components 
stimulate TLR2 receptors on the plasma membrane and MDP, the minimal bioactive structure 
of PGN, is commonly detected by the intracellular receptor NOD2 (22,42). From the 
observation of increased plasma PGN, TLR2, and NOD2 expression in AD patients, it can be 
concluded that PGN likely crossed the gut barrier and stimulated specific inflammatory 
pathways in PBMCs, which has not been reported to date. Activation of the receptors was 
confirmed by exposure of PBMCs in culture to physiologically relevant doses of LPS or PGN 
during a short time period, showing increased TNFα and IL-1β gene transcription and protein 
concentrations in culture medium in AD subjects. These observations suggest that 
inflammatory pathways are more intensely activated by LPS and PGN in AD than in control 
cells.  
We next assessed the intracellular signaling pathways regulated by these receptors. 
TLRs activate MyD88-dependent and independent intracellular signaling pathways and 
usually involve the NFκB proinflammatory pathway leading to TNFα and IL-6 transcription, 
and the MAPK pathway culminating in AP-1 activation (19).  MyD88 mRNA levels and p-
IRAK1 protein expression were increased in PBMCs of actively drinking patients, suggesting 
that chronic exposure to alcohol and TLR ligands stimulate MyD88-dependent pathways. 
Surprisingly, several elements indicated inhibition of the NFκB proinflammatory cytokines 
pathway in AD subjects: 1) mRNA levels of NFκB p105 (the p50 precursor) and p65 subunits 
did not change; 2) IκBα, which inhibits NFκB nuclear translocation, was strongly up-
regulated; 3) the DNA binding activity of the p65 subunit was strongly decreased; 4) TNFα 
and IL-6 mRNA, which are cytokines tightly regulated by NFκB, were reduced or unchanged, 
respectively. In line with the inhibition of the NFκB proinflammatory pathway are reports of 
suppression of NFκB activity in response to LPS in animal and in vitro models of chronic 
alcohol exposure (43,44). 
On the other hand, mRNA levels of the cytokines IL-1β and IL-18 and of the 
chemokine IL-8 were up-regulated in AD subjects, which could not be ascribed to NFκB 
activation. We observed activation of the MAPK (p38, JNK) and of the AP-1 (c-Fos/c-Jun) 
pathways, known to be associated with IL-1β, IL-8, and IL-18 transcription (45-47). IL-1β 
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and IL-18, synthesized as nonfunctional pro-IL-1β and pro-IL-18, need to be cleaved into 
bioactive cytokines by caspase-1. Caspase-1 belongs to the multiprotein complex 
inflammasome, containing the adaptor proteins ASC and NLRP3, which may serve as an 
inflammasome activation marker. Increased NLRP3, IL-1β, and IL-18 mRNA expression, 
plasma IL-1β protein up-regulation, and secretion of the active form of the IL-1β protein in 
the culture medium of PBMCs from AD subjects provide evidence for activation of the 
inflammasome. However, in our study, the ATP/P2X7 receptor pathway did not seem to be 
involved in inflammasome activation. Finally, we did not find evidence in favor of the 
activation of the interferon pathway, which can be triggered by TLR4. 
The strong correlations observed between these inflammatory factors and the amount 
of alcohol consumed as well as the total or partial recovery of several factors observed after 
18 days of abstinence, suggest that alcohol is likely the main factor in inducing the 
inflammatory response. The incomplete recovery of the PGN-receptors TLR2 and NLRP3, as 
well as the absence of modification of NOD2 expression suggest that longer term abstinence 
might be required to obtain PGN clearance and concomitant down-regulation of PGN-
receptors. 
Interestingly, mRNA expression of the molecules belonging to the activated 
inflammatory pathways was positively correlated with alcohol craving and more particularly 
with the obsessive dimension of craving at T1. IL-8 was found to be the best predictor of the 
outcome. The correlations disappeared at T2, but positive correlations between difference 
scores (Δ = T1-T2) of inflammation and craving were observed, suggesting that large 
recovery of inflammation during withdrawal is associated with a large improvement in 
alcohol craving (48). This specific relation between the obsession of drinking and 
inflammation supports the general hypothesis of an involvement of inflammation in anxious 
symptoms of alcohol dependence (49), as previously observed in other anxious disorders (50).  
Our data are consistent with involvement of these gut-activated inflammatory 
pathways, in particular the PGN-activated pathway, in the pathophysiology of alcohol 
dependence, at least in active drinkers. It might be less relevant after they have stopped 
drinking. However, our observation of increased plasma levels of IL-6 and TNFα but 
inhibition of mRNA levels of these cytokines in PBMCs suggests that PBMCs are not the 
only source of circulating cytokines. Inflammation likely also arises from other sources as, for 
instance, in the liver and/or in the gut wall itself. Additional analyses in liver and/or small 
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bowel biopsies would be required to determine the respective contribution of each 
compartment to the inflammatory process. 
Furthermore, alcohol might also stimulate inflammation directly at the brain level (2). 
Previous studies performed on animal models supporting a role for inflammation in alcohol 
dependence have all supported a specific role for LPS, TLR4, and NFKβ pathways (51,52). 
Furthermore, Alfonso-Loeches et al. (52) showed that heavy alcohol consumption failed to 
induce AD behaviors and to activate inflammation in the cortex of TLR4-/- knockout mice. 
Our data, however, suggest a stronger role for PGN than the LPS-activated pathway in human 
populations. Together, the results of this study support that gut-derived inflammatory 
pathways are interesting targets to study in order to improve our understanding of the 
pathophysiology of alcohol dependence. They also represent potent sites of interventions for 
the treatment of the disease, perhaps by the use of probiotics or prebiotics that might change 
the composition of the gut microbiota. 
 
 
Acknowledgments: We thank all patients and controls who participated in this study, as well 
as the nurses of the Unité Intégrée d’Hépatologie for their technical help. We also thank the 
Professors Jean-Christophe Jonas and Patrick Henriet for their help in ATP measurement and 
Moïra Mikolajczak for her statistical advices. SL is the recipient of a grant (5.1.049.11.F) 
from FRIA (Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture, 
Belgium); PS and PdT received financial support via FRSM (Fonds de recherche scientifique 
médicale) grants (3.4570.11and  3.4614.12, respectively).   
Financial disclosures: All authors declare that there are no conflicts of interest. 
 
 
 
 
Results and discussion - Chapter 2 
132 
 
2.6 References 
1. Felger JC and Lotrich FE (2013): Inflammatory cytokines in depression: neurobiological 
mechanisms and therapeutic implications Neuroscience 246: 199-229. 
2. Kelley KW and Dantzer R (2011): Alcoholism and inflammation: neuroimmunology of 
behavioral and mood disorders Brain Behav Immun 25 Suppl 1: S13-S20. 
3. Anderson P and Baumberg B (2006): Alcohol in Europe - Public Health Perspective: 
Report summary. Drugs: Education, Prevention & Policy 13: 483-488. 
4. Keshavarzian A, Farhadi A, Forsyth CB, Rangan J, Jakate S, Shaikh M, Banan A, and 
Fields JZ (2009): Evidence that chronic alcohol exposure promotes intestinal oxidative stress, 
intestinal hyperpermeability and endotoxemia prior to development of alcoholic 
steatohepatitis in rats. J Hepatol 50: 538-547. 
5. Parlesak A, Schafer C, Schutz T, Bode JC, and Bode C (2000): Increased intestinal 
permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in 
different stages of alcohol-induced liver disease. J Hepatol 32: 742-747. 
6. Leclercq S, Cani PD, Neyrinck AM, Starkel P, Jamar F, Mikolajczak M, Delzenne NM, 
and de Timary P (2012): Role of intestinal permeability and inflammation in the biological 
and behavioral control of alcohol-dependent subjects. Brain Behav Immun 26: 911-918. 
7. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, 
Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, and Cave M (2008): Probiotics restore 
bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. 
Alcohol 42: 675-682. 
8. Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, and Gillevet P (2009): 
Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic 
steatohepatitis in rats. Alcohol Clin Exp Res 33: 1836-1846. 
9. Bode JC, Bode C, Heidelbach R, Durr HK, and Martini GA (1984): Jejunal microflora in 
patients with chronic alcohol abuse. Hepatogastroenterology 31: 30-34. 
 Results and discussion - Chapter 2 
 
133 
 
10. Yan AW, Fouts E, Brandl J, Starkel P, Torralba M, Schott E, Tsukamoto H, Nelson E, 
Brenner A, and Schnabl B (2010): Enteric dysbiosis associated with a mouse model of 
alcoholic liver disease. Hepatology  
11. Silhavy TJ, Kahne D, and Walker S (2010): The bacterial cell envelope Cold Spring Harb 
Perspect Biol 2: a000414- 
12. Akira S, Uematsu S, and Takeuchi O (2006): Pathogen Recognition and Innate Immunity. 
Cell 124: 783-801. 
13. Takeuchi O and Akira S (2010): Pattern recognition receptors and inflammation. Cell 140: 
805-820. 
14.  Kawai T and Akira S (2007): Signaling to NF-kappaB by Toll-like receptors. Trends Mol 
Med 13: 460-469. 
15. Yamamoto M and Takeda K (2010): Current views of toll-like receptor signaling 
pathways. Gastroenterol Res Pract 2010: 240365- 
16. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, and Mathison JC (1990): CD14, a 
receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 
1431-1433. 
17. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, and Kimoto M (1999): 
MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4. 
The Journal of Experimental Medicine 189: 1777-1782. 
18. Kagan JC, Su T, Horng T, Chow A, Akira S, and Medzhitov R (2008): TRAM couples 
endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 9: 361-
368. 
19. Kawai T and Akira S (2007): TLR signaling. Semin Immunol 19: 24-32. 
20. Guha M and Mackman N (2001): LPS induction of gene expression in human monocytes. 
Cell Signal 13: 85-94. 
Results and discussion - Chapter 2 
134 
 
21. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha 
PM, and Golenbock DT (2003): LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the 
toll adapters TRAM and TRIF. J Exp Med 198: 1043-1055. 
22. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, and 
Sansonetti PJ (2003): Nod2 is a general sensor of peptidoglycan through muramyl dipeptide 
(MDP) detection. J Biol Chem 278: 8869-8872. 
23. Martinon F, Agostini L, Meylan E, and Tschopp J (2004): Identification of bacterial 
muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14: 1929-
1934. 
24. Schroder K and Tschopp J (2010): The inflammasomes. Cell 140: 821-832. 
25. American Psychiatric Association. (1994): Diagnostic and Statistical Manual of Mental 
Disorders, ed 4.   
26. Maisto SA, Sobell LC, Cooper AM, and Sobell MB (1982): Comparison of two 
techniques to obtain retrospective reports of drinking behavior from alcohol abusers. Addict 
Behav 7: 33-38. 
27. de Timary P, Cani PD, Duchemin J, Neyrinck AM, Gihousse D, Laterre PF, Badaoui A, 
Leclercq S, Delzenne NM, and Starkel P (2012): The Loss of Metabolic Control on Alcohol 
Drinking in Heavy Drinking Alcohol-Dependent Subjects. PLoS ONE 7: e38682- 
28. Starkel P, Bishop K, Horsmans Y, and Strain AJ (2003): Expression and DNA-binding 
activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to 
normal liver and primary biliary cirrhosis in humans. Am J Pathol 162: 587-596. 
29. Anton RF, Moak DH, and Latham P (1995): The Obsessive Compulsive Drinking Scale: a 
self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. 
Alcohol Clin Exp Res 19: 92-99. 
30. Ansseau M, Besson J, Lejoyeux M, Pinto E, Landry U, Cornes M, Deckers F, Potgieter A, 
and Ades J (2000): A French translation of the obsessive-compulsive drinking scale for 
craving in alcohol-dependent patients: a validation study in Belgium, France, and 
Switzerland. Eur Addict Res 6: 51-56. 
 Results and discussion - Chapter 2 
 
135 
 
31. Pelegrin P and Surprenant A (2006): Pannexin-1 mediates large pore formation and 
interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J 25: 5071-5082. 
32. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, Vandenabeele P, and 
Nunez G (2007): Pannexin-1-mediated recognition of bacterial molecules activates the 
cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26: 433-443. 
33. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, and Van de Water J 
(2011): Elevated plasma cytokines in autism spectrum disorders provide evidence of immune 
dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 25: 
40-45. 
34. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, and Berger M (1997): 
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the 
acute state and after remission.  Eur Arch Psychiatry Clin Neurosci 247: 228-233. 
35. Maes M (1999): Major depression and activation of the inflammatory response system. 
Adv Exp Med Biol 461: 25-46. 
36. Irwin MR and Miller AH (2007): Depressive disorders and immunity: 20 years of 
progress and discovery. Brain Behav Immun 21: 374-383. 
37. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, 
Wheeler M, and Zou J (2006): Cytokines and alcohol. Alcohol Clin Exp Res 30: 720-730. 
38. He J and Crews FT (2008): Increased MCP-1 and microglia in various regions of the 
human alcoholic brain.  Exp Neurol 210: 349-358. 
39. Spanagel R (2009): Alcoholism: a systems approach from molecular physiology to 
addictive behavior. Physiol Rev 89: 649-705. 
40. McClain CJ and Cohen DA (1989): Increased tumor necrosis factor production by 
monocytes in alcoholic hepatitis. Hepatology 9: 349-351. 
41. Hill DB, Barve S, Joshi-Barve S, and McClain C (2000): Increased monocyte nuclear 
factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab 
Clin Med 135: 387-395. 
Results and discussion - Chapter 2 
136 
 
42. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, and Boneca IG 
(2004): Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan 
recognition. EMBO Rep 5: 1000-1006. 
43. Kishore R, Hill JR, McMullen MR, Frenkel J, and Nagy LE (2002): ERK1/2 and Egr-1 
contribute to increased TNF-alpha production in rat Kupffer cells after chronic ethanol 
feeding. Am J Physiol Gastrointest Liver Physiol 282: G6-15. 
44. Shi L, Kishore R, McMullen MR, and Nagy LE (2002): Chronic ethanol increases 
lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages: contribution to 
enhanced tumor necrosis factor alpha production. J Biol Chem 277: 14777-14785. 
45. Kang JS, Yoon YD, Lee KH, Park SK, and Kim HM (2004): Costunolide inhibits 
interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-
stimulated RAW 264.7 cells. Biochem Biophys Res Commun 313: 171-177. 
46. Hoffmann E, Dittrich-Breiholz O, Holtmann H, and Kracht M (2002): Multiple control of 
interleukin-8 gene expression. Journal of Leukocyte Biology 72: 847-855. 
47. Yun W and Li C (2010): JNK pathway is required for TNCB-induced IL-18 expression in 
murine keratinocytes. Toxicology in Vitro 24: 1064-1069. 
48. Cordovil De Sousa UM, Luminet O, Cortesi M, Constant E, Derely M, and de Timary P 
(2010): Distinct effects of protracted withdrawal on affect, craving, selective attention and 
executive functions among alcohol-dependent patients. Alcohol Alcohol 45: 241-246. 
49. de Timary P, Luts A, Hers D, and Luminet O (2008): Absolute and relative stability of 
alexithymia in alcoholic inpatients undergoing alcohol withdrawal: relationship to depression 
and anxiety. Psychiatry Res 157: 105-113. 
50. Camacho A (2013): Is anxious-depression an inflammatory state? Med Hypotheses  
51. Crews FT and Nixon K (2009): Mechanisms of neurodegeneration and regeneration in 
alcoholism. Alcohol Alcohol 44: 115-127. 
52. Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, and Guerri C (2010): 
Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J 
Neurosci 30: 8285-8295. 
 Results and discussion - Chapter 2 
 
137 
 
2.7 Supplemental information 
Diagnosis of cirrhosis 
Liver biopsy is still regarded as the gold standard for grading and staging liver disease. 
However, this invasive procedure carries the risk of potential life-threatening complications 
(e.g., bleeding); therefore, for obvious ethical reasons, liver biopsy cannot be justified in all 
patients for study purposes. All of the subjects were instead systematically evaluated by blood 
tests (biochemistry, hematology, coagulation), by gastrointestinal endoscopy (to check for 
signs of portal hypertension such as esophageal and gastric varices), by liver Doppler-
ultrasound (to evaluate the shape of the liver, splenomegaly with collateral intra-abdominal 
venous circulation, or slowed down or inverted portal venous blood flow), and by 
measurement of transient liver elastography (Fibroscan®). This new noninvasive technique 
has been designed to quantify liver stiffness, which has been correlated to liver fibrosis grades 
based on the METAVIR classification system of fibrosis. A validated cut-off has been 
published and studies clearly show that this technique is reliable in ruling out significant 
fibrosis and in confirming cirrhosis (1). Accordingly, we selected only F0 and F1 patients 
(i.e., absence of significant fibrosis) for the study (2,3). Liver biopsy was performed only in 
patients in whom advanced fibrosis/cirrhosis was suspected after noninvasive work-up; these 
patients were, by definition, excluded from the study. 
References 
(1) Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The 
METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. 
(2) Nahon P, Kettaneh A, Tengher-Barna I, Ziol M, de Lédinghen V, Douvin C, Marcellin P, 
Ganne-Carrié N, Trinchet JC, Beaugrand M. Assessment of liver fibrosis using transient 
elastography in patients with alcoholic liver disease. J Hepatol. 2008; 49:1062-8 
(3) Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, 
Grignon P, Lion S, Le Page L, Dupas JL. Assessment of asymptomatic liver fibrosis in 
alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory 
tests. Aliment Pharmacol Ther. 2008; 28:1188-98 
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Isolation of Human Peripheral Blood Mononuclear Cells (PBMCs) 
PBMCs were isolated from blood by centrifugation on a Ficoll-Paque Plus gradient 
(GE Healthcare, Uppsala, Sweden). Twenty mL of blood was diluted with Hank’s balanced 
salt solution (HBSS) (Invitrogen, California, USA). Twenty milliliters of the diluted blood 
was layered on 15 mL of Ficoll-Paque Plus and centrifuged at 400g for 40 minutes. The 
plasma layer was discarded and the PBMCs layer at the interface was collected, washed with 
HBSS, and centrifuged at 100g for 10 minutes. The supernatant was discarded and the cell 
pellet was washed with HBSS and centrifuged at 100g for 10 minutes. PBMCs were then 
suspended in 1 mL of TRIzol Reagent (Invitrogen) and kept at -80°C until analysis. 
Short-term Cell Culture and In Vitro Stimulation 
PBMCs from four AD patients and four healthy controls were used to test TLR 
activation. Isolated PBMCs were cultured in six-well plates in RPMI-1640 culture medium 
(700,000 cells/mL) containing L-glutamine (Sigma-Aldrich, Schnelldorf, Germany), 10% 
fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 µg/mL) (all Life 
Technologies) in a 5% CO2-humidified incubator at 37°C for 3 h. Thereafter, cells were 
stimulated with 1, 5, and 10 ng/mL of either LPS from Escherichia coli (Sigma-Aldrich) or 
PGN from Micrococcus luteus (Sigma-Aldrich) for 6 h and resuspended in TRIzol Reagent 
for determination of TNFα (LPS stimulation) and IL-1β (PGN stimulation) mRNA levels. 
Culture medium was recovered for measurements of TNFα and IL-1β protein levels 
(QuantiGlo R&D Systems, Minneapolis, MN, USA). 
Plasma ATP measurement 
Blood was drawn from antecubital vein and collected into EDTA tube. Plasma was 
diluted 1:25 using Hepes-MgCl2-KOH buffer (pH 7.75) and ATP was measured with the 
ATP Bioluminescence Assay Kit CLS II (Roche, Mannheim, Germany) following 
manufacturer’s instructions. 
Assessment of alcohol craving 
The Obsessive-Compulsive Drinking Scale (OCDS) is a self-report questionnaire that 
measures the cognitive aspects of alcohol craving during the preceding 7 days. This 
questionnaire comprises a total of 14 items, which can be divided into two subscales, a 6-item 
“obsessive” subscale (e.g., How much of your time where you are not drinking is occupied by 
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ideas, thoughts, impulses, or images related to drinking?) and an 8-item “compulsive” 
subscale (e.g., How much of an effort do you make to resist consumption of alcoholic 
beverages?). Participants responded to each OCDS item on a Likert scale ranging from 0 to 4. 
Four compulsive items are related to alcohol consumption (e.g., How many drinks do you 
drink each day?). Because alcohol was prohibited during withdrawal, these items were 
eliminated and a modified 4-item “compulsive” subscore and a modified 10-item “total” score 
were computed. Correlations between alcohol craving and inflammation were performed with 
the modified scores to avoid bias linked to alcohol consumption. A validated French version 
was administered to all participants (4). 
Reference  
(4) Ansseau M, Besson J, Lejoyeux M, Pinto E, Landry U, Cornes M, et al. 2000. A French 
translation of the obsessive-compulsive drinking scale for craving in alcohol-dependent 
patients: A validation study in Belgium, France, and Switzerland. Eur Addict Res 6: 51-56. 
Statistical analysis 
Data for transcription factor activation, plasma PGN concentrations, and densitometry 
were analyzed with non-parametric tests (Mann-Whitney test to compare AD to CT subjects). 
When the levels of plasma cytokines were below the minimal detectable concentration, we 
drew a 2 X 2 contingency table in which numeric values were transformed into categorical 
variables (below and above the limit of assay sensitivity), and Fisher’s exact test on 
frequencies was applied to compare AD and CT. 
As several possible parameters were found to predict the craving, a more detailed 
statistical analysis to test the association between craving (outcome) and inflammation 
(predictor) using a multiple regression model was performed. In order to limit the number of 
predictors to improve the quality of the model, it was decided to enter in our model only the 
inflammatory parameters that were significantly associated with alcohol craving (IL-1β, IL-8, 
c-Fos, c-Jun, NLRP3, NOD2 and IκBα) and a Stepwise method was used which is the 
appropriate method for exploratory model building. 
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Supplemental table 1 : Primer sequences used for real-time quantitative PCR 
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Supplemental table 2 : Antibodies and working conditions for Western blotting 
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2.8 Complementary discussion and conclusion 
The increased mRNA expression of TLR4 and TLR2 receptors on PBMCs leads us to 
suggest that LPS and PGN were both present in blood. Plasma LPS levels in alcohol-
dependent subjects have already been assessed in our previous study (Chapter 1) and were 
found to be higher than in healthy subjects. However, the presence of PGN in blood of 
alcohol-dependent subjects has been poorly described in the literature. We measured, in 
PBMCs, the mRNA expression of NOD2 which is an intracellular marker of the presence of 
PGN and found that it was largely increased in alcohol-dependent subjects, which suggest that 
PGN were actually circulating in blood of patients. Finally, we assessed the plasma PGN by 
using a commercially available ELISA kit. The results of the assay indicated that plasma PGN 
levels were significantly higher in the alcohol-dependent group compared to controls. 
Information provided by the manufacturer revealed that the specificity of the assay is limited 
by the fact that cross-reactivity with analogue compounds is possible. Therefore, we are not 
sure to measure reliably the PGN concentrations in blood as we are limited by the current 
technical skills. This kit was the only way to assess the PGN levels, but indirect markers 
(TLR2 and NOD2) confirm our hypothesis that PGN may contribute to the systemic 
inflammation in alcohol-dependent subjects. 
Although LPS and PGN are present in the systemic circulation, it was essential to check 
whether they actually activate their receptors expressed on PBMCs. Therefore, PBMCs of 
alcohol-dependent and control subjects were cultured in presence of very low concentration of 
LPS and PGN and pro-inflammatory cytokines were then measured in the medium or in the 
cells to evaluate receptors activation. We were attentive to minimize the duration of culture 
and the cells were stimulated with expected “physiological” doses of LPS and PGN ranking 
from 0,1 to 10 ng/ml which were at least 1000 times less concentrated than doses commonly 
used (10µg/ml) in other studies to assess the inflammatory response. As alcohol-dependence 
is a condition that “naturally” increased the plasma levels of LPS and PGN, the cells that we 
extracted from the patients have already been in contact and “primed” by the bacterial toxins. 
This may explain why it was not necessary to over-accentuate the inflammatory response with 
extra artificial pathogen stimulation to observe a response. In keeping with our observation, 
shortly after the publication of this study, this concept of physiological stimulation was 
applied by American researchers where they tested the effect of acute binge drinking on 
bacterial translocation and immune response in healthy humans and showed that physiological 
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dose of LPS (100 pg/ml) is sufficient to induce an increase in inflammatory cytokines [250]. 
In the second part of the study, the expression of molecules involved in the inflammatory 
pathways (receptors, adaptor molecules, kinases, transcription factors, cytokines) were always 
measured under naturalistic conditions, without culturing cells or applying bacterial toxin 
stimulation. Our results are therefore expected to reflect the real and the pathophysiological 
impact of gut-derived bacterial products on the inflammatory response. 
In these conditions, we found strong evidences of NFκB-pathway inhibition, which is 
in contrast with a lot of previous experimental studies that consider NFκB as the key 
transcription factor responsible for inflammation, in particular in animal model of chronic 
alcohol consumption. This discrepancy reminds us that in vitro models could be far away 
from physiological conditions and that results obtained in animal models are not inevitably 
transposable to humans, particularly in psychiatric diseases such as alcohol-dependence. On 
the other hand, the MAPK/AP-1 pathway was largely activated in alcohol-dependent subjects 
and was suggested to up-regulated the synthesis of IL-1β and IL-8. 
As for the study described in Chapter 1, we assessed the effect of a short-term alcohol 
withdrawal on the inflammatory pathways. We found that abstinence was associated with a 
total recovery of LPS-dependent receptors CD14/TLR4. This is consistent with the total 
recovery of plasma LPS levels observed in the first study. By contrast, the PGN-dependent 
receptors TLR2, NOD2 and NLRP3 remained largely expressed after 3 weeks of abstinence. 
This suggests that PGN are still present in blood at the end of the detoxification program and 
could contribute to the persistence of plasma inflammatory cytokines at T2. Unhappily, the 
direct measure of PGN in the plasma of abstinent subjects was not performed in the study 
because we did not have plasma samples collected in an appropriate way.  
Interestingly, the decrease in inflammatory markers, in particular IL-8, during alcohol 
withdrawal correlated with the improvement of craving scores, suggesting that inflammation 
might play an important role in the drinking behavior. IL-8 is also called “neutrophil 
chemotactic factor” meaning that it is able to induce chemotaxis of neutrophils and other 
inflammatory cells which therefore move toward the site of infection. In this study, we 
analyzed the inflammatory pathways in PBMCs, which consist in monocytes and 
lymphocytes. These cells were obtained by using a Ficoll gradient that excluded neutrophils 
from the whole blood. However, this important class of immune cells which express TLRs 
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could also play a role in the induction of inflammation following LPS and PGN exposure. 
Monocytes levels are higher in alcohol-dependent patients compared to healthy controls while 
the levels of neutrophils did not differ significantly from both groups (fig 1-1). However, after 
splitting the AD subjects into “high” and “low” intestinal permeability groups (see Chapter 3 
for detailed explanations), we found that the monocytes and neutrophils levels were actually 
higher in subjects with “high” intestinal permeability compared with controls (fig 1-1). Also, 
among all white blood cells, monocytes and neutrophils positively correlated with gut 
permeability (r = 0.37, p < 0.05 for monocytes; r = 0.42, p < 0.05 for neutrophils, n = 28).  
  
 
Figure 1-1. Blood monocytes and neutrophils levels (absolute values) measured in healthy controls (CT) and 
alcohol-dependent subjects (AD) with high (red) and low (green) intestinal permeability (IP) at the beginning 
(T1) and end (T2) of alcohol withdrawal. * p < 0.05 vs CT, ** p < 0.01 vs CT, *** p < 0.001 vs CT. $ p < 0.05 
AD high IP vs AD low IP. 
Regarding the significant correlations between inflammation and craving, we decided 
to investigate whether inflammation could have an impact on cognitive and executive 
functions that are known to be involved in drinking motivation. Experiments are in progress. 
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The conclusions and perspectives of Chapter 2 are the following: 
 In addition to LPS, the peptidoglycans cross the gut barrier and stimulate 
specific inflammatory pathways in PBMCs. 
 Under “natural” physiopathological conditions, NF-κB is strongly inhibited 
whereas MAPK/AP-1 pathway and inflammasome are activated. 
 PBMCs may contribute to the enhanced plasma level of IL-1β and IL-8, but are 
not the source of systemic TNFα and IL-6 observed in AD subjects. Additional 
analyses of liver tissue and intestinal biopsies would be required to determine 
the potential source of systemic TNFα and IL-6. 
 The improvement of craving score during detoxification correlates with the 
decrease in inflammatory markers, in particular IL-8. This suggests that 
inflammation may influence drinking behavior. 
 As IL-8 is a “neutrophils chemotactic factor”, we suggest testing in future 
studies the inflammatory pathways in neutrophils and their potential 
contribution in behavioral changes. 
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3 CHAPTER 3 
INTESTINAL PERMEABILITY, GUT BACTERIAL DYSBIOSIS, AND 
BEHAVIORAL MARKERS OF ALCOHOL DEPENDENCE SEVERITY 
 
Recent findings support that the gut microbiota plays a key role in the onset of gut 
barrier alterations and inflammation. Dysbalance of the gut microbiota composition has been 
reported in somatic diseases such as obesity and metabolic disorders, intestinal bowel 
diseases, allergy. More recently, dysbiosis has also been shown in animal models of autism 
and alcohol dependence as well as in psychiatric subjects. These observations support the 
hypothesis that the gut bacteria may interact with the central nervous system and influence 
mood and behavior. 
The originality of this study resides in the fact that we have analyzed in parallel the gut 
microbiota – from a taxonomic and metabolomics point of view, the intestinal permeability, 
the systemic inflammation and the psychological symptoms of alcohol-dependent subjects. To 
our knowledge, this is the first report to combine all these parameters in one clinical study. 
The main strength of this study is that gut microbiota has been analyzed in details. On the one 
hand, the composition of gut bacteria has been investigated by using two complementary 
culture-independent approaches: the next-generation sequencing of the 16S rRNA gene and 
the quantitative PCR. On the other hand, the functionality of the bacteria inhabiting the gut 
has been assessed by using metabolomics analysis. Identifying the bacterial changes that 
occurs upon chronic alcohol consumption is an important step. However, it is likely that the 
gut-brain interactions are mediated by the metabolites produced by the bacteria rather than 
bacteria themselves. Therefore, the metabolomic analysis was useful to identify bacterial 
products that are suspected to have beneficial or detrimental effects on the host health. 
The results related to this chapter have been published in Proceedings of the National 
Academy of Sciences (PNAS) 21;111(42):E4485-93. 
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3.1 Abstract 
Alcohol dependence has traditionally been considered a brain disorder. Alteration in the 
composition of the gut microbiota has recently been shown to be present in psychiatric 
disorders, which suggests the possibility of gut-to-brain interactions in the development of 
alcohol dependence. The aim of the present study was to explore whether changes in gut 
permeability are linked to gut microbiota composition and activity in alcohol-dependent 
subjects. We also investigated whether gut dysfunction is associated with the psychological 
symptoms of alcohol dependence. Finally, we tested the reversibility of the biological and 
behavioral parameters after a short-term detoxification program. We found that some, but not 
all, alcohol-dependent subjects developed gut leakiness, which was associated with higher 
scores of depression, anxiety, and alcohol craving after 3 weeks of abstinence, which may be 
important psychological factors of relapse. Moreover, subjects with increased gut 
permeability also had altered composition and activity of the gut microbiota. These results 
suggest the existence of a gut-brain axis in alcohol dependence, which implicates the gut 
microbiota as an actor in the gut barrier and in behavioral disorders. Thus, the gut microbiota 
appears to be a new target in the management of alcohol dependence. 
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3.2 Introduction 
Alcohol consumption is the world’s third largest risk factor for disease and disability 
and accounts for 5.9% of all deaths worldwide (1). Although alcohol exerts large deleterious 
effects on health, studies to date on the pathophysiology of alcohol dependence have mainly 
focused on the influence of alcohol consumption on neuronal functions in the brain (2). A 
limited number of studies have, however, suggested that gut functions might also be altered 
by chronic alcohol consumption (3,4). Accordingly, we and others have shown that actively 
drinking alcohol-dependent (AD) subjects exhibited increased intestinal permeability (IP) and 
increased plasma levels of gut-derived bacterial products such as lipopolysaccharides and 
peptidoglycans (5–8). These bacterial products activate specific inflammatory pathways that 
partially recover after a 3-week period of alcohol abstinence (5,6). These recent observations 
indirectly suggest the possibility that the composition of gut microbiota could be altered in 
AD subjects and related to behavioral symptoms.  
The human gut microbiota consists of a complex community exceeding 100 trillion 
microorganisms (9) whose collective genome—the microbiome—encodes 100 times more 
genes than the human genome (10). It is now widely accepted that the gut microbiota should 
be considered an “exteriorized” organ placed within the body, which provides important 
physiological functions and is indispensable for human life (10–12). However, the microbial 
composition or activity of the gut can be modified by diet, antibiotic use, host genetics, and 
other environmental factors (13). Data suggest that an imbalance of the intestinal microbiota, 
known as dysbiosis, may contribute to a variety of somatic diseases such as obesity (14), type 
2 diabetes (15), inflammatory bowel diseases (16,17), and allergy (18). 
Recent studies suggest that the gut bacteria also influence brain functions and behavior 
and may therefore play a role in the development of psychiatric disorders (19). Indeed, in 
experimental studies, researchers observed that germ-free mice displayed reduced anxiety-like 
behavior compared with mice with normal gut microbiota, demonstrating evidence of gut-to-
brain interactions (20,21). Further studies brought forward evidence that the pathways 
underlying the gut-brain axis are multiple and highly complex, involving brain biochemistry, 
the vagus nerve, pro-inflammatory cytokines and tryptophan metabolism, (22). Furthermore, 
inflammation and tryptophan/kynurenine pathways have been related to the development of 
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depression-like behavior (23–26).  In addition, gut bacteria produce neurotransmitters 
(serotonin, GABA, dopamine, acetylcholine), and bacterial fermentation of dietary fiber 
induces the release of short-chain fatty acids, which are metabolites with potential neuroactive 
properties (22). Recent evidence also suggests that Bacteroides fragilis may prevent autism 
spectrum disorder in a mouse model (27) and administration of probiotic Bifidobacterium 
infantis may have anti-depressant properties in rats through changes in tryptophan/kynurenine 
pathway (26). Although several animal studies support a relation between the gut microbiota 
and behavior, major questions remain regarding this relation in human health. 
Depression and anxiety frequently develop in actively drinking AD subjects and play an 
important role in the negative reinforcement of drinking tendency (28). These factors are 
strongly related to the urge to drink, hereafter referred to as alcohol craving (29,30), an 
important predictor of relapse after detoxification (31). The possibility that these 
psychological symptoms of addiction are related to a dysbiosis has so far never been 
investigated. The aim of the present study was to determine whether gut permeability could be 
associated to the severity of psychological symptoms (depression, anxiety and craving) 
developed by human AD subjects. Then, we assessed the composition and activity of the gut 
microbiota and tested whether they are related to gut permeability. Finally, we analyzed 
whether alterations in gut permeability, microbiota composition and metabolome are 
reversible after 3 weeks of alcohol withdrawal, which is known to induce partial recovery of 
psychiatric symptoms (32). 
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3.3 Results  
IP is increased in a subset of AD subjects 
Intestinal permeability was measured by using the 
51
Cr-EDTA method. Results 
revealed that, at the 2nd day of alcohol withdrawal (T1), 26 of 60 (43%) patients had elevated 
gut permeability, whereas the remaining 34 (57%) patients had normal gut permeability 
compared with control subjects (Figure 1A). Subjects were therefore split into 2 groups: AD 
patients with “high” IP and AD patients with “low” IP. This separation of subjects was 
calculated according to a deviance criterion at a threshold of 1.65 standard deviations of the 
mean of the control group. In a normal distribution, this corresponds to the 5th percentile, 
which is a common threshold to highlight deviance from the mean. The gut permeability level 
was not related to the amount of alcohol consumed, which was similar in both subgroups of 
patients (P = 0.72).The demographic characteristics of the subjects included in this 
preliminary study are shown in Table 1. After 19 days of alcohol abstinence (T2), the gut 
permeability of AD subjects with high IP decreased significantly, the mean being equivalent 
to that observed in the control group and in the group of AD subjects with low IP at T1 
(Figure 1B). The detailed results of small bowel and colon permeabilities are presented in 
Table S1.We also examined the type of alcoholic beverages consumed by each subject and 
found that, on average, the consumption of beer was similar in both groups of AD patients 
(with high and low IP). However, the consumption of wine tended to be lower in AD subjects 
with high IP and the consumption of spirits tended to be higher in AD subjects with high IP 
(Figure S1). 
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Figure 1 : Intestinal permeability was measured by using the 
51
Cr-EDTA method. (A) Results revealed that, 
at T1, 26 of 60 patients had elevated gut permeability, whereas the remaining 34 patients had normal gut 
permeability compared with control subjects. Subjects were therefore split into 2 groups: AD patients with 
“high” IP and AD patients with “low” IP. (B) A 3-week alcohol withdrawal induced a total recovery of gut 
permeability in AD subjects with high IP. Subjects that relapsed during the detoxification program were 
excluded from analysis and results were obtained in 43 subjects. CT: control subjects; AD: alcohol dependent 
subjects; IP: intestinal permeability. T1 and T2 refer to the beginning and end of alcohol withdrawal, 
respectively. *** and ### P < 0.001 
Table 1: Demographic and clinical characteristics of the control and alcohol-dependent groups in the 
preliminary and main studies. Data are means ± SD. AD high IP and AD low IP refer to alcohol-dependent 
subjects with high and low intestinal permeability, respectively. CT refers to the control group. M: male; F: 
female; nd: not defined.*** P < 0.001 (AD vs. CT). 
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Gut barrier alteration is associated with the persistence of psychological symptoms at 
the end of alcohol withdrawal 
We assessed the psychological status of AD subjects, as alcohol dependence is firstly a 
psychiatric disorder. At the beginning of detoxification, all psychological scores (depression, 
anxiety, and alcohol craving) were higher in AD subjects than in controls, as described in our 
previous study (4). Alcohol withdrawal is known to be associated with an improvement in 
psychological symptoms. Indeed, we found that at the end of the detoxification, the 
depression and anxiety scores of AD subjects with low IP recovered completely and returned 
to the same level as that of controls. However, the AD subjects with high IP were still 
characterized by higher levels of depression, anxiety, and craving (Figure 2A). Correlation 
analysis revealed that IP measured at the beginning of withdrawal was positively associated 
with all of the psychological symptoms measured at the end of the detoxification program 
(Figure 2B). These results suggest that the gut barrier function could be involved in the 
persistence of psychological symptoms after detoxification. 
 
Figure 2: Increased intestinal permeability of AD subjects was associated with the persistence of 
psychological symptoms at the end of alcohol withdrawal.  (A) Scores of psychological factors in CT and AD 
subjects at the beginning (T1) and end (T2) of withdrawal showing that AD subjects with high IP had higher 
score of depression, anxiety, and alcohol craving at T2. * P < 0.05 vs. CT; ** P < 0.01 vs. CT; *** P < 0.001 vs. 
CT; $ P < 0.05. (B) Associations of IP measured at T1 with psychological factors assessed at T2. Values are 
Pearson’s moment correlation coefficients. AD subjects with high IP and low IP are depicted in red and green, 
respectively. IP: intestinal permeability; CT: control; AD: alcohol dependent. 
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The gut microbiota profile is altered in AD subjects with high IP  
In a subset of 13 AD subjects, we analyzed the gut microbiota composition and 
functionality and tested whether they could be related to the gut permeability. The 
demographic and clinical characteristics of these 13 subjects, which were also split into high 
and low IP groups, are shown in Table 1. Both groups of AD subjects had elevated 
concentrations of all inflammatory markers (TNFα, IL-1β, IL-6, IL-8 and IL-10) and of high-
sensitivity C-reactive protein (Figure S2). However, the level of IL-8 was significantly higher 
in AD subjects with high IP than it was in AD subjects with low IP, and this cytokine was 
positively correlated with IP (r = 0.79, p = 0.01).  
The overall gut microbiota composition was analyzed by pyrosequencing of the 16S 
rRNA gene, and profiles of microbial abundance were obtained from each subject. Nonmetric 
multidimensional scaling revealed that the bacterial profiles of AD subjects with a high IP 
differed from those of the controls and the AD subjects with low IP (Figure 3A). We then 
investigated which bacterial groups were responsible for the changes observed in the profile 
of AD subjects with high IP. We did not find significant differences between the 3 groups of 
subjects at the phylum level of the bacteria. However, at the family level, bacteria from 
Ruminococcaceae and Incertae Sedis XIII were less abundant, while those from 
Lachnospiraceae and Incertae Sedis XIV were more abundant in AD subjects with high IP 
compared with AD subjects with low IP and controls (Figure 3B). At the genus level of the 
bacterial groups, AD subjects with high IP had a drastic decrease in the abundance of 
Ruminococcus, Faecalibacterium, Subdoligranulum, Oscillibacter, and Anaerofilum. All of 
these genera belong to the Ruminococcaceae family. The abundance of Dorea, which belongs 
to the family Lachnospiraceae, was increased in AD subjects with high IP. Additionally, the 
genera Blautia and Megasphaera were increased, whereas Clostridia was decreased in AD 
subjects with high IP (Figure 3B). These analyses also revealed that the relative abundance of 
the taxa mentioned above was similar in AD subjects with low IP and the controls. 
The abundance of common bacterial species was also assessed by using quantitative 
PCR (qPCR) (Figure 3C). We found that the total amount of bacteria was significantly lower 
in AD subjects with high IP compared with the other 2 groups. We then quantified the level of 
Faecalibacterium prausnitzii, a bacterial species known for its anti-inflammatory properties 
(33), and found that it was drastically decreased (up to 4 log units) in AD subjects with high 
IP. This result is consistent with those obtained with the pyrosequencing approach. In 
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addition, F. prausnitzii was negatively correlated with plasma IL-8 levels (r = -0.65, P = 
0.003)  Finally, we assessed the levels of  Bifidobacterium spp. and Lactobacillus spp., and 
found that the level of Bifidobacterium spp. was significantly lower in AD subjects with high 
IP compared with controls and AD subjects with low IP. The decrease was not significant for 
the level of Lactobacillus spp. 
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Figure 3: Gut microbiota profiles of AD subjects with high and low intestinal permeability at the 
beginning of alcohol withdrawal. (A) Gut bacterial profiles were calculated for each subject using the 
abundance of the bacterial families from 454 pyrosequencing data. Bacterial taxa for which the sum of sequences 
in all the samples was less than 0.01% of the total number of sequences were removed from the analysis. 
Hellinger transformation was applied to the resulting matrix. Subjects were plotted in the map by using 
nonmetric multidimensional scaling. (B) Relative abundance of bacterial families and genera at the beginning of 
withdrawal. No significant differences were observed between AD subjects with low IP and controls. 
Differences observed between AD subjects with high IP and the other 2 groups are depicted. Results of relative 
abundance obtained from pyrosequencing are expressed in % sequences/taxon. * P < 0.05 vs. CT, ** P < 0.01 
vs. CT, *** P < 0.001 vs. CT, $ P < 0.05 vs. ADT1 low IP, $$ P < 0.01 vs. ADT1 low IP.  (C) Total bacteria, F. 
prausnitzii, Bifidobacterium spp., and Lactobacillus spp. were quantified by qPCR in CT and AD subjects at the 
onset (T1) of alcohol withdrawal. * and $  P < 0.05, $$ P < 0.01, *** and $$$ P < 0.001. (D) Chart depicting the 
correlations between IP and gut bacteria detected by pyrosequencing and qPCR methods at the beginning of 
detoxification. * indicates significant correlations (P < 0.05) and # 0.1 < P < 0.05. (E) Correlations between IP at 
T1 and gut bacteria measured by qPCR. r indicates Pearson’s coefficient. AD subjects with high IP and low IP 
are depicted in red and green, respectively. IP: intestinal permeability; RA: relative abundance; AD: alcohol 
dependent; CT: control. T1 refers to the beginning of alcohol withdrawal.  
 
An altered microbiota composition is associated with gut barrier dysfunction 
As only the AD subjects who presented increased IP had an altered gut microbiota 
composition compared with control subjects, we hypothesized that some bacteria could be 
involved in the regulation of the gut barrier function. We therefore tested the correlations 
between gut bacteria and IP at T1 (Figure 3D,E). Our analysis revealed a negative correlation 
between IP and the total amount of bacteria, indicating that subjects with a low number of 
bacteria in the gut had a higher IP. Negative correlations were also found for the bacteria 
belonging to the Ruminococcaceae family, especially for F. prausnitzii. Bifidobacterium was 
also negatively correlated with IP. The genera Dorea and Blautia that were increased in AD 
subjects with high IP were positively correlated with IP. These results support the hypothesis 
that the microbiota composition may influence gut barrier function. 
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Effect of short-term alcohol withdrawal on gut microbiota composition  
The microbial composition of AD subjects was also assessed at the end of a 3-week 
detoxification program (T2). We found that alcohol abstinence induced a significant increase 
in Ruminococcaceae in subjects with high IP. The genera Ruminococcus and 
Subdoligranulum also increased at T2 although not significantly. However, the family 
Erysipelotrichaceae and the genus Holdemania decreased significantly from T1 to T2 in all 
AD subjects (Figure 4A). Alcohol withdrawal had no impact on the abundance of the other 
families or genera that were found to be modified in AD subjects with high IP at T1. 
However, qPCR analysis revealed that the total amount of bacteria, as well as the levels of 
Bifidobacterium spp. and Lactobacillus spp., increased significantly during withdrawal in AD 
subjects with high IP and returned to the levels of controls (Figure 4B). In contrast, the levels 
of F. prausnitzii remained unchanged at the end of the detoxification program (Figure 4B). 
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Figure 4: Effect of alcohol withdrawal on gut microbiota composition. (A) A significant increase in 
Ruminococcaceae was observed from T1 to T2 in AD subjects with high IP (*P < 0.05). The genera 
Ruminococcus and Subdoligranulum also increased during withdrawal in AD subjects with high IP but not 
significantly (#P = 0.11). The family Erysipelotrichaceae and the genus Holdemania decreased significantly 
during withdrawal (*P < 0.05) in all subjects. Results of relative abundance obtained from pyrosequencing are 
expressed in % sequences/taxon. (B) Abundance of total bacteria, F. prausnitzii, Bifidobacterium spp., and 
Lactobacillus spp. after 3 weeks of alcohol abstinence as measured by qPCR. * P < 0.05 in AD high IP from T1 
to T2. AD high IP and low IP are depicted in red and green, respectively. AD: alcohol dependent; CT: control; 
IP: intestinal permeability. T1 and T2 refer to the beginning and end of alcohol withdrawal, respectively. 
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The metabolic profile is altered in AD subjects with gut barrier dysfunction 
Metabolomic analyses of fecal samples were also performed in the subset of 13 AD 
subjects in order to investigate whether bacterial metabolites could be associated with the 
altered gut barrier function. A total of 155 volatile organic compounds (VOCs) were 
identified. Subject-specific compounds and metabolites present in less than 20% of subjects in 
both groups (AD and control) were discarded from statistical analysis. Ninety-nine VOCs 
remained and were considered in the analysis of metabolic profiles. No outlier was detected 
with principal component analysis. Thirty-eight compounds were common to 80% of the 
samples (Table S2). Some metabolites, including 2-methyl-1-butanol and methanethiol, were 
commonly found in controls but were absent in AD subjects (Table S3). On the other hand, 
metabolites belonging to alcohols, alkanes, and benzenes were found only in AD and not in 
control subjects (Table S4). 
We then performed additional analyses that considered the gut barrier function of the 
individuals. Partial least squares-discriminant analysis (PLS-DA) revealed that the metabolic 
profiles of AD subjects with high IP differed from those with low IP (Figure 5A). The 
corresponding loading plot (Figure S3), showing the metabolites, was used to identify 
discriminating metabolites, whose relative indices are shown in Figure S4A-G. Among them, 
phenolic and indolic compounds, which arise from the metabolism of aromatic amino acids, 
were found to be associated with the gut barrier status. Phenol was present in high amount in 
patients with high IP, whereas it was almost absent in subjects with low IP (Figure 5B). 
However, the level of 4-methyl phenol was higher in AD subjects with low IP compared with 
AD subjects with high IP (Figure 5B). Indole and 3-methyl indole were present in high 
amounts in AD subjects with low IP, but were lower or almost totally absent in AD subjects 
with high IP (Figure 5C). 
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Figure 5: Metabolomic profiling of AD subjects with high and low IP. (A) Score plots showing clustering of 
the metabolite profiles analyzed with partial least squares-discriminant analysis. (B-C) Volatile organic 
compounds belonging to the chemical classes (B) phenols, (C) indoles. * P < 0.05 compared with CT,  *** P < 
0.001 compared with CT, $ P < 0.05 AD high IP vs. AD low IP at the same study time, $$ P < 0.01 AD high IP 
vs. AD low IP at the same study time,  # P < 0.05 compared with ADT1 high IP. AD subjects with high IP and 
low IP are depicted in red and green, respectively. CT subjects are depicted in blue. IP: intestinal permeability; 
RI: relative indices; CT: control subjects; AD: alcohol-dependent subjects. T1 and T2 refer to the beginning and 
end of alcohol withdrawal, respectively. 
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3.4 Discussion 
Gut permeability is associated with the severity of behavioral markers of alcohol 
dependence  
A limited number of human studies (7,34–36) have analyzed gut permeability in AD 
subjects, who are often also diagnosed with alcoholic liver disease . Most of these studies 
reported an increase in small bowel permeability, while a few pointed to increased colon 
permeability. We have observed two different clusters of AD subjects with distinct 
permeability features. The high IP group of subjects had a large increase in small bowel and 
colon permeabilities that recovered after a detoxification program. In the low IP group, the 
gut barrier function remained normal throughout the process.  
AD subjects also presented with psychological symptoms, including depression, 
anxiety, and alcohol craving, which contribute to the negative reinforcement process, a major 
mechanism involved in the persistence of alcohol dependence (38) that is related to a higher 
probability of relapse after detoxification. In our previous studies (5,6), we observed that 
alcohol withdrawal induced only a partial recovery of these behavioral markers. The present 
study shows that the recovery of these markers is not evenly distributed among AD subjects. 
AD subjects with low IP recovered completely at T2 for depression and anxiety. This 
population seems to present with a less severe form of dependence where affective symptoms 
recover after detoxification. Conversely, in AD subjects with high IP, the scores of 
depression, anxiety and craving remained largely increased, even when they had stopped 
drinking for more than two weeks. These observations suggest that gut permeability is related 
to psychological status at the end of alcohol withdrawal.  
If gut permeability does play a role in behavioral changes, one must pay attention to 
the potential mechanisms by which alterations of the gut barrier function occur. The 
possibility of a toxic effect of ethanol on the small bowel epithelium has been described in 
healthy subjects (34,39) and in in vitro studies (40–43). However, patients from both groups 
consumed the same amount of alcohol, which lessens the implication that ethanol itself is 
involved in permeability disturbance. The difference in IP in this context might be ascribed to 
changes in microbial composition and activity. This hypothesis is supported by a rodent study 
in which antibiotic treatment abolished the ethanol-induced increase in colonic paracellular 
permeability (44).  
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Increased gut permeability is associated with dysbiosis in AD subjects 
Consistent with the hypothesis that dysbiosis is linked to gut barrier alteration, only 
the subgroup of AD subjects with high IP had altered gut microbiota composition. It consisted 
of a large decrease in the overall bacterial load, a drastic decrease in abundance in the 
Ruminococcaceae family (Ruminococcus, Faecalibacterium, Subdoligranulum, Oscillibacter, 
Anaerofilum), and an increase in abundance in the Lachnospiraceae family (Dorea) and the 
genus Blautia.  
Preclinical studies have shown that chronic ethanol administration induces in rats a 
dysbiosis (45), and in mice a decrease in the level of Ruminococcaceae (46), or a decrease in 
the level of Firmicutes and an increase in Bacteroidetes (47). In humans, few studies have 
evaluated the gut microbiome of AD subjects and never in relation to gut permeability. 
Kirpich et al. (48) observed a decrease in Bifidobacterium and Lactobacillus in the stool 
cultures of AD subjects compared with those of healthy controls. In 2012, Mutlu et al. showed 
alterations of the mucosal-associated colonic microbiome in only a subset (31%) of AD 
subjects (49), indicating that not all alcoholics were dysbiotic, which is in line with our 
observation that only part of the AD patients had an altered gut microbiota profile. 
Furthermore, in the same study, the dysbiotic group included actively drinking and sober 
alcoholics (>1 month), suggesting long-lasting dysbiosis, which is consistent with the 
incomplete recovery of the gut microbiota that we observed after 3 weeks of abstinence. 
Interestingly, we observed that Lactobacillus spp. and Bifidobacterium spp., as well as 
bacteria from the family Ruminococcaceae, increased during alcohol abstinence, suggesting 
that these bacteria, known to have a beneficial impact on gut barrier function (50), could 
contribute to the recovery of IP at T2. This suggestion is supported by the strong negative 
correlations that we observed between IP and Bifidobacterium as well as Ruminococcaceae 
bacteria, particularly F. prausnitzii. This species is also depleted in Crohn’s disease (33) and 
ulcerative colitis (51) and has been shown to have anti-inflammatory properties both in vitro 
and in vivo (33) and therefore seems to be crucial for gut homeostasis. Indeed, supernatants 
from F. prausnitzii cultures inhibited IL-8 secretion and NF-κB activation in Caco-2 cells 
stimulated with IL-1β (33). In our study, AD patients who presented with low levels of F. 
prausnitzii had higher plasma IL-8 levels, and these variables were significantly and 
negatively correlated. Taken together, our results show that alterations in microbial 
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composition are associated with increased IP and increased plasma levels of pro-inflammatory 
cytokines.  
We also hypothesize that metabolites produced by gut bacteria might be at the origin 
of gut barrier dysfunction and inflammation. The metabolic profiles calculated by PLS-DA 
were clearly distinct between control, low IP, and high IP AD subjects. Overall, this 
observation supports the existence of a relation between metabolites and IP. Basically, 2 types 
of microbial fermentation occur in the colon: saccharolytic fermentation and proteolytic 
fermentation (52). The former is generally considered to be beneficial to the host, and the 
latter is presumed to be detrimental and might be involved in the etiology of colon cancer and 
ulcerative colitis (53). The main products of carbohydrate fermentation, i.e., SCFA, which 
present with beneficial functions (54), were not different between AD and control subjects 
and unrelated to IP. Metabolite differences among groups hence resulted mainly from the 
protein fermentation that leads to the formation of branched-chain fatty acids, indolic 
compounds, and potentially toxic metabolites such as phenolic and sulfur-containing 
compounds. The production of phenolic compounds in the gut depends on microbial 
composition (55) or microbial metabolic activities (56). Phenol that derives from tyrosine 
breakdown was largely increased in high IP AD subjects compared with the other 2 groups. 
The toxic effect of phenol on intestinal epithelial cells has been demonstrated in 2 
independent in vitro studies (57,58) suggesting that phenol is a potential driver of gut barrier 
alterations. Another phenolic compound, 4-methyl phenol (also called p-cresol), was 
decreased in AD subjects with high IP compared with the other 2 groups and increased upon 
alcohol withdrawal; the latter effect could be associated with the increase in Lactobacillus 
spp., Bifidobacterium spp., and Ruminococcaceae from T1 to T2 observed in AD subjects 
with high IP, as these genera and this family have been shown to be related to the production 
of p-cresol (59–62). Tryptophan bacterial metabolism results in a large variety of indolic 
compounds (62–65). In in vitro studies, indolic compounds were shown to improve intestinal 
cell barrier function and to decrease pro-inflammatory IL-8 expression (66,67). Interestingly, 
the level of 3-methylindole was completely blunted in high IP AD subjects who also 
presented with a higher IL-8 plasma level. Moreover, a study showed that the beneficial 
impact of probiotics on gut barrier function was induced by a protein factor (50). Taken 
together, these observations are consistent with a protective role of gut microbes that produce 
indolic compounds and p-cresol on the gut barrier and inflammation and with a detrimental 
role of bacteria producing phenol.  
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Study limitation 
The existence of distinct populations of AD subjects with differences in intestinal 
permeability that are related to differences in psychological symptoms could be established on 
a large group. There is however one limitation of this study that is the size of the sample for 
which we could obtain large details on the composition and function of the gut microbiota and 
on inflammation. The small size of the sample is due to the fact that deep analysis of gut 
microbiota are expensive and time consuming and that we used a test retest design that 
doubles the number of samples.  
In conclusion, this is the first study to investigate gut permeability, gut microbiota 
composition and activity and their relationship with the behavioral markers of addiction 
severity in AD subjects (Figure 6). The observation that some, but not all, AD subjects 
develop gut leakiness indicates that chronic alcohol dependence is necessary but not sufficient 
to cause gut dysfunction. Thus, other cofactors besides direct toxicity of alcohol may be 
involved. Here we showed that AD subjects presenting with increased IP also had altered gut 
microbial composition and activity. These results strongly suggest that the bacteria present in 
the gut and/or the metabolites produced by the bacteria may be involved in the regulation of 
the gut barrier function and could therefore contribute to the indirect toxicity of alcohol 
consumption. Moreover, we showed that AD subjects with gut dysfunction had higher scores 
for depression, anxiety, and alcohol craving at the end of the detoxification program, which is 
expected to influence the probability of relapse through a negative reinforcement mechanism. 
These results suggest the existence of a gut-brain axis in alcohol dependence, in which the gut 
microbiota could alter the gut barrier and influence the severity of alcohol-dependence 
behaviors. However, the mechanisms underlying the communication between the gut and the 
brain have not been analyzed in this study but deserve further investigation, in particular the 
involvement of the vagus nerve as well as the tryptohan/kynurenine pathway in alcohol-
dependent subjects. 
Overall, the gut microbiota appears to be a new target in the management of patients 
who are being treated for alcohol dependence. In view of the bacteria that were modulated 
upon alcohol consumption, which characterize increased gut permeability, we propose that 
more attention be paid to the nutritional follow-up of abstinent patients. Probiotics and 
prebiotics are known to improve the composition of the gut microbiota in favor of bacteria 
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that decrease gut barrier alterations (50,68) and inflammation  (13,69), and they may improve 
mood and behavior in several pathological contexts (27,70–73). Therefore, the use of these 
nutritional tools to improve gut function and mental health in patients diagnosed with alcohol 
use disorders deserves interest. 
 
Figure 6: Model representing the relationship between alcohol consumption, gut dysfunction and affective 
symptoms in the two subsets of alcohol-dependent subjects at both times of alcohol withdrawal. At the 
beginning of withdrawal (T1), a subset of AD subjects developed affective symptoms that were likely induced 
by ethanol and that were not associated with gut disorders. In the other subset of AD subjects, alcohol 
consumption was associated with gut leakiness, gut microbiota alterations and affective symptoms. After 3 
weeks of abstinence (T2), affective symptoms recovered completely in the subset of AD subjects that did not 
present with gut dysfunction at T1. In the other subset of AD subjects, the gut barrier was restored upon 
abstinence, but gut dysbiosis was still present at T2 and might be responsible for the persistence of affective 
symptoms. From this, we hypothesize that gut microbiota alterations could be associated with a more severe 
form of alcohol-dependence and a higher probability of relapse through negative reinforcement mechanisms 
linked to higher levels of depression, anxiety and alcohol craving.   
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3.5 Material and methods 
Subjects 
A group of AD subjects presenting with a diagnosis of alcohol dependence according 
to the Diagnostic and Statistical Manual of Mental Disorders (4th ed.) (74) who were 
clinically evaluated by a psychiatrist (PdT), were incorporated in to the study when admitted 
to the gastroenterology ward for a 3-week detoxification and rehabilitation program. Subjects 
had kept drinking until the day of admission to the detoxification ward, or the day before, and 
were tested twice, on the day following admission (T1) and on day 19 (T2) corresponding to 
the last day of detoxification. Patients who had metabolic disorders such as obesity (BMI > 30 
kg/m2) and diabetes, inflammatory bowel disease, other chronic inflammatory diseases (such 
as rheumatoid arthritis), or cancer, as well as those who took antibiotics, probiotics, 
glucocorticoids, or nonsteroidal anti-inflammatory drugs during the 2 months preceding 
enrollment were excluded from the study. Transient liver elastography (Fibroscan) was 
performed in all patients on the day of admission in order to quantify liver stiffness, which 
correlates with fibrosis grades according to the METAVIR classification system of fibrosis 
(75). From this evaluation, only patients without significant fibrosis (F0 and F1 scores) were 
selected. Patients with overt cirrhosis, on the basis of laboratory and imaging tests, were 
excluded (see Supplemental Material). A complete medication and medical history was taken 
at admission, as well as basic demographic and clinical data related to nutritional status. For a 
preliminary study, we could select a group of 60 AD subjects that were tested at T1 for 
intestinal permeability and psychological symptoms. Among them, 44 subjects who had 
remained abstinent until the end of the detox period were also tested at T2. This sample of 
subjects was split into high and low IP groups. From this preliminary group, a subset of 13 
subjects (8 men and 5 women) was tested for additional gut microbiota composition and 
functionality measurements both at T1 and T2. AD subjects were compared for intestinal 
permeability, psychological dimensions, gut microbiota composition and functionality with 15 
age-, gender-, and BMI-matched controls who socially consumed less than 20 g of alcohol per 
day. 
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Assessment of alcohol consumption 
The amount of alcohol consumed the week prior to hospitalization was evaluated with 
the time-line follow-back approach (76), as detailed in de Timary et al. (77). 
Measurement of IP 
IP was assessed by using the radioactive probe 51Cr-EDTA as described previously 
(5). Briefly, after an overnight fast and emptying of the bladder, patients drank a Nutridrink 
(200 ml, 150 kcal/100 ml) (Nutricia, Brussels, Belgium) containing 50 µCi (1.85 MBq) 51Cr-
EDTA. Urine was collected for 24 hours. Radioactivity was measured in urine collections 
with a gamma counter (Cobra5003 Canberra Packard, Downers Grove, IL). Urinary excretion 
was expressed as the percentage of the ingested dose (ID) normalized to creatinine 
concentration (% ID/g creatinine). 
Gut microbiota analysis 
Gut microbiota was analyzed by using 2 culture-independent methods; 
pyrosequencing and qPCR of 16S rDNA. These methods are complementary, since 
pyrosequencing allows the creation of a qualitative bacterial profile that considers most of the 
bacteria present in the gut, whereas qPCR is used to quantify specific bacterial targets of 
particular interest. Moreover, qPCR is more sensitive and can quantify some bacteria that are 
not detected with pyrosequencing, such as Bifidobacterium spp. 
Fecal samples were collected in a sterile container and immediately stored at -80oC 
until further processing. Bacterial DNA extraction was performed by using the repeated bead 
beating procedure with a modified protocol for the QIAamp Stool DNA Mini Kit (Qiagen, 
Hilden, Germany).  
A detailed description of both methods is provided in the supplemental material and 
primer sequences are mentioned in Supplemental Table 5. 
Analysis of VOCs in fecal samples 
Stool samples were transferred to a headspace vial and VOCs were analyzed on a gas 
chromatography-mass spectrometry quadrupole (Trace GC Thermoquest, Rodano, Italy and 
DSQ II, Thermo Electron, San José, CA), which was coupled online to a purge-and-trap 
system. Before analysis, 125 mg fecal aliquots were suspended in 5 ml water. Diethyl acetic 
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acid (1.5 mg/L) was added as an internal standard. A magnetic stirrer, sulfuric acid, and a 
pinch of sodium sulphate were added to the sample to acidify and salt out the solution. The 
chromatograms thus obtained were processed by using AMDIS (Automatic Mass Spectral 
Deconvolution and Identification Software version 2.71) provided by the US National 
Institute of Standards and Technology (NIST, Gaithersburg, MD). Identification of the 
metabolites in the samples was achieved by manual visual inspection of the mass spectra of 
unknown peaks with the NIST library. All compounds were relatively quantified compared 
with diethyl acetic acid. A detailed description of the method is provided in the supplemental 
material. 
Assessment of mood and psychological symptoms 
At the beginning and end of detoxification, all patients were tested for depression, 
anxiety, and alcohol craving with the French versions of self-reported questionnaires: the 
Beck Depression Inventory, the State-Trait Anxiety Inventory (form YA), and the Obsessive-
Compulsive Drinking Scale. These tests have been described in detail previously (5). 
Statistical analysis 
Statistical analyses were performed by using SPSS version 20.0 (IBM Corp, Armonk, 
NY). Assumptions of normality and equality of variances were checked with the 
Kolmogorov-Smirnov and Levene tests, respectively. If the assumptions were not met, 
Kruskal-Wallis tests were used to compare controls, AD subjects with high IP, and AD 
subjects with low IP. If the assumptions were met, parametric ANOVAs were performed. 
Significant ANOVA results were followed by Bonferroni’s post hoc test for pairwise 
comparisons. The effect of alcohol withdrawal was assessed by using Wilcoxon or paired t-
tests to compare data at T1 and T2. Bivariate correlations were performed with Spearman’s 
rho or Pearson’s product-moment correlation coefficient, depending on data assumptions. 
The absolute number of sequences for identified and unclassified taxa obtained by 
pyrosequencing in each sample was transformed by using the Hellinger method after 
removing taxa representing less than 0.01% of total abundance. The resulting matrix was used 
to construct nonmetric multidimensional scaling by using Bray-Curtis dissimilarity with 
PCOrd V6.08 (MjM Software, Gleneden Beach, OR, USA). The Bray-Curtis coefficient is a 
statistic used to quantify the compositional dissimilarity between 2 different bacterial profiles. 
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Relative abundances of taxa were analyzed by using Kruskal-Wallis tests and qPCR data were 
analyzed with ANOVA after log-transformation. 
Unscrambler X Version 10.2 (CAMO A/S, Trondheim, Norway) was used to perform 
cluster analyses of metabolite profiles. Subject-specific compounds (those detected in only 1 
person) and metabolites present in less than 20% of subjects in both groups (AD and control) 
were discarded from statistical analysis. 10 control samples were available for this analysis. 
Principal component analysis was applied to detect outliers. Clustering of similar metabolite 
patterns of the samples according to control, AD with high IP, and AD with low IP groups at 
T1 was then performed by using PLS-DA and was presented as a score plot. The 
corresponding loading plot, showing the metabolites, was used to identify discriminating 
metabolites. Kruskal-Wallis tests were applied to compare the relative indices of metabolites 
between controls, AD subjects with high IP, and AD subjects with low IP. 
Study approval 
The study protocol was approved by the local Ethical Committee and all subjects 
signed an informed consent form prior to the investigation (B40320096274, Commission 
d’éthique biomédicale hospitalo-facultaire de l’UCL). 
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3.7 Supporting information 
3.7.1 Supporting material 
 
Diagnosis of cirrhosis  
Liver biopsy is still regarded as the gold standard for grading and staging liver disease. 
However, this invasive procedure carries the risk of potential life-threatening complications 
(e.g., bleeding); therefore, for obvious ethical reasons, liver biopsy cannot be justified in all 
patients for study purposes. All of the subjects were instead systematically evaluated by blood 
tests (biochemistry, hematology, coagulation), by gastrointestinal endoscopy (to check for 
signs of portal hypertension such as esophageal and gastric varices), by liver Doppler-
ultrasound (to evaluate the shape of the liver, splenomegaly with collateral intra-abdominal 
venous circulation, or slow or inverted portal venous blood flow), and by measurement of 
transient liver elastography (Fibroscan). This new noninvasive technique has been designed to 
quantify liver stiffness, which has been correlated to liver fibrosis grades based on the 
METAVIR classification system of fibrosis. A validated cut-off has been published and 
studies clearly show that this technique is reliable in ruling out significant fibrosis and in 
confirming cirrhosis (1). Accordingly, we selected only F0 and F1 patients (i.e., absence of 
significant fibrosis) for the study (2, 3). Liver biopsy was performed only in patients in whom 
advanced fibrosis/cirrhosis was suspected after noninvasive work-up; these patients were, by 
definition, excluded from the study. 
Gut microbiota analysis by pyrosequencing and qPCR 
Fecal microbiota composition was studied by pyrosequencing of the V1-V2 region of 
the 16S rRNA gene. 16S rDNA was amplified by using 27F and 338R primers fused with 454 
titanium sequencing adapters. 338R primers contained unique error-correcting 12-base 
barcodes that allowed us to tag PCR products from different samples (4). Each sample was 
amplified in triplicate in a reaction volume of 25 μL containing 1.5 U of FastStart Taq DNA 
Polymerase (Roche), 0.2 μM of each primer, and 20 ng of genomic DNA. PCR was carried 
out under the following conditions: initial denaturation for 3 min at 95°C, followed by 25 
cycles of denaturation for 20 s at 95°C, annealing for 20 s at 52°C and elongation for 60 s at 
72°C, and a final elongation step for 8 min at 72°C. The amplification of the 16S rDNA was 
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not successful for 2 control samples, which were therefore excluded from the pyrosequencing 
analysis. Triplicates were combined, purified with the NucleoSpin Gel and PCR Clean-up kit 
(Macherey-Nagel, Germany), and then quantified by using the Quant-iT PicoGreen dsDNA 
kit (Invitrogen, Carlsbad, CA). Purified PCR products were diluted to a concentration of 20 
ng/μl and pooled in equal amounts. The pooled amplicons were purified again with the 
Ampure magnetic purification beads (Agencourt, Danvers, MA) to remove short 
amplification products. Sequencing was performed by using 454 GS FLX titanium chemistry 
at GATC Biotech (Konstanz, Germany).  
Raw data were quality filtered to remove sequences that were shorter than 200 
nucleotides or longer than 1000 nucleotides, or that contained primer mismatches, ambiguous 
bases, uncorrectable barcodes, or homopolymer runs in excess of 6 bases. Quality-filtered 
reads were trimmed of 454 adapter and barcode sequences and analyzed with the software 
package Quantitative Insights Into Microbial Ecology (QIIME) (5) (version 1.6.0). A total of 
517808 sequences were obtained for the 39 samples (13 controls and 13 AD subjects sampled 
before and after alcohol withdrawal). Sequences were demultiplexed and an average of 13277 
sequences were attributed to each sample (range: 6636-16482 sequences). Sequences were 
assigned to operational taxonomic units (OTUs) by using UCLUST with a 97% threshold of 
pairwise identity. The most abundant sequence was picked as representative for each OTU 
and was given a taxonomic assignment by using the Ribosomal Database Project (RDP) 
Classifier (6). Representative OTUs were aligned with Pynast (7). Sequences were checked 
for the presence of chimeras by using ChimeraSlayer, and chimeric sequences were excluded 
from all downstream analyses. Similarly, sequences that could not be aligned with Pynast 
were also excluded. 
qPCR of 16S rDNA was used to quantify the abundance of selected members of the 
gut microbiota. The primers used to detect total bacteria, Bifidobacterium spp., Lactobacillus 
spp., and Faecalibacterium prausnitzii are mentioned in Supplemental Table 5. PCR 
amplification was carried out as follows: 10 min at 95°C, followed by 45 cycles of 3 s at 
95°C, 26 s at 58°C or 60°C, and 10 s at 72°C. Detection was achieved with the STEP one 
PLUS instrument and software (Applied Biosystems, Foster City, CA) using the MESA 
FAST qPCR MasterMix Plus for SYBR Assay (Eurogentec, Verviers, Belgium). BSA was 
added to samples. Each assay was performed in duplicate in the same run. For construction of 
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standard curves, 5-fold dilution series from target species genomic DNA preparations 
(DSMZ, Braunschweig, Germany) were applied to the PCR. 
Analysis of volatile organic compounds (VOCs) in fecal samples by GC-MS 
VOCs from stool samples were analyzed on a gas chromatography-mass spectrometry 
(GC-MS) quadrupole (Trace GC Thermoquest, Rodano, Italy and DSQ II, Thermo Electron, 
San José, CA), which was coupled online to a purge-and-trap system. Before analysis, 125 mg 
fecal aliquots were suspended in 5 ml water. Diethyl acetic acid (1.5 mg/L) was added as an 
internal standard. A magnetic stirrer, sulfuric acid, and a pinch of sodium sulphate were added 
to the sample to acidify and salt out the solution. 
Briefly, VOCs were purged out of the sample with a helium flow (high purity 
(>99.99%)) at a rate of 40 ml/min for 20 min at 70 °C. Consequently, helium was carried over 
a “dry flow” column (Trap Tenax, Velocity, Interscience, Louvain-la-Neuve, Belgium) to 
control moisture transfer, and VOCs were concentrated on a second polar trap column (Trap 
Vocarb, Velocity, Interscience, Louvain-la-Neuve, Belgium). By raising the temperature to 
250 °C, the VOCs were desorbed from the column to the injector of the GC, where they were 
separated on an analytical column (AT Aquawax DA, 30 m  0.25 mm I.D., 0.25 µm film 
thickness, Grace, Deerfield, IL). The oven starting temperature was 35 °C for 1 min and 
increased by 5 °C/min to 100 °C and by 10 °C/min to 240 °C. The final temperature was held 
constant for 5 min. Masses between m/z 33 and m/z 200 were detected in full scan mode at 
1.5 scans/s. XCalibur software (Version 1.4 SR1, Thermo Electron) was used for 
automatization of the GC-MS and for data acquisition.  
The chromatograms that were obtained were processed by using AMDIS (Automatic 
Mass Spectral Deconvolution and Identification Software version 2.71) provided by the US 
National Institute of Standards and Technology (NIST, Gaithersburg, MD). This software 
provides quality matching by using advanced spectral algorithms, adjacent peak 
deconvolution, and background subtraction, which enables unambiguous identification 
together with quantitative indication of the metabolite levels. Identification of the metabolites 
in the samples was achieved by manual visual inspection of the mass spectra of unknown 
peaks with the NIST library. All compounds were relatively quantified compared with diethyl 
acetic acid.  
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3.7.2 Supporting figures  
 
 
Supplemental figure 1 : Types of alcoholic beverages consumed by AD subjects with high and low IP. 
Alcohol consumption was calculated by using the time-line follow-back approach and is based on the week prior 
to the hospitalization. AD: alcohol dependent; IP: intestinal permeability. 
 
Supplemental figure 2 : Increased plasma inflammatory markers in AD subjects at the beginning and end 
of detoxification (T1 and T2). # P < 0.10 vs. CT, * P < 0.05 vs. CT, ** P < 0.01 vs. CT, *** P < 0.001 vs. CT. 
CT: control; AD: alcohol dependent; IP: intestinal permeability. 
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Supplemental figure 3 : Loading plot resulting from PLS-DA analysis of metabolite profiles. This plot, 
showing the metabolites listed according their chemical class, was used to identify discriminating metabolites. 
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Supplemental figure 4: Volatile organic compounds belonging to the chemical classes (A) alcohols, (B) 
aldehydes, (C) medium-chain fatty acids (MCFAs), (D) branched-chain fatty acids (BCFAs), (E) phenols, 
(F) indoles, and (G) sulfides. * P < 0.05 compared with CT, ** P < 0.01 compared with CT, *** P < 0.001 
compared with CT, $ P < 0.05 AD high IP vs. AD low IP at the same study time, $$ P < 0.01 AD high IP vs. AD 
low IP at the same study time, $$$ P < 0.001 AD high IP vs. AD low IP at the same study time,  # P < 0.05 
compared with ADT1 high IP. AD subjects with high IP and low IP are depicted in red and green, respectively. 
CT subjects are depicted in blue. IP: intestinal permeability; RI: relative indices; CT: control subjects; AD: 
alcohol-dependent subjects. T1 and T2 refer to the beginning and end of alcohol withdrawal, respectively. 
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3.7.3 Supporting tables 
 
Supplemental table 1. Average values of intestinal permeability (IP) in CT and AD subjects at the 
beginning (T1) and end (T2) of alcohol withdrawal.  
 
Results are expressed as the percentage of the ingested dose of 
51
Cr-EDTA found in urine normalized for 
creatinine. Urine was collected for 24 h during 2 periods that were expected to reflect small bowel (0-4 h) and 
colon (4-24 h) permeability. From the total intestinal permeability value at T1, AD patients were split into high 
IP and low IP groups. Data are means ± SD. *** P < 0.001 vs. CT; $$ P < 0.01 vs. AD-Low IP; $$$ P < 0.001 
vs. AD-Low IP. CT: control; AD: alcohol dependent; nd: not defined. 
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Supplemental table 2. Volatile organic compounds found in more than 80% of the CT and AD study 
subjects.  
Chemical class Metabolite % presence 
 in CT 
% presence  
in ADT1 
Alcohol 1-Butanol 100 100 
Aldehyde Acetaldehyde 100 100 
Aldehyde Propanal 100 100 
Aldehyde Propanal, 2-methyl- 91 85 
Aldehyde Aldehyde RT 19,73 82 100 
Aldehyde Aldehyde RT 22,42 91 85 
Aldehyde Aldehyde RT 23,23 100 100 
Benzene Benzene 82 85 
Benzene Toluene 100 100 
Benzene x-Xylene RT 7,07  91 100 
Benzene Benzene, RT 9,86 100 100 
Benzene Benzene, RT 10,27 82 100 
Cycloalkene D-Limonene  100 100 
Cycloalkene 3-Cyclohexene-1-methanol, 
.alpha.,.alpha.4-trimethyl- 
91 85 
SCFA Acetic acid 100 100 
SCFA Propanoic acid 100 100 
SCFA Butanoic acid 100 100 
BCFA Propanoic acid, 2-methyl- 100 100 
BCFA Butanoic acid, 3-methyl- 100 100 
BCFA Butanoic acid, 2-methyl- 100 100 
BCFA Pentanoic acid, 4-methyl- 100 85 
MCFA Pentanoic acid 100 100 
MCFA Hexanoic acid 100 100 
Ether Ethyl ether 100 100 
Furan Furan 100 85 
Furan Furan, tetrahydro- 100 92 
Halogenide Trichloromethane 100 92 
Halogenide Bromochloronitromethane 100 100 
Halogenide Methane, tribromo- 91 92 
Indole Indole 100 100 
Phenol Phenol 82 92 
Phenol Phenol, 4-methyl- 100 100 
Sulfide Carbon disulfide 100 100 
Sulfide Disulfide, dimethyl 100 100 
Sulfide Dimethyl trisulfide 100 92 
Thiol 3,4-Dimethylthiophene 100 100 
Other Benzaldehyde 100 100 
Other Benzoic acid, 4-ethoxy-, ethyl ester 100 100 
Some aldehydes and benzenes were not identified. CT: control; AD: alcohol dependent; RT: retention time; 
SCFA: short-chain fatty acid; BCFA: branched-chain fatty acid; MCFA: medium-chain fatty acid. T1 refers to 
the beginning of alcohol withdrawal. 
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Supplemental table 3. Volatile organic compounds found in CT subjects but in less than 10% of alcohol-
dependent AD subjects.  
Chemical class Metabolite % presence 
 in CT 
% presence  
in ADT1 
Alcohol 1-Butanol, 2-methyl- 64 0 
Aldehyde Butanal, 3-methyl- 36 < 10 
Aldehyde Hexanal 55 < 10 
Benzene Benzene, RT 11,26 27 0 
Cycloalkane Cyclopentane, methyl- 27 0 
Furan Furan, 2-ethyl-5-methyl-  27 < 10 
Ketone 2-pentanone 27 < 10 
Thiol Methanethiol 55 0 
Other Anisole, p-allyl- 36 < 10 
The metabolite benzene RT 11,26 was not identified. CT: control; AD: alcohol dependent; RT: retention time. 
T1 refers to the beginning of alcohol withdrawal. 
 
Supplemental table 4. Volatile organic compounds found in AD subjects but in less than 10% of CT 
subjects.  
Chemical class Metabolite % presence 
 in CT 
% presence  
in ADT1 
Alcohol 1-Propanol < 10 46 
Alcohol 1-Nonanol 0 46 
Benzene Benzene, RT 9,23 < 10 31 
Benzene Styrene 0 92 
Benzene Benzene, RT 10,66 < 10 31 
Benzene Benzene, RT 11,82 0 46 
Benzene Benzaldehyde, 3,5-dimethyl-  0 100 
Benzene 4-Hydroxy-2-methylacetophenone  < 10 31 
Alkane Hexane 0 46 
Ester Propanoic acid, 2-methyl-, 3-hydroxy-
2,4,4-trimethylpentyl ester  
0 31 
Furan Furan, 2-ethyl-5-methyl-  < 10 23 
The metabolites benzene RT 9,23, benzene RT 10,66, and benzene RT 11,82 were not identified.  CT: control; 
AD: alcohol dependent; RT: retention time. T1 refers to the beginning of alcohol withdrawal. 
Results and discussion - Chapter 3 
188 
 
Supplemental table 5. Primer sequences used for qPCR analysis 
Target Forward and reverse primers T° annealing (°C) 
Total bacteria F: ACT-CCT-ACG-GGA-GGC-AGC-AG 
R: ATT-ACC-GCG-GCT-GCT-GG 
60 
Bifidobacterium spp. F: GAT-TCT-GGC-TCA-GGA-TGA-ACG-C 
R: CTG-ATA-GGA-CGC-GAC-CCC-AT 
60 
Lactobacillus spp. F: AGC-AGT-AGG-GAA-TCT-TCC-A 
R: CAC-CGC-TAC-ACA-TGG-AG 
58 
Faecalibacterium prausnitzii F: GAG-CCT-CAG-CGT-CAG-TTG-GT 
R: CCA-TGA-ATT-GCC-TTC-AAA-ACT 
60 
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3.8 Complementary discussion and conclusion 
In this complementary discussion, we will have the opportunity to discuss into details 
the data presented in the article, where several important aspects were only shortly discussed 
due to word count limitation. 
Discussion of the data of the intestinal permeability 
In Chapter 1, we found that intestinal permeability of alcohol-dependent subjects was, 
on average, increased at the beginning of alcohol withdrawal and recovered totally at the end. 
We also found that, on average, the psychological symptoms of alcohol dependence recovered 
partially during the detoxification program. In this Chapter 3, we found that only a subset of 
alcohol-dependent subjects developed gut leakiness. Those patients presented with high score 
of depression, anxiety and craving at the end of withdrawal whereas the patients which had 
normal intestinal permeability recovered completely for depression and anxiety.  
Discussion on metabolomics data 
In vitro studies have shown that ethanol can induce a decrease in epithelial resistance of 
Caco-2 cells [79]. However, the authors used a high dose of ethanol to see a small effect on 
epithelial cells permeability. On the other hand, acetaldehyde has been reported to have more 
deleterious effect on paracellular permeability than ethanol in vitro [86]. These results were 
confirmed in colonic tissues extracted from rats after alcohol intake [75]. In our study, both 
patients with high and low intestinal permeability drank similar amounts of alcohol. All these 
observations suggest that a direct effect of ethanol on epithelial cells is not the main 
mechanisms involved in vivo upon chronic alcohol consumption. Ferrier et al. suggested that 
the increase in colonic permeability of rats after alcohol intake was induced by ethanol 
oxidation into acetaldehyde by the colonic microflora [75]. In their study, antibiotic treatment 
abolished the ethanol-induced increase of intestinal permeability and reduced colonic 
acetaldehyde concentration. In our study, luminal acetaldehyde levels of both low and high 
intestinal permeability alcohol-dependent patients were lower than that of controls. However, 
as human cells and gut bacteria possess ADH (to oxidize ethanol into acetaldehyde as well as 
to reduce acetaldehyde into ethanol) and ALD (to oxidize acetaldehyde into acetate or to 
reduce acetate into acetaldehyde) make the results of acetaldehyde levels found in feces 
Results and discussion - Chapter 3 
190 
 
difficult to interpret. Furthermore, at the time of feces collection, the AD subjects had not 
ingested ethanol for more than 24 hours that make the importance of acetaldehyde for gut 
permeability difficult to conclude. Whatever the case, the fact that only dysbiotic subjects 
developed gut leakiness suggests that ethanol induces gut barrier alteration by an indirect 
mechanism involving the gut microbiota. Phenolic and indole compounds which are 
metabolites produced by the gut microbiota are good candidates to play a role in the 
regulation of the gut barrier function. The problem is that many different bacterial genera and 
species could be involved in the production of these metabolites. A key issue would be to 
identify which bacteria produce which metabolites. 
Short-chain fatty acids (SCFAs) like acetate, propionate and butyrate are known to play 
important role in the regulation of immune system, gut barrier and gut physiology. We did not 
find differences in the levels of SCFAs between controls and alcohol-dependent groups. 
However, the SCFAs measured in fecal samples do not necessary represent the real 
production in the upper part of the intestine. Indeed, SCFAs, mainly butyrate, are important 
source of energy for colonocytes and are therefore absorbed and metabolized and the 
concentrations obtained in fecal samples are the remaining non-absorbed SCFAs found in the 
most distal part of the gut. It is plausible that the SCFAs produced in the proximal intestine 
could have an effect on gut barrier and immunity but their concentrations are much more 
difficult to obtain in humans. Therefore, the data related to the fecal levels of metabolites 
must be carefully interpreted. 
Discussion on psychological data 
We found that intestinal permeability was correlated with the psychological markers of 
addiction severity such as depression, anxiety and alcohol craving. This suggests that the gut 
may influence the brain functions and emotions. We also measured a personality factor called 
emotional intelligence in alcohol-dependent and controls subjects. Emotional intelligence 
reflects the ability to adaptively perceive, understand, regulate and utilize one’s emotions and 
those of others [251]. Alcohol-dependent and control subjects filled in a self-reported 
questionnaire consisting in 75 items and that encompasses four factors: well-being, self-
control, emotionality and sociability. The scores of all factors were lower in alcohol-
dependents subjects compared with controls (figure 3-1). 
 Results and discussion - Chapter 3 
 
191 
 
 
Figure 3-1 : Score of emotional intelligence in alcohol-dependent (AD) and control (CT) subjects. 
 
We found that intestinal permeability was negatively correlated with the sociability 
factor of emotional intelligence, suggesting a possible relation between intestinal permeability 
and the expression of a personality trait, that may be relevant for interpersonal relations 
(figure 3-2). The personality trait sociability refers to social competence, emotion 
management and assertiveness. High scorers for this trait usually perceive themselves as 
accomplished networkers with excellent social skills and capable of influencing other 
people’s feelings whereas low scorers considered themselves as followers rather than leaders. 
Furthermore, in a limited number of subjects for which we have analyzed the gut microbiota, 
we observed a positive correlation between the sociability factor and the genus 
Bifidobacterium spp (figure 3-3). This bacterium was also negatively correlated with the score 
of alcohol craving. The observation of these relations does not allow to prove a causal link 
between gut permeability or gut bacteria and personality. However, if this came to be verified, 
it would mean that strategies aiming at improving the gut microbiota and restoring gut barrier 
function might help patients to improve their psychological well-being and might potentially 
influence personality trait.  
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Figure 3-2: Association of intestinal permeability and the sociability factor of emotional intelligence 
 
Figure 3-3: Association of Bifidobacterium spp with the sociability factor of emotional intelligence and with the 
score of alcohol craving (OCDS). 
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The conclusions of Chapter 3 are the following: 
 Only a subset of alcohol-dependent subjects presents gut leakiness. A direct toxic 
effect of ethanol on intestinal epithelial cells is likely not to be the main mechanism 
upon chronic alcohol consumption, since subjects with high and low intestinal 
permeability exhibit similar amount of alcohol intake. 
  Only subjects with leaky gut have gut dysbiosis. This result suggests that alteration of 
the gut microbiota is an indirect mechanism by which ethanol induces increase in 
intestinal permeability.  
 Alteration of the gut microbiota composition consists mainly in reduced abundance of 
Ruminococcaceae (Ruminococcus, Faeacalibacterium, Suboligranulum, Oscillibacter 
and Anaerofilum) and Bifidobacterium and increased abundance of Lachnospiraceae 
(Dorea) and Blautia.  
 Alterations of the gut microbiota functionality are revealed by using fecal 
metabolomics and consist mainly in significant changes in the level of phenolic and 
indole-derived compounds. Phenol is considered to be detrimental for intestinal 
epithelial cells while indole-derived compounds and para-cresol are more susceptible 
to exert beneficial effects on the gut barrier.  
 Higher intestinal permeability is associated with the persistence of psychological 
symptoms at the end of alcohol withdrawal. Patients with leaky gut suffer from a more 
severe addictive behavior and may be more susceptible to relapse after a detoxification 
program.  
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1 GENERAL CONCLUSIONS 
The harmful use of alcohol ranks as the leading risk factor for death and disability 
when considering people aged 15-59 years [2]. The prevalence of alcohol use disorders 
reaches 7.5 and 6% of the population in Europe and America, respectively, and all social 
classes are concerned [2]. Alcohol addiction has traditionally been considered a brain disease. 
Neurobiological studies have identified ethanol-induced changes in the concentration of 
neurotransmitters involved in the brain reward circuit. However, pharmacological treatments 
that target the brain neurotransmitters have been disappointing and the relapse rate in this 
disease is still very high. That is why alcohol dependence is defined as a chronic relapsing 
disease. In addition to the deleterious effect of ethanol on the brain, many other peripheral 
organs are damaged. In this PhD work, we have focused on the effect of heavy and chronic 
alcohol consumption on the gut and more particularly on the gut microbiota which is now 
seen as an “exteriorized” organ placed within the body, which plays a key role in the 
regulation of host physiology and behavior. Abnormal composition of the gut microbiota has 
been reported in several somatic diseases such as obesity and metabolic disorders, Crohn’s 
disease, ulcerative colitis and more recently in animal models of autism and alcohol 
dependence [90, 160]. Using germ-free animals and interventions that modify the gut 
microbiota composition (pro- and prebiotics, antibiotics) as well as behavioral tests that 
mimic human depression and anxiety, experimental researches of the last few years have 
suggested several mechanisms underlying the communication between the gut bacteria and 
the central nervous system. These data evoked a role for the inflammatory cytokines, the HPA 
axis, the vagus nerve, the metabolites produced by the bacteria and the alterations of 
tryptophan metabolism by inflammation as potential mediators [164]. However, it remains an 
intriguing idea that the composition of the gut microbiota might be associated with psychiatric 
conditions and data showing associations between the gut and the brain are scarce in humans 
[191–194]. The aim of this thesis was to test whether alterations in the gut microbiota 
composition and functions occur in alcohol-dependent subjects and whether these changes 
could be related to psychological symptoms of addiction. 
In the first study, we developed the 
51
Cr-EDTA method to assess both small bowel and 
colon permeability in alcohol-dependent subjects that had not developed liver damage. We 
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found that these patients presented with leaky gut, elevated plasma LPS levels and low-grade 
systemic inflammation. A short term alcohol withdrawal permitted the total recovery of leaky 
gut and endotoxemia but inflammation was still present. This suggests that LPS is not the 
only agent inducing an inflammatory response.  Furthermore, this study points out for the first 
time an important relationship between inflammatory markers and alcohol craving which play 
a central role in the drinking behavior. 
As inflammation may be a communication pathway between the gut and the brain, we 
looked for the origin of systemic inflammation in alcohol-dependent subjects. In the second 
chapter, we found that, in addition to LPS, another bacterial product called peptidoglycan that 
derived from Gram positive bacteria also crossed the gut barrier and reached the systemic 
circulation. These gut-derived bacterial toxins activated the peripheral blood mononuclear 
cells (PBMCs) which may contribute to the elevated plasma pro-inflammatory cytokines IL-
1β and IL-8. Activated inflammatory pathways in PBMCs were related to the amount of 
alcohol consumed. While a short-term alcohol withdrawal was associated with LPS recovery, 
peptidoglycan seemed to be still present in the circulation, in parallel with the persistence of 
inflammatory markers at the end of the detoxification program. The improvement of alcohol 
craving score during the withdrawal was associated with the decrease in inflammatory 
markers, and IL-8 was found to be the best predictor of the psychological outcome.  
In the last chapter, our attention was paid on the role of the gut on psychological and 
emotional disturbances. We observed that some, but not all, alcohol-dependent subjects 
developed gut leakiness. Direct toxicity of ethanol does not seem to be the causal factor of the 
increase in intestinal permeability as both subjects with and without leaky gut drank similar 
amount of alcohol. However, deep analysis of the gut microbiota composition and 
functionality revealed that subjects with leaky gut had also altered gut microbiota. Some 
specific bacteria like Ruminococcaceae and Lachnospiraceae or bacterial metabolites like 
phenolic and indole compounds may be involved in the regulation of the gut barrier function. 
Therefore, alteration of the gut microbiota is suggested to be an indirect mechanism by which 
ethanol would increase intestinal permeability. More importantly, subjects with leaky gut and 
altered gut microbiota presented with a more severe form of dependence including higher 
levels of depression, anxiety and alcohol craving compared to subjects without dysbiosis. The 
results of this third study showed, for the first time in human alcohol-dependent subjects, an 
association between the gut and the psychological symptoms of addiction.   
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All these data are in favor of the existence of gut-brain axis in alcohol-dependent 
subjects, where inflammation could play a role in the communication between the organ 
originally devoted “simply” to absorption or fermentation of nutrients, and the central nervous 
system. The high fraction of patients who resume alcohol drinking few months, few weeks or 
even directly after a detoxification program (which is supposed to restore a neurochemical 
equilibrium and suppress the dependent state) is a reality difficult to accept for the medical 
community, for the patients and their family. The persistence of inflammation and dysbiosis 
observed at the end of detoxification supports the idea that new strategies, targeting the gut 
and not the brain, might be beneficial in the treatment of alcohol dependence. More 
particularly, the use of nutritional factors called prebiotics appears to be the most promising 
strategy to improve, naturally and in a safe way, gut and psychological health in alcohol-
dependent subjects. 
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2 DISCUSSION AND PERSPECTIVES 
 
In this section, we will provide additional elements of discussion concerning the overall 
principles of the rationale of the PhD work, but also concerning results that we had obtained 
during the course of the different studies presented in the results section. We will also present 
and briefly discuss additional preliminary data that offer new perspectives for future studies.  
 
Specificity of our study design 
During this PhD work, all tests were performed in human subjects. Alcohol-dependent 
subjects were recruited the day of their admission at the hospital for a detoxification program. 
One advantage of the studies presented here resides in the fact that we have not only analyzed 
the effect of heavy and chronic alcohol consumption but also the effect of short-term alcohol 
abstinence on biological and psychological parameters related to alcohol dependence. The 
effect of alcohol withdrawal has, indeed surprisingly, been very poorly described in the 
literature while it is a critical period that occurs repeatedly during this chronic relapsing 
disease. Contrary to experimental studies on animal models, we only have few possibilities of 
interventions in humans to test specific hypothesis. Alcohol withdrawal is a very specific 
condition that allows the distinction between the effects of intoxication and those of chronic 
alcohol exposure that can persist even after several weeks of abstinence. The patients 
incorporated into our studies were tested twice, at the beginning and at the end of the 
detoxification program using the same tests, methods and conditions. Within the test re-test 
period, all patients have maintained abstinence during a period of 18 days.  Moreover, they 
received the same hospitalization program, the same psychological support and they went 
back home after the same period of time. It is therefore a highly controlled design, and these 
conditions have generally not been met in the previous human studies. 
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Investigation of the gut barrier function 
Alteration of the gut barrier has been analyzed using in vivo permeability test and results 
showed that some, but not all alcohol-dependent subjects developed leaky gut. However, it 
would be interesting to analyze other parameters that are associated with the gut barrier 
function such as TJs expression, antimicrobial peptides and mucins. During the detoxification 
program, alcohol-dependent inpatients underwent small intestinal biopsies usually 2 days after 
the last drink. We therefore have material for deeper analysis of the gut barrier function. The 
gene expression of TJs that regulate the paracellular permeability has been assessed by 
quantitative PCR. Results showed that the expression of claudin-1, occludin and ZO-1 in 
intestinal epithelial cells of alcohol-dependent subjects did not differ from that of controls 
(figure 2-1). However, if alcohol exerts a direct toxic effect on epithelial cells, one could 
expect that the protein expression rather the gene expression would be altered. Western-blot 
and immunohistochemistry targeting the TJs are in progress. 
 
Figure 2-1: TJs mRNA expression in small bowel biopsies obtained from alcohol-dependent subjects and 
controls. Experiments performed by Peter Stärkel and Christine de Saeger, data not published. 
Regarding antimicrobial compounds, Yan et al. [90] observed that the gene and 
protein expressions of Reg3b and Reg3g were reduced in the small intestine of mice fed 
alcohol compared to control mice. The authors suggested that the decrease in antimicrobial 
proteins might contribute to the enteric dysbiosis following alcohol administration. They also 
showed that prebiotic fructo-oligosaccharides restored Reg3g levels. Moreover, the same 
authors reported a decrease in Reg3g gene and protein expression in duodenal biopsies 
obtained from actively drinking alcoholic patients.  
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Concerning the intestinal mucus layer, which forms a physical barrier between the 
underlying epithelium and the gut lumen, Hartmann et al. [252] recently investigated its 
functional role, and in particular the role of Muc2, using a mouse model of alcoholic liver 
injury. Muc2 is the most abundant secreted mucin in the gastrointestinal tract and its absence 
results in a significantly thinner mucus layer. The results of this study showed that, following 
alcohol administration, knockout Muc2
-/-
 mice exhibited lower plasma LPS levels despite an 
increased intestinal permeability compared with wild-type mice. This could be explained by 
the fact that Muc2
-/-
 mice are protected from intestinal bacterial overgrowth and alcohol-
induced dysbiosis, potentially through up-regulation of antimicrobial factors such as Reg3b 
and Reg3g. They tested the hypothesis in alcoholic patients and observed an increased 
thickness of the mucus layer on duodenal biopsies compared with healthy humans. The 
authors speculated that following chronic alcohol consumption, the increase in mucus 
thickness (which could be seen as a good reaction of the intestine) prevent the bacterial 
ligands to access enterocytes and therefore prevent the production of antimicrobial 
compounds. Less antimicrobial molecules reach the lumen and the proliferation of intestinal 
bacteria is less controlled. We could therefore expect that Muc2 is up-regulated in intestinal 
biopsies of alcoholic patients but this result has never been reported.  
We propose to measure the expression of antimicrobial compounds and Muc2 in intestinal 
biopsies of alcoholic patients in parallel with the in vivo permeability test that showed that 
only a subset of patients developed leaky gut and dysbiosis. We also propose to test the effect 
of short-term alcohol abstinence (which is associated with decreased LPS levels and intestinal 
permeability) on mucins and antimicrobial peptides. One limitation of these proposed studies 
is that although we can easily have small bowel biopsies as this medical examination is 
integrated in the patient’s hospitalization program, we can hardly have access to colonic 
mucosa which would be more influenced by the gut microbes. 
 
The gut microbiota and its relation with intestinal permeability 
Our study is the first to assess, in human alcohol-dependent subjects, the intestinal 
permeability, the gut microbiota composition and the fecal bacterial metabolites. Our results 
showed that only a subset of alcohol-dependent subjects developed gut leakiness that was 
associated with alteration of the gut microbiota. Dysbiosis, consisting mainly in decrease in 
Ruminococcaceae and increase in Lachnospiraceae, was suggested to influence the gut barrier 
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function possibly through microbially-derived metabolites such as phenolic and indole 
compounds which have been proved to modify the permeability of intestinal epithelial cells in 
vitro. The levels of other metabolites described in the supplemental section of Chapter 3 of 
the results section, and in particular medium chain fatty acids and branched chain fatty acids 
were also very different between subjects with high and low intestinal permeability. However, 
until now, no experimental data exist in the literature to confirm their involvement in the gut 
barrier regulation.  
We suggest that alcohol induces gut dysbiosis that in turn induces an increase in intestinal 
permeability. However, the correlations between gut bacteria and permeability do not imply a 
cause-effect relationship and it could be possible that alcohol alters the intestinal epithelial 
cells (that form the gut barrier) which results in dysbiosis through, for instance, a reduced 
production of antimicrobial compounds, as shown in animal study [90]. To test whether gut 
dysbiosis is responsible for increased intestinal permeability, we could design an experiment 
in which the gut microbiota of an alcoholic with dysbiosis is introduced in a germ-free mouse, 
in parallel with another germ-free mouse which receives the gut microbiota of an alcoholic 
without dysbiosis, and then measure the intestinal permeability of these mice.  
 
The potential pathways underlying the gut microbiota-brain axis 
1) The bacterial metabolites 
The bacterial metabolites have been considered a potential mechanism underlying gut-
brain axis [164].  We assess, in our study, the fecal metabolome of alcohol-dependent 
subjects. As fecal metabolites may likely influence the gut barrier function, we found 
consistent to test the association between specific fecal bacterial metabolites and the host 
intestinal permeability. However, it is unlikely that fecal metabolites directly influence brain 
functions but it is possible that the metabolites produced in the gut lumen stimulate intestinal 
cells which in turn secrete other neuroactive compounds that could be transmitted to the brain. 
Also, fecal metabolites are absorbed through the gut mucosa and then access the blood 
compartment and are further metabolized by host enzymes (liver, kidney). As shown in a 
recent study using mouse model of autism [253], it is possible that blood metabolites, that 
initially originate from the gut microbes, influence brain functions and behavior. 
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It would therefore be interesting to assess in parallel fecal and blood metabolomes and to 
test the association between blood metabolites and brain functions. 
 
2) The tryptophan metabolism 
In the gut lumen, tryptophan (TRP) is metabolized by the bacteria that form the end-
products indole and 3-methyl indole (skatole) which seem important regarding to gut barrier 
function. Gut bacteria are also able to convert TRP into kynurenine (KYN) but this compound 
was not detected in our GC-MS fecal analysis. However, TRP can cross the gut mucosa and 
reach the systemic circulation where it can be converted into either serotonin (5-HT) or KYN 
depending on the inflammatory conditions. As described in the introduction, TRP is the 
precursor of 5-HT an important neurotransmitter involved the regulation of emotional states. 
Pro-inflammatory cytokines can activate the enzyme indoleamine-2,3-dioxygenase (IDO) 
expressed in immune cells to degrade TRP into KYN and other metabolites which are 
neuroprotective (kynurenic acid, KYNA) or rather neurotoxic (quinolinic acid, QUIN) (figure 
2-2). 
 
Figure 2-2 : Tryptophan metabolism pathway. Tryptophan is the precursor of serotonin but upon inflammation, 
tryptophan is converted into kynurenine. 
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In collaboration with Dr. Aye-Mu Mynt (Ludwig-Maximilian University, Germany), we 
obtained data on the blood concentration of the tryptophan metabolites in 55 alcohol-
dependent subjects at the beginning (T1) and end (T2) of a 3-week alcohol withdrawal. The 
results are shown below (figure 2-3). 
 
Figure 2-3: Plasma levels of tryptophan metabolites in alcohol-dependent (AD) and control (CT) subjects at the 
beginning (T1) and end (T2) of a 3-week detoxification program.  ** p < 0.01 vs CT, *** p < 0.001 vs CT, ## p 
< 0.01 vs ADT1 and ### p < 0.001 vs ADT1. 
We found that the levels of TRP and 5-HT in alcohol-dependent subjects were similar to 
those of controls. However, the levels of KYN and of 3-hydroxykynurenine (3-OH-KYN) 
were significantly decreased in the patients at the beginning of withdrawal. Therefore, the 
ratio KYN/TRP was significantly decreased in alcohol-dependent subjects. In experimental 
studies in which inflammatory response was induced by a pathogen stimulus, the ratio 
KYN/TRP is generally increased, due to conversion of TRP into KYN by IDO.  
The results of the plasma concentrations of TRP and KYN metabolites are difficult to 
interpret because they did not necessary reflect the brain concentrations. Also, the surprising 
decreased plasma level of KYN may be due to:  
1) Its further conversion into 3-OH-KYN and then into 3-hydroxyanthranilic acid (3-OH-
AA). The latter metabolite is the precursor of QUIN which has been shown to be neurotoxic 
but this end-product metabolite was not yet measured in our study.  
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2) The fact that KYN enters the brain via large amino acid transporter, which also allows 
the transport au TRP across the blood-brain barrier. We therefore could measure the plasma 
levels of other large neutral amino acids such as tyrosine, valine, leucine, isoleucine, 
phenylalanine which also compete for the transporter and could affect the availability of brain 
TRP. 
 As mentioned above, it is possible that some blood metabolites might influence brain 
function and behavior. We therefore tested the correlation between the tryptophan metabolites 
and the psychological symptoms developed by alcohol-dependent but we did not find 
convincing results suggesting that this pathway does not seem to have significant effect on 
behavioral dimensions tested so far.  
 
3) The vagus nerve 
The importance of the vagus nerve in gut-brain interactions is controversial. Some 
studies have shown that the effects of gut microbiota or potential probiotics on brain functions 
are dependent of vagal activation [182, 183]. However, the mechanisms through which vagal 
afferents become activate by gut bacteria are still unclear. Vagus-independent mechanisms 
have also been demonstrated. For instance, infection with parasite Trichuris muris induced 
gastrointestinal inflammation and anxiety-like behavior in mice. Vagotomized mice infected 
with the parasite display similar anxiety-like behavior [184]. In another study, mice received 
orally a mixture of antimicrobials that altered the composition of the microbiota and the 
exploratory behavior. The effect of antimicrobials on behavior was still present in previously 
vagotomized mice [169].  
In humans, it is not an easy task to determine the role of the vagus nerve in the 
communication between the gut and the brain but it is possible to obtain, quite easily, data on 
the vagus nerve activity which is reflected by the heart rate variability (HRV). In a continuous 
electrocardiographic record, each QRS complex is detected and the so-called normal-to-
normal intervals, i.e. all intervals between adjacent QRS complexes resulting from sinus node 
depolarization, are determined [254]. We therefore performed on alcohol-dependent subjects 
electrocardiograms from which we extracted two indices of the HRV called time-domain 
measures: Standard Deviation of Normal-to-Normal intervals (SDNN) and Root Mean Square 
of Successive Differences between normal-to-normal intervals (RMSSD). 
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Our preliminary results showed a decrease in HRV in alcohol-dependent subjects 
(SDNN: 26 ±14 ms; RMSSD: 29 ± 17 ms) compared to values obtained in healthy population 
(SDNN: 50 ±16 ms; RMSSD: 42 ± 15 ms) [255]. The results are consistent with a recent 
meta-analysis that revealed that alcohol dependence is associated with a reduced HRV [256] . 
Interestingly, we found significant negative correlations between HRV and pro-inflammatory 
cytokines, particularly TNFα (table 2-1). This result is in line with the anti-inflammatory 
capacity of vagal activation [257]. 
 
Table 2-1 : Correlation between heart rate variability (HRV), alcohol consumption and cytokine TNFα. 
HRV vs. Spearman r p-value n 
Alcohol consumption (g/day) - 0.584 0.011 18 
Plasma TNFα (pg/ml) - 0.595 0.006 20 
 
To summarize the data, we observed that high alcohol consumption is related to 
reduced vagal activity. The more reduced the vagal activity, the higher the inflammation. The 
higher the inflammation, the higher the depression and craving. From this data, we can 
hypothesize that the vagus nerve could mediate the effect of peripheral inflammatory 
cytokines on the psychological symptoms of alcohol dependence. 
The effect of a short-term alcohol withdrawal on vagus nerve activity is currently 
under investigation, in collaboration with Dr Yori Gidron, from Vrije Universiteit van 
Brussels. 
 
4) The inflammatory cytokines 
Alcohol-dependent subjects are characterized by a chronic low-grade inflammation which 
was shown to be associated with psychological dimensions like depression and alcohol 
craving. It is challenging to investigate the behavioral consequences of chronic inflammatory 
process. While many studies have been performed in animals, data in humans are limited. 
Behavioral tests (force swim test, tail suspension test, elevated-plus maze, open field test) 
have been designed to assess mood changes in animals. Overall, they are limited to the 
measurement of depression-like or anxiety-like behavior. In patients, mood assessment is 
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done by questionnaires and it is possible to distinguish a lot of symptoms associated with 
mood such as feeling of guilt, anhedonia, fatigue, irritability, suicidal thoughts, feeling of 
helplessness. It is obvious that many aspects of human behavior and psychology cannot be 
modeled in laboratory animals. To counteract this problem, human models of systemic 
inflammation have been proposed. One model, developed by Capuron et al., is based on the 
therapeutic administration of cytokines (IFNα or IL-2) in cancer patients and then analysis of 
anxious and depressive symptoms [209]. IFN therapy is also commonly proposed in the 
treatment of hepatitis C and is associated with the development of major depressive episodes 
[258, 259]. However, injecting a single cytokine does not very much mimic a natural immune 
response induced by a pathogen. Another model consists in injecting intravenously bacterial 
endotoxins (LPS) to raise circulating cytokines levels in healthy volunteers and then 
analyzing mood and neuropsychological competences [214, 215, 260–263]. The main 
limitations of these models reside in the fact that LPS injection induces an acute and transient 
inflammatory response and therefore do not reproduce chronic inflammatory conditions 
which are more frequently encountered in the clinic. Moreover, one drawback of such type of 
study is the potential bias linked to the patient’s subjectivity or social desirability when filling 
in psychological questionnaires and more importantly, these types of studies raise ethical 
concerns and are therefore not easily approved. On the other hand, another important point 
has been raised recently by Seok et al. regarding the extensive use of murine models in 
biomedical research [264]. They found very low correlation of expression changes between 
human genes and their mouse orthologs in several inflammatory conditions demonstrating 
that the genomic responses to inflammatory stimuli in mouse models cannot be extrapolated 
to human conditions. Therefore, it is essential to design experimental studies in animal models 
to understand the complex interactions between peripheral immune response and brain 
functions and behavior but it is also important to confirm data obtained in animals models in 
humans whenever possible and give higher priority to translational medical research.  
In this PhD work, we had the opportunity to measure inflammatory response elicited by 
chronic alcohol drinking under naturalistic conditions. We provided data on the relationship 
between peripheral inflammatory markers and the severity of depression and alcohol craving 
in alcohol-dependent subjects. As pro-inflammatory cytokines are known to influence many 
brain functions, we are currently performing studies in order to test the association between 
inflammatory markers and cognitive and executive functions such as working memory, 
selective attention, inhibition, flexibility and decision making in alcohol-dependent subjects. 
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These functions are, as described in the introduction, other important factors playing a role in 
the loss of control over drinking and other behaviors observed in alcohol-dependent subjects. 
Most of these functions cannot be tested on laboratory animals and up to now human data are 
lacking.    
Also, as mood disorders are recognized as having a strong association with a pro-
inflammatory state, one could therefore imagine that reducing inflammation may have a 
positive impact on mood. The first strategy aiming at reducing inflammatory state is the use 
of anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAID), 
minocycline (a tetracycline antibiotic) and anti-TNFα agents (etanercept, infliximab). The use 
of these anti-inflammatory drugs to treat mood disorders has shown controversial results 
[265] and they are definitely not recommended in alcohol-dependent subjects for several 
reasons: NSAID has been demonstrated to increase the gut permeability [64], antibiotics are 
known to strongly alter bacterial diversity [266] and more importantly, anti-inflammatory 
compounds have the potential to compromise resistance to infection. However, another, more 
interesting, indirect strategy to reduce inflammation would be the use of pro- or prebiotics 
which can target the origin of inflammation. Indeed, these dietary compounds have been 
shown to improve gut microbiota composition [267] and reduce gut leakiness as well as 
endotoxemia and inflammation [126, 177, 268] also in the context of chronic alcohol 
consumption [92, 93, 269]. Moreover, recent findings support the idea that they can have 
beneficial effect for mental health in animal models [182, 253, 270] and humans studies [191, 
193, 194]. However, exposing an extremely leaky intestine to additional live bacteria, albeit 
apparently “friendly” probiotics may be unsafe. Therefore, the use of prebiotics appears to be 
the most promising strategy to improve, naturally and in a safety way, gut and mental health 
in alcohol-dependent subjects.  
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Potential factors that could be responsible for the development of gut 
leakiness and dysbiosis in a subset of alcohol-dependent subjects. 
Despite the demonstration of a direct toxicity of ethanol on intestinal epithelial cells in 
vitro, we failed to found a relation between ethanol intake and intestinal permeability in our 
study on human alcohol-dependent subjects. Hence, an indirect mechanism involving changes 
in the gut microbiota may underlie ethanol-induced increase in intestinal permeability. 
However, we still do not know why some subjects resist to microbial changes upon heavy 
alcohol consumption whereas other patients presented with drastic dysbiosis. A major 
challenge was therefore to determine the factors that are responsible for the development of 
gut leakiness and dysbiosis in only a subset of alcoholics, or conversely factors that may 
protect alcohol-dependent subjects from gut dysfunction.  
It is well established that changes in the microbial composition could be induced by 
several environmental factors including antibiotics use, life-style, stress, diet, as well as age 
and genetics.  We were able to control two of these factors: subjects with high and low 
intestinal permeability did not differ for age and subjects who took antibiotics were excluded 
from the study. Concerning the dietary intakes we failed to control them in the study 
presented in chapter 3. This is important information missing in our study since we know that 
nutritional intakes are strongly altered in alcohol dependence [271]. However, this has been 
evaluated in a previous, independent study conducted on a population of alcohol-dependent 
subjects recruited in the same conditions [271]: on average, alcohol accounted for almost 40% 
of caloric intake and proteins, lipids and carbohydrates intakes were significantly reduced 
compared to those of healthy controls. This observation of frequent dietary deficits in this 
population could be responsible for the development of dysbiosis observed in a subset of 
patients. However, the two groups of patients, although presenting with large differences in 
microbiota composition, consumed similar amounts of ethanol. If diet was a major cause for 
differences in gut microbiota, this would happen independently of the amount of ethanol 
consumed. This hypothesis has never been tested so far. Mutlu et al. [94] reported no 
difference in fat and fiber intakes between non-dysbiotic and dysbiotic alcohol-dependent 
subjects, even if they admit that nutritional assessments were performed on very limited 
number of subjects. In our study, plasma pre-albumin level which could be seen as a marker 
of nutritional status [272], did not differ between low and high intestinal permeability groups. 
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These observations do not support a major influence of diet to distinguish dysbiotic from non-
dysbiotic alcohol-dependent subjects.  
Other factors may explain dysbiosis in alcohol-dependent subjects: genetics, life-style 
and stress. It is plausible that genetic variation exist between subjects with dysbiosis and 
subjects with a normal gut microbiota. Moreover, evidence of genetic influences on addiction 
has been provided by adoption or twin studies which support the conclusion that the 
proportion of risk for alcohol dependence explained by genes is between 40 and 60% [273]. 
American researchers are currently testing the hypothesis that disrupted circadian rhythms 
may contribute to the differential susceptibility for alcohol-induced gut leakiness in a subset 
of alcoholics [81, 274, 275]. Circadian rhythms control a variety of biological processes 
including sleep/wake cycles, body temperature, hormone secretion, glucose homeostasis, 
immune function as well as intestinal function since circadian genes control the expression of 
TJs genes involved in the regulation of intestinal permeability [276]. Disruption of circadian 
rhythms has deleterious consequences for health and has been associated with metabolic 
syndrome, cardiovascular disease, cancers and intestinal disorders. Life-style and 
environmental factors such as shift work, late-night activity, jet lag but also timing of food 
intake and alcohol consumption are obvious disrupters of circadian rhythmicity [277]. An in 
vitro study [81] has shown that alcohol disrupts intestinal epithelial cells permeability in 
parallel with up-regulation of protein levels of circadian clock genes CLOCK and PER2. 
Moreover, knock down of these genes expression by siRNA prevent alcohol-induced 
hyperpermeability in Caco-2 cells [81]. Further studies are therefore needed to determine 
whether the expression of intestinal circadian genes is altered in alcoholic patients and 
whether change in circadian gene expression can differentiate alcoholics with and without 
leaky gut.  
Finally, the question of stress also deserves interest since changes of microbial 
composition under stress conditions have been reported in animal studies [172, 278] and in 
humans [279, 280]. In some individuals, alcohol drinking is an attempt to cope with stress 
[281]. Life-stress has been shown to alter the activity of the HPA axis. Indeed, stress triggers 
the release of corticotropin-releasing factor (CRF) in the hypothalamus, causing 
adrenocorticotrophic hormone (ACTH) secretion from the pituitary gland and subsequently 
glucocorticoids (corticosterone in rodents, cortisol in humans) from the adrenal glands. In 
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animal models, maternal separation (MS) during the neonatal period is used to mimic early-
life stress. MS in rodents is associated with enhanced activity of the HPA axis resulting in 
increased CRH content in hypothalamic neurons [282] and elevated levels of serum 
corticosterone [283]. CRF has been also implicated in stress-induced intestinal abnormalities 
[284] such as increased colonic permeability [285] and colonic mucin release [286]. 
Probiotics (L. rhamnosus and L.helveticus) treatment of MS rat pups was reported to 
normalize corticosterone levels and ameliorate colonic dysfunction [283].  In adult rats, 
chronic peripheral administration of CRF, mimicking chronic stress, also caused increase in 
serum corticosterone levels and colonic barrier dysfunction [287]. In clinic, elevated plasma 
cortisol concentrations and enhanced CRH levels in cerebrospinal fluid have been repeatedly 
observed in patients suffering from depression and anxiety [282, 288]. Therefore, we assessed 
the salivary cortisol level in alcohol-dependent and controls subjects. Our preliminary data 
revealed that patients with high intestinal permeability had higher cortisol level than subjects 
with low intestinal permeability at both times of withdrawal (figure 2-4). Moreover, cortisol 
level was positively correlated with intestinal permeability (r = 0.43, p = 0.03).  
 
Figure 2-4 : Salivary cortisol levels of alcohol-dependent (AD) and control (CT) subjects at the beginning (T1) 
and end (T2) of alcohol withdrawal. * P < 0.05 vs CT, # P < 0.05 vs AD low IP at the same study time point. 
From these results, we can hypothesize that gut microbiota and gut barrier alterations 
associated with higher activity of the HPA axis could reflect a higher stress state or a 
decreased potential to cope with stress in a subset of alcohol-dependent subjects.  
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Main conclusions: 
 Alcohol-dependent subjects are characterized by a chronic low-grade systemic 
inflammation. Plasma pro-inflammatory markers positively correlated with depression 
and craving. 
 
 Leaky gut permits the translocation of gut-derived bacterial toxins like LPS and 
peptidoglycans which reached the systemic circulation and stimulated peripheral blood 
mononuclear cells to induce the expression of IL-1β and IL-8. The activated 
inflammatory pathways in these immune cells are correlated with alcohol consumption 
and alcohol craving. 
 
 Only a subset of alcohol-dependents subjects developed gut leakiness which is related 
to alteration of the gut microbiota. Dysbiosis is suggested to be an indirect mechanism 
by which ethanol induced increased intestinal permeability. Leaky gut and dysbiosis 
are associated with the persistence of psychological symptoms at the end of alcohol 
withdrawal. Gut dysfunction is therefore related to a more severe form of dependence 
and could influence the probability of relapse after detoxification. 
 
 A short term alcohol-withdrawal is associated with the total recovery of intestinal 
permeability and plasma LPS levels whereas peptidoglycans, inflammatory markers 
and gut dysbiosis persist. The psychological symptoms of alcohol-dependence 
improved largely during alcohol withdrawal but are still present, at the end of the 
detoxification program, only in alcohol-dependent subjects with altered gut 
microbiota.  
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Main perspectives:  
 To analyze the blood metabolome and test association between blood metabolites and 
psychological symptoms. 
 
 To analyze other components of the gut barrier function such TJs protein, 
antimicrobial peptides and mucins expression in small bowel biopsies at the beginning 
and end of alcohol withdrawal. To check their relation with in vivo permeability test 
showing that only a subset of alcohol-dependent subject develop gut barrier 
alterations. 
 
 To test the association between inflammatory markers and cognitive and executive 
functions.  
 
 To perform a randomized, double-blind, placebo-controlled clinical trial to test the 
effect of prebiotic supplementation on gut microbiota, intestinal permeability, 
systemic inflammation, and psychological symptoms during a detoxification program, 
and evaluate the relapse rate within 6 months. Detailed nutritional assessments should 
be reported. 
 
 To test the effect of alcohol withdrawal on vagus nerve activity. 
 
 To measure plasma quinolinic acid level, a neurotoxic metabolite and end-product of 
the TRP/KYN pathway. 
 
 To determine whether the expression of intestinal circadian genes is altered in 
alcoholic patients and whether change in circadian gene expression can differentiate 
alcoholics with and without leaky gut. 
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“The thing that was the most exciting about it all is that I found that without drugs, I was still 
writing very well, and that was probably the most rejuvenating aspect of it all, is that you 
don’t need to get stoned out of your gourd to write well. It was an incredibly important period 
for me. I can‘t say it was like night and day that suddenly I was this different person. It was 
not. It took quite a long time. But I think I did see light at the end of the tunnel, and it was not 
a train.” 
David Bowie.  
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1 ABREVIATION LIST 
 
AD alcohol-dependent 
ADH alcohol dehydrogenase  
AJs adherens junctions  
ALD alcoholic liver disease  
ALDH aldehyde dehydrogenase  
ANOVA analysis of variance 
AP-1 activator protein 1  
BAWL batterie d’attention de William Lennox 
BCAAs branched-chain amino acids 
BCFAs branched-chain fatty acids  
BDI beck depression inventory 
BDNF brain-derived neurotrophic factor  
BMI body mass index 
CD14 cluster of differentiation 14 
CNS central nervous system  
CRP C-reactive protein 
CT controls 
 DSM diagnostic and statistical manual of mental disorders 
FOS fructo-oligosaccharide 
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GC-MS gas chromatography - mass spectrometry 
GLP-2 glucagon-like-peptide 2  
HPA hypothalamus-pituitary-adrenal (axis) 
hsCRP high-sensitivity C-reactive protein 
IDO indoleamine-2,3-dioxygenase  
IFNβ interferon-beta  
IFNγ interferon-gamma 
IL interleukine 
 iNOS inducible nitric oxide synthase  
IRAK1 IL-1 receptor-associated kinase  
IRF3 interferon regulatory factor 3 
JNK c-Jun amino-terminal kinase 
LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase  
MDP muramyl dipeptide  
MLCK myosin-light chain kinase  
MUC2 mucin 2 
 MyD88 myeloid differentiation factor 88 
NFκB nuclear factor kappa-B  
NLRs nucleotide oligomerization domain receptors 
NLRP3 NLR family, pyrin domain containing 3 
NMR nuclear magnetic resonance spectroscopy  
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NOD2 nucleotide-binding oligomerization domain containing 2 
OCDS obsessive-compulsive drinking scale 
PAMPs pathogen-associated molecular patterns 
PBMCs peripheral blood mononuclear cells 
PCA principal component analysis  
PEG polyethylene glycol 
PGN peptidoglycan 
PLS-DA principal least square-discriminant analysis 
PPARγ peroxisome proliferator-activated receptor-γ  
PRRs pattern recognition receptors 
qPCR quantitative polymerase chain reaction  
Reg3g regenerating islet-derived 3-gamma (mRNA) 
RegIIIγ regenerating islet-derived 3-gamma (protein) 
ROS reactive oxygen species  
RT retention time  
SCFAs short-chain fatty acids  
SD standard deviation 
SEM standard error of the mean 
STAI state-trait anxiety inventory 
TJs tight junctions 
TLFB time-line follow-back 
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TLR2 toll like receptor 2 
TLR4 toll like receptor 4 
TLRs toll-like receptors 
TNFα tumor necrosis factor-alpha 
TRIF TIR domain-containing adapter inducing IFN-beta  
VOCs volatile organic compounds  
ZO-1 zonula occludens 1 
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